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ABSTRACT
Minor myocardial injury (MMI) is relatively common after complicated percutaneous 
coronary interventions (PCI) and is associated with increased risk of future cardiac events. It 
is possible that MMI may be detected by elevation of cardiac markers (e.g. enzymes and 
cardiac troponins). However, the occurrence, mechanism and long term outcome of minor 
myocardial injury after uncomplicated successful elective PCI in patients with stable angina 
has not been assessed previously.
Cardiac troponins have been shown to be more sensitive and specific than CKMB for the 
detection of MMI. Therefore, the first purpose of our work was to study the occurrence of 
MMI after uncomplicated successful elective PCI in patients with stable angina by measuring 
cardiac troponin levels in serum after the procedure and to compare these results with serum 
CKMB. Much recent evidence supports the inflammatory nature of atherosclerotic coronary 
artery disease. Several inflammation markers have been implicated in this process with their 
serum concentrations increased in a variety of atherosclerotic disease. With this rapidly 
developing field in mind, the second purpose of our work was to examine the association of 
the systemic inflammatory state, reflected by different inflammation markers, with the 
occurrence of MMI. Such an association has never been studied before in this selected group 
of patients. Since relating the occurrence of MMI after PCI to outcome has important 
implications for clinical practice of interventional cardiology, the third purpose of the study 
was to prospectively evaluate the long-term prognostic significance of MMI after elective 
uncomplicated successful PCI which has never been reported before in patients with stable 
angina.
Serum cardiac troponin I (cTnl), cardiac troponin T (cTnT) and creatine kinase MB (CK­
MB) levels were measured before and after uncomphcated, successfiil elective PCI in 
patients with stable angina. The frequencies of elevated cTnl and cTnT levels were 
significantly higher than that of CKMB after coronary intervention {p = 0.00016 and 0.015, 
respectively).
Inflammatory markers including serum levels of high-sensitivity C-reactive protein (CRP), 
interleukin-6, tumor necrosis factor-a, and intercellular adhesion molecule-1 were measured 
before PCI and were related to the occurrence of MMI after the procedure, and subjects were
followed-up for adverse cardiac events for 24 months. Serum CRP was the only 
inflammatory marker that related to the occurrence of MMI after the procedure. CRP levels 
were above the reference range in 41% of patient group; of these, 46% developed MMI after 
PCI compared to 18% of patients that had a serum CRP within the reference range {p— 
0.008). Patients with and without presumed MMI, identified by elevated cTnl levels, did not 
differ significantly with respect to age, body mass index, conventional coronary risk factors, 
medications, or severity of pre-existing coronary arteiy disease. Over a follow-up period of 
24 months there was no significant difference in the medication used between the MMI 
positive and negative groups. The incidence of recurrent angina, repeat PCI, coronary bypass 
surgery and cardiac death was 54, 46, 4 and 4 % respectively in the cTnl positive patients 
versus 27, 16, 4 and 0 % in the cTnl negative patients. Kaplan-Meier survival analysis 
showed that cTnl elevation was significantly related to cardiac events (p -  0.0198, by log 
rank analysis).
In conclusion, MMI identified by elevated serum levels of cardiac markers is not uncommon 
after elective uncomplicated successful PCI in patients with stable angina. Serum cardiac 
troponins, especially cTnl, were more sensitive than serum CKMB in detecting MMI. 
Cardiac troponin I elevation after elective uncomplicated successfiil PCI in patients with 
stable angina might be a marker of adverse long-term outcome. Increased serum CRP is 
common in patients with stable angina and is a significant and independent determinant of 
MMI after elective uncomplicated PCI indicating involvement of the systemic inflammatory 
state in the etiology of this periprocedural myocardial injury.
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PREFACE
Being highly sensitive and specific markers for myocardial injury, cardiac troponins opened 
the door for a very interesting and rich area for clinical research. The study idea came obout 
few years ago while I was doing the evaluation of cardiac troponins inorded to introduce 
them in our lab.
There were no reports about measuring cardiac tropnin levels after uncomplicated successful 
elective PCI in patients with stable angina. Therefore, we thought about conducting such 
study in our institution where fairly large number of patients undergoes PCI. At that time, 
cardiac troponin measurement was not routinely done in our hospital and I performed all the 
tests as part of the research protocol of the study. The results from the first part of the study 
were very interesting as we demonstrated that MMI detected by elevated cardiac troponins is 
not uncommon, occurring in 29% of the patients, after elective uncomplicated successfiil 
PCI. These interesting findings were presented during many national and important 
international meetings such as the Congress o f the European Society o f Cardiology and the 
Annual Scientific Session o f The American College o f Cardiology and was published as a full 
paper in the Catheterisation and Cardiovascular Intervention
Much recent evidence supports the inflammatory nature of atherosclerotic coronary artery 
disease. Several inflammation markers have been implicated in this process with their serum 
concentrations increased in a variety of atherosclerotic disease. With this rapidly developing 
field in mind, we thougt about examining the association of systemic inflammatory state, 
reflected by different inflammation markers, with the occurrence of MMI. Such an 
association has never been studied before in this selected group of patients. We studied serum 
levels of high-sensitivity C-reactive protein (CRP), interleukin-6 (IL-6) tumor necrosis 
factor-a, (TNF-a) and intercellular adhesion molecule-1 (ICAM) before PCI and related them 
to the occurance of MMI after the procedure. None of these markers is measured routinely in 
our lab. Therefore, I performed all these tests as part of the research protocol of the study. 
Results obtained from this part of the study were also interesting as we could demonstrate 
that the occurrence of MMI after PCI was significantly related to the systemic inflammatory 
state reflected by CRP levels. These findings were also presented during national and 
important international meetings such as the European Atheosclerosis Society Congress and 
the World Congress o f Cardiology Meeting and accepted for publication in the 
Journal o f Cardiology.
xvii
Since relating the occurrence of MMI after PCI to outcome has important implications for 
clinical practice of interventional cardiology, we decided to prospectively evaluate the long­
term prognostic significance of MMI after elective uncomplicated successful PCI which has 
never been reported before in patients with stable angina. After a 24 month follow-up period 
we demonstrated that elevated cardiac troponin levels after elective uncomplicated successfiil 
PCI might be a marker of long-term outcome. This finding was also accepted for presentation 
during the World Congress Meef/wg for publication as a fiill paper in the
Annal o f Clinical Biochemistry journal.
With these findings in mind, it is adviseblc not to perform elective PCI in patients with 
elevated CRP levels to decrease the chance of developing MMI after the procedure which 
will prevent the long-term sequelae of this injury. Also, measurement of cTnl after the 
procedure may help to identify patients who would require aggressive preventive measures to 
prevent subsequent ischemic events and their expected detrimental effects on outcome. I 
hope that my findings help in understanding the pathophysiology of minor myocardial injury 
after percutaneous coronary intervention and benefit patients udergoing such procedure.
Salam Saadeddin
X V lll
Biochemical Detection of Minor Myocardial Injury
After Elective Uncomplicated Successful 
Percutaneous Coronary Intervention in Patients with Stable Angina.
CHAPTER-1
Introduction
hi CORONARY ARTERY DISEASE
1.1.1 Pathogenesis of Coronary Artery Disease
1. 1. 1.1 Risk factors
Throughout life, a number of nonmodifiable and modifiable risk factors (Table 
1.1) increase our risk of developing clinically significant atherosclerotic 
changes leading to clinical disease (1). In addition to these classical risk 
factors, several newly recognized risk factors have been established. We now 
recognize atherogenic influences, such as lipid abnormalities, in addition to 
prothrombogenic abnormalities (1) (Table 1.2).
Nonmodifiable
Factors
Modifiable
Factors
Age Cigarette smoking
Sex Hypertension
Family history Diabetes mellitus
Menopausal status Hypercholesterolemia
Elevated LDL
Reduced HDL
Obesity
Physical activity
Triglycerides
Table 1.1 Classical cardiovascular disease risk factors* LDL; Low-
density-lipoprotein cholesterol, HDL; high- density-lipoprotein cholesterol
Proatherogenic Prothrombogenic
Homocysteine Plasminogen
Lipoprotein particle oxidation Fibrinogen
Hyperinsulinemia Factor VII
LDL receptor deficiency tPA inhibitor 1
Lipoprotein (a)
Table 1.2 Proposed Cardiovascular Disease Risk Factors. LDL, Low- 
density-lipoprotein; tPA, tissue plasminogen activator.
1.1.1.2 Molecular and cellular mechanisms of atherogenesis
Clinical studies and experimental animal models have provided an improved 
insight into molecular events that transform healthy coronary arteries into the 
clinically diseased vessels with multifocal lesions. Accumulating evidence 
indicates that atherosclerosis is an inflammatory process involving a network 
of vascular wall cells, monocytes, T-lymphocytes, proinflammatory cytokines, 
chemoattractant cytokines (chemokines) and growth factors (2-7). 
Proinflammatory stimuli such as oxidatively modified low- density lipoprotein 
(LDL) cholesterol, firee radicals, cigarette smoke, elevated plasma 
homocysteine and infectious organisms cause endothelial dysfunction which 
lead to compensatory responses that alter the normal properties of the 
endothelium (2). A cascade of events ensues leading to the accumulation of 
isolated macrophages, their transformation into lipid-laden foam cells, fatty 
streak formation and finally stable or unstable fibrous plaques (2-4). This 
cascade of events is mediated by proinflammatory cytokines, chemoattractant
cytokines (chemokines), growth factors and adhesion molecules produced by 
activated inflammatory, vascular smooth muscle and endothelial cells (2- 
4,8,9).
Molecular mechanisms: Proinflammatory risk factors cause either local 
(vascular) or systemic (extravascular) inflammation which triggers the 
production of first-wave proinflammatory cytokines such as interleukin-Ip 
(IL-lp) and tumor necrosis factor - a  (TNF-a) (10,11). IL-lp and TNF-a may 
mediate the inflammatory response occurring in the vascular wall during 
atherogenesis by activating monocytes and expression of adhesion molecules 
on endothehal cells, inducing secretion of other cytokmes, chemokines and 
growth factors (12,13). In addition, IL-ip and TNF-a may enhance 
atherogenesis by promoting vascular smooth muscle cell proliferation (14,15) 
and increasing endothelial cell procoagulant activity (16). Induction of the 
expression of adhesion molecules on the surface of endothelial cells results in 
the recruitment of mononuclear leukocytes to the intima and the initiation of 
the atherosclerotic lesion. Members of the selectin family of adhesion 
molecules including lymphocyte L-selectin and endothehal E-selectin and P- 
selectin, mediate sticking and rolling adhesion of leukocytes and slow their 
passage across the endothelial surface to allow more stable interactions to 
occur (16-18). On the other hand, members of the immunoglobulin 
superfamily including ICAM-1 and VCAM-1 mediate leukocyte arrest and 
migration between the endothelial cells into the vessel wall (16-18).
First-wave proinflammatory cytokines can also stimulate the production of
chemoattractant cytokines (chemokines) such as MCP-1 and IL-8 which may
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play a major role in atherogenesis (11). Both molecules are chemotactic for 
monocytes and activated T-cells and are also involved in the induction of 
adhesion of monocytes (16,17).
Moreover, first-wave proinflammatory cytokines stimulate the production of 
interleukin-6 (IL-6), a second-wave proinflammatory cytokine (11), which in 
turn stimulates the production of acute-phase proteins by the liver (20). 
Because of its central role in the inflammatory responses, it is possible that IL- 
6 is linked to the pathogenesis of CAD. In addition to being a major inducer of 
acute phase proteins and other cytokines and growth factors (21), IL-6 itself 
can activate platelets (22) and has procoagulant activity (23-25) and mitogenic 
activity for smooth muscles (26).
The role of CRP in atherosclerosis remains to be defined. The presence of 
CRP immunoreactivity has been demonstrated in vulnerable and ruptured 
plaque (27). Whether this is locally expressed or absorbed from the blood 
stream is not yet clear. The possible mechanisms for direct involvement of 
CRP in atherosclerosis and thrombosis include complement activation through 
binding of damaged cell membranes (28) and eUciting tissue factor production 
by monocytes (29). Recent evidence suggests that CRP may contribute 
directly to the proinflammatory state by stimulating monocyte release of 
proinflammatory cytokines (such as IL-ip,TNF-a and IL-6) (30), causing 
expression of ICAM-1 and VCAM-1 by endothelial cells (31), mediating 
MCP-1 induction in endothelial cells (32) and causing opsonization of LDL 
that mediates LDL uptake by macrophages (33). Although SAA has been 
shown to be present in human atherosclerotic plaque (34). Its precise role in
atherogenesis has not been fully elucidated. On the other hand fibrinogen 
plays a central role in thrombosis and strongly affects homeostasis, serum 
viscosity and platelet aggregation. All these processes play significant roles in 
the evolution of the atherosclerotic plaque (35,36).
Regulation of inflammation by cytokines involves an intricate balance ofpro- 
and anti-inflammatory mediators. Among the anti-inflammatory cytokines, IL- 
10 is the one studied most in recent years. IL-10 is produced by various 
inflammatory cells, especially macrophages (37). It is a major inhibitor of 
cytokine synthesis, suppresses macrophage function, and inhibits the 
production of proinflammatory cytokines (37,38). IL-10 expression has been 
identified within human atherosclerotic plaques (39,40) and animal studies 
have shown that IL-10 has a protective effect in both atherosclerotic lesion 
formation and stability (41,42). Also a very recent study has shown that serum 
levels of IL-10 are decreased in patients with unstable angina (43).
Cellular mechanisms: During their movement in and around the endothelial 
cells and through the endothelial layer into the subendothelial space, 
monocytes undergo a change in gene expression that allows for uptake of 
lipids through phagocytic mechanism. This occurs in response to the secretion 
of macrophage-colony stimulating factor (M-CSF) by activated endothelial or 
smooth muscle cells. M-CSF can augment the expression of a scavenger 
receptor for modified lipoproteins on the surfece of the monocytes (44). These 
transformed monocytes, now known as macrophages, also become sensitive to 
growth factors, such as platelet derived growth factor (PDGF) and cytokines
such as IL-ip and TNF-a which are also responsible for the activation and 
increased proliferation of the endothelial and smooth muscle cells.
Oxidation of LDL in the intimai space by free radicals and lipoxygenases 
causes alteration of the apolipoprotein B receptor-binding domain. The 
oxidized LDL no longer has the native recognition site and cannot undergo 
normal LDL uptake by apolipoprotein B sensitive LDL receptor (45). The 
oxidized LDL then becomes available for uptake by the scavenger receptor of 
macrophages instead, resulting in the formation of a foam cell, which is the 
characteristic cell present in early plaque formation (44,46). It is the 
deposition of lipid into the extracellular matrix following death and rupture of 
the foam cells that leads to the observed lipid-rich core that has been 
demonstrated to be a progenitor of the fibrous plaque (47,48). As these foam 
cells aggregate with each other and with leukocytes (monocyte-derived 
macrophages and T lymphocytes), and smooth muscle cells migrate from the 
media into the intima in response to the released growth factors and cytokines, 
a fatty streak is produced (49).
The early fatty streak progresses sequentially to the bulging foam cell-filled 
fibro-fatty plaque (Fig. 1.1), the fixed stenotic lesions visible on coronary 
arteriography (Fig. 1.2) (50,51), and hence to the complicated lesion. With 
the accumulation of foam cells, there is a significant thickening of the intimai 
space. Smooth muscle cells replicate and corrupt the architecture of the 
subendothelial layer. This proliferation of smooth muscle cells at the edge of 
the fatty streak results in the formation of a fibrous cap (52,53). They continue 
to replicate until this cap covers the entire lesion. The lesion increases further
in size as monocytes continuously adhere to and penetrate the vessel wall. At 
this point, the foam cells in the center of the lesion become necrotic. This 
lesion is now known as fibrous plaque and may undergo further degeneration 
characterized by calcium deposits.
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 ^ TCell
Smooth Muscle
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ENDOTHELIUM
Foam Cells
Platelets
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Fibrous Plaque
y
Figure 1.1 Pathogenesis o f  coronary artery disease. (From Ross R.: 
Arteriosclerosis, an overview. In Haber E  [ed]: Molecular cardiovascular 
medicine. New York, Scientific America, 1995, p. IS.)
According to classification of the American Heart Association and the 
American College of Cardiology lesions are classified into three types (52):
1- Type A lesion -  Discrete (<10 mm in length), concentric and non- 
angulated and generally has a high success rate (>85%) during 
percutaneous transluminal coronary angioplasty (PTCA).
Type B lesion -  Tubular (10-20 mm in length), eccentric, moderately 
angulated and has a moderate success rate (60-85%) during PTCA.
Type C lesion -  Diffused (>20 mm in length), with excess tortuosity of 
proximal segment and extremely angulated a low success rate (<60%) 
during PTCA.
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3-
vÆ- f *
Figure 1.2 Stenotic lesion involving the right coronary artery o f 
one o f the patients included our study as shown by coronary 
arteriography.
Patients with stable lesions (Fig. 1.3) (i.e lesions with fibrous caps that are not 
susceptible to rupture) may develop stable angina (Table 1.) with reversible 
tissue ischemia and are at low risk for adverse events. With lesion progression, 
the presence of inflammatory cells appears to contribute to the development of 
unstable plaque (Fig. 1.3) (53).
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Figure 1.3 Cellular interactions in the development and progression o f 
atherosclerosis, VSMS, vascular smooth muscle cells. (From Weissberg  PL. 
Atherosclerosis: current understanding o f the cause o f atheroma. Heart, 2000;
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1.1.1.3 Lesion progression and clinical syndromes
The most important determinant of plaque stability is the composition of the 
fibrous cap. Inflammatory cells can weaken the fibrous cap by interfering with 
the maintenance and repair of its fi-amework of extracellular matrix molecules 
(Fig. 1.4). Activated T cells secrete proinflammatory cytokines, in particular 
interferon j  (IFN- y), which inhibits vascular smooth muscle cell proliferation 
and collagen synthesis and activates macrophages to produce specific 
enzymes, matrix metalloproteinases (MMPs), that selectively digest the 
individual components of the matrix (50). Degradation of matrix proteins can 
weaken the fibrous cap making it susceptible to rupture leading to the 
precipitation of acute coronary syndromes. On the other hand,
microvasculature endothelial cells as well as vascular smooth muscle cells 
produce tissue inhibitors of metalloproteinases (TIMPs). The net effect of 
cytokines on the vascular wall may be to tip the balance between the 
production of MMPs and TIMPs in favor of extracellular matrix degradation 
and remodeling (50).
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Figure 1.4 Metabolism o f collagen and elastin in the fibrous cap o f the plaque,
IFN-y, interferon-y; INF- a, tumor necrosis factor- a; M-CSF, macrophages colony- 
stimulating factor; MCP-1, macrophage chemoattractant protein-I. (From re f 2)
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Plaque rupture leads to the exposure of thrombogenic elements within the 
arterial wall triggering thrombogenesis (Fig. 1.5), a process that may occur 
repeatedly without clinical recognition and without proceeding to occlusion 
(50). The propagation of thrombus, with subsequent occlusion, may produce 
ischaemic injury and myocyte necrosis (54,55). Nonocclusive thrombi produce 
the syndromes of unstable angina and non Q-wave myocardial infarction while 
occlusive thrombi produce typical Q-wave myocardial infarction (Table 1.3). 
Hence the destabilization of a fatty plaque may precipitate complete, sudden 
occlusion with distal infarction and an obvious clinical event, or it may occur 
silently unrecognized except by biochemical markers of myocyte necrosis.
Pathology
Normal
Clinical
Coronary Artery Disease
Early
Lesion
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Minor Nonocclusive
Growing
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Unstable Angina 
Non Q- Wa ve M I
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Rupture
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Formation
Angina
Angina
4
4  Coagulability 
Vasoconstriction
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Figure 1.5 Coronary artery disease-Pathology and Clinical Syndromes.
(Modifiedfrom ref. 6)
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Syndrome Description
Stable angina Chronic pattern of transient angina pectoris*, precipitated by 
physical activity or emotional upset, relieved by rest within a few 
minutes; episodes often associated with temporary depression of 
the ST-segment, but permanent myocardial damage does not 
result.
Unstable angina Pattern of increased frequency and duration of angina episodes, 
produced by less exertion, or at rest; associated with high 
frequency of progression to myocardial infarction if untreated.
Non Q-wave myocardial Pattern of myocardial necrosis that is usually limited to the inner
Infarction third of the ventricular wall (nontransmural), typically presents as 
ST-segment depression and/or T-wave inversion with a lack of 
development of an abnormal Q-wave on the EGG.
Q-wave myocardial Pattern of myocardial necrosis that is usually involves the full
infarction thickness of the ventricular wall (transmural), typically presents 
as ST-segment elevation with the development of an abnormal Q- 
wave on the ECO.
*Angina pectoris = Uncomfortable sensation in the chest produced by myocardial ischemia.
Table 1.3 Clinical definitions o f the acute coronary syndromes.
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1.1.2 Cardiac Vessels
1.1.2.1 Coronary Arteries
The heart is supplied with oxygen and nutrients by the right and left coronary 
arteries, which arise at the root of the aorta ( Fig. 1,6 A).
Left main 
coronary artery
Aorta
Left circumflex 
coronary artery
Left anterior descending 
y /c o ro n a ry  arteryRight coronary artery
Figure 1.6 (A) A schematic representation o f the right and left coronary 
arteries demonstrates their orientation to one another. (From Hyver S, Kim P, 
and Rhines L : Basic cardiac structure and function. In Lilly LS. [ed.]: 
Pathophysiology o f heart disease. Malvern, Lea &Febiger, 1993, p. 7.)
The right coronary artery (RCA) travels between the right atrium and 
ventricle, where it gives off very small atrial and ventricular branches, and 
passes to the inferior border of the heart where it gives off the marginal branch 
(Fig. 1.6 B). This branch makes its way toward the apex, where as the RCA 
continues to the posteroinferior aspect of the heart and gives rise to its largest 
branch, the posterior descending coronary artery (Fig. 1.6 C).
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coronary eft»ry
Figure 1.6 (B) Anterior view o f the heart demonstrating the coronary arteries and 
their major branches. (Q Posterior view demonstrating the terminal portions o f the 
right and circumflex coronary arteries and their branches (Ref. same as Fig. 1.6 A).
The left coronary artery divides into the left anterior descending coronary 
artery (LAD) and the left circumflex coronary artery (LCx) (Fig. 1.6 A). 
During its descent on the anterior surface of the heart, the LAD gives off 
septal branches that supply the interventricular septum and diagonal branches 
that supply the anterior surface of the left ventricle (Fig. 1.6 B). The LCx 
artery passes around the left border of the heart to reach the superior surface 
and gives off obtuse marginal branches that supply the lateral and left 
posterior wall of the left ventricle (Fig. 1.6 C).
1.1.2,2 Coronary Microvasculature
The small arterioles are widely distributed throughout the myocardial wall
from the epicardial to endocardial surface (Figure 1.7). The large epicardial
coronary artery gives intramyocardial vessels that penetrate through the wall.
These are vessels that branch immediately and supply the midwall. There are
longer branches that go directly through the wall to supply blood to an
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extensive subendocardial network of vessels. These serve as an important 
source of collateral blood supply when any occlusion occurs in a large 
proximal epicardial branch. There are also interarterial collateral channels 
between the vascular systems of the large coronary arteries. The collateral 
flow in these channels is initiated only when a significant pressure gradient 
develops between the adjacent vascular beds due to occlusion of a major 
vessel. The complexity of these vascular collaterals is a major contributing 
factor accounting for the wide variations in ECG changes and the release of 
cardiac markers that occur with myocardial injury and infarction, especially in 
those that are nontransmural.
Large epicardial artery
Epicardial Surface
Endocardial Surface
Subendocardial plexes
Intramyocardial 
-  vessels
Figure 1.7 Subendocardial plexes o f the left ventricle and epicardial 
communications through a section o f left ventricular free wall (From Fulton 
WFM.: The coronary Arteries, Springfield, IU,Charles C ThomasPublisher, 1965, 
P. 95).
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1.1.2.3 Coronary veins
The coronary veins follow a distribution similar to that of the major coronary 
arteries. These vessels return blood from the myocardial capillaries to the right 
atrium predominantly via the coronary sinus. The major veins lie in the 
subepicardial fat, usually superficial to the coronary arteries.
1.1.3 Histology of Ventricular Myocardial Cells
The mature myocardial cell is approximately 25 |im  in diameter and 85 to 100 
pm in length. The cell shows a cross-striated banding pattern similar to that of 
skeletal muscle. However, unlike the multi-nucleated skeletal myofibers, 
myocardial cells contain only one or two centrally located nuclei. Surrounding 
each myocardial cell is connective tissue with a rich capillary network. The 
myocardial cell plasma membrane (sarcolemma) contains many ion channels 
and pumps, which are important in excitation-contraction coupling. A 
specialized region of the membrane is the intercalated disk, a distinct 
characteristic of cardiac muscle tissue. Intercalated disks are seen on light 
microscopy as darkly staining transverse lines that establish structural and 
electrical continuity within the myocardium.
Each myocardial cell contains numerous myofibrils (Figure 1.8), which are 
long chains of individual sarcomeres, the fimdamental contractive units of the 
cell. Each sarcomere is made up of two groups of overlapping thick (myosin) 
and thin (actin) filaments of contractile proteins, (Figure 1.3). Biochemical
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and biophysical interactions occurring between these myofilaments produce 
muscle contraction.
Muscle fibers 
in muscle bundle
Mitochondria
Myofibril
Thick filam ent 
(Myosin) — Thin filam ent (Actin)
Sarcomere
Figure 1.8 Myocardial structure - viewed under light microscopy showing 
longitudinal section o f an individual fiber schematized from  electron microscope 
demonstrating parallel myofibrils composed and horizontal mitochondria as well as 
diagrammatic representation o f a sarcomere showing overlapping arrangement o f  
thick (myosin) and thin (actin) filaments. (Modifiedfrom Wikman-CoffeltJ, Mason 
DT: Mechanisms o f cardiac contraction. In Sodeman W (ed): Pathological 
Physiology, ed Philadelphia, WB Saunders, 1984)
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1.1.4 Excitation-Contraction Coupling
Excitation-contraction coupling is the mechanism by which cardiac myocytes 
translate chemical energy in the form of high energy phosphate compounds 
into mechanical energy in the form of muscle contraction, and is briefly 
reviewed here.
There are four distinct proteins responsible for cardiac myocyte contraction. 
Two of the proteins, troponin and tropomyosin, are regulatory; the other two, 
actin and myosin, are contractile in nature. Myosin (molecular weight 500,000 
Dalton) is arranged in thick filaments (Figure 1.9 - A), each composed of 
lengthwise stacks of approximately 300 molecules. Each thread like myosin 
molecule consists of a head section and a much longer tail section. The tail 
section consists mainly of myosin light chain (MLC) proteins and the two 
lobed head section consists of myosin heavy chain (MHC) proteins. The 
globular heads of the myosin filament are evenly spaced along its length, and 
contain myosin ATPase necessary for contraction. Actin, a smaller molecule 
(molecular weight 47,000 Dalton), is arranged in thin filaments as an a  helix 
consisting of two strands. Troponin is composed of three subunits filaments 
(Figure 1.9 - B). The troponin C (cTnC) subunît is responsible for binding 
calcium ions that regulate the contractile process. The troponin I (cTnl) 
subunit inhibits the ATPase activity of the actin-myosin interaction. The 
troponin T (cTnT) subunit attaches the troponin complex to the actin and 
tropomyosin molecules. Tropomyosin (molecular weight 35,000 Dalton) is 
double helix that lies in the grooves of the actin molecules and, in the resting 
state, inhibits the myosin heads from interacting with actin.
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Figure 1.9 Structure o f the troponin-tropomysin complex. cTnC, cardiac troponin 
C; cTnT; cardiac troponin T; cTnl, cardiac troponin I. (From Collinson PO, Boa FG, 
Gaze DC. Measurement o f cardiac troponins. Ann Clin Biochem, 2001;38:423-449).
The entry of calcium into the cell triggers additional more marked release of 
calcium from the sarcoplasmic reticulum. As calcium, interacts with cTnC, it 
inhibits the binding of cTnl to actin, and causes tropomyosin to undergo a 
conformational change (Figure 1.9 - C), so that the latter no longer interferes
with the binding of the myosin to actin, but rather promotes it.
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Contraction ensues by myosin heads binding to the actin filaments and 
“flexing,” thus pulling them together in an ATP-dependent reaction. The first 
step in this process is activation of the myosin head by hydrolysis of ATP, 
following which the myosin head binds to actin and forms a crossbridge. The 
myosin head then pulls the actin filament inward. Next, while still attached, 
additional ATP binds to the myosin head and displaces the ADP that had 
resulted from the previous ATP hydrolysis. The myosin head then releases the 
actin filament and is prepared to repeat the cycle. The coupling and 
uncoupling of actin and myosin cause the muscle fiber to shorten, and the 
process continues as long as the calcium concentration remains sufficient to 
inhibit the troponin-tropomyo sin action.
1.1.5 Spectrum of Acute Coronary Syndromes (ACSs)
For much of the past three decades and according to the World Health 
Organization (WHO) recommendations, MI was defined by using one of two 
of three characteristics: typical chest discomfort, enzyme rise and atypical 
ECG pattern involving the development of Q waves. However, current clinical 
practice and the advent of sensitive and specific serologic biomarkers 
necessitate réévaluation of established definitions of MI. Acute coronary 
syndrome has evolved as a usefiil operational term to refer to any constellation 
of clinical symptoms that are compatible with acute myocardial ischemia (Fig. 
1.10).
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Figure 1.10 Clinical classification o f acute coronary syndromes. NQMI = 
non-Q wave myocardial infarction; NSTEMI = non-ST elevation myocardial 
infarction; Q wMI = Q wave myocardial infarction; ST -  segment of ECG 
tracing. (Adapted from Antman EM, Braunwald E. Acute myocardial 
infarction. In: Braunwald EB, ed Heart disease: a textbook o f cardiovascular 
medicine. Philadelphia, PA: WB Saunders, 1997.)
Patients with ischemic discomfort may present with or without ST-segment 
elevation ultimately develop a Q-wave MI (QwMI), whereas a minority 
develop a non-Q-wave MI (NQMI). Patients who present without ST-segment 
elevation are experiencing either UA or an ( non ST segment elevation MI 
(NSTEMI). The distinction between these 2 diagnoses is ultimately made 
based on the presence or absence of a cardiac marker detected in the blood. 
Most patients with NSTEMI do not evolve a Q wave on the 12-lead ECG and 
are subsequently referred to as having sustained a non-Q-wave MI (NQMI); 
only a minority of NSTEMI patients develop a Q wave and are later diagnosed 
as having Q-wave MI. The spectrum of clinical conditions that range from US 
to non-Q-wave MI and Q-wave MI is referred to as ACSs. In addition to 
reflecting the pathophysiological process of acute myocardial ischemia, the
continuum of ACSs is a continuum of risk (Fig. 1.11).
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Figure 1.11 Risk o f Acute Coronary Syndromes (ACSs) in relation to pathologic
activation and tissue injury.
Recently, the European Society of Cardiology (ESC), the American College of 
Cardiology (ACC), and the American Heart Association (AHA) made specific 
recommendations on the use of biomarkers for the detection of myocardial 
infarction (MI) (56-58). The redefined criteria used to classify acute coronary 
syndrome (ACS) patients presenting with ischemic symptoms as acute, 
evolving, or recent MI are heavily dependent on an increased cardiac troponin 
concentration. Furthermore, in the new ACC/AHA guidelines for management 
of patients with unstable angina and NSTEMI (59), an increased cardiac 
troponin value establishes the diagnosis of NSTEM, whereas a normal cardiac 
troponin value establishes the diagnosis of unstable angina in ACS patients 
with ischemic discomfort.
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1.2 CARDIAC MARKERS
1.2.1 Markers of Inflammation
Many recent experimental and clinical studies have clearly established that 
atherosclerosis is an inflammatory process involving a network of vascular 
wall cells, monocytes, T-lymphocytes, proinflammatory cytokines, 
chemoattractant cytokines (chemokines) and growth factors (2-7). Ongoing 
inflammatory reactions within coronary atherosclerotic plaques are thought to 
be crucial determinants of the clinical course of patients with coronary artery 
disease (CAD) (8,9). These facts lead to a search for reliable markers 
reflecting the inflammatory process in the atherosclerotic plaques. Circulating 
markers may consist of cytokines directly released from inflammatory cells 
present in the plaques and tissues exposed to recurrent ischemia as well as 
other reactants produced in response to these cytokines such as adhesion 
molecules and acute phase proteins (10,11,60).
1.2.1.1 Classification and interrelation o f markers o f inflammation
Proinflammatory risk factors cause either local (vascular) or systemic
(extravascular) inflammation which triggers the production of first-wave
proinflammatory cytokines such as interleukin-ip (IL-lp) and tumor necrosis
factor - a  (TNF-a) (10,11). Measurement of these cytokines in serum can
provide information about the systemic inflammatory state of an individual
(60). First-wave proinflammatory cytokines and oxidatively modified LDL
can activate the endothehum and upregulate the expression of adhesion
molecules that are crucial to the recruitment of inflammatory cells from blood
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stream into the vessel wall (8,61). These adhesion molecules may be released 
in a soluble form into the blood stream and can serve as markers for vascular 
inflammation (60,62-65). First-wave proinflammatory cytokines can also 
stimulate the production of chemoattractant cytokines (chemokines) which (as 
will be described later in this section) may play a major role in atherogenesis 
(11) and these too have the potential to be used as markers of inflammation. 
Moreover, first-wave proinflammatory cytokines stimulate the production of 
interleukin-6 (IL-6), a second-wave proinflammatory cytokine (11), which in 
turn stimulates the production of acute-phase proteins by the liver (20). 
Examples of these proteins include C-reactive protein (CRP), serum amyloid 
A (SAA) and fibrinogen (66). Both IL-6 and acute-phase proteins can be used 
as markers of inflammation. Thus it is possible to measure markers of 
inflammation (Table-1.4) at different levels of atherosclerotic inflammatory 
reactions (Figure 1.12).
1. Cytokines
a) First-wave proinflammatoiy cytokines (IL-1, TNF-a)
b) Second-wave proinflammmatory cytokines (IL-6)
c) Chemoattractant cytokines -chemokines- (IL-8, MCP-1)
2. Adhesion Molecules
a) Selectins (P-selectin, E-selectin, L-selectin)
b) Cellular adhesion molecules (ICAM-1, VCAM-1)
3. Acute Phase Proteins
a) Produced in very high concentration (CRP, SAA)
b) Produced in low concentration (Fibrinogen)
Table 1.4 Potential Markers o f Inflammation,
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Figure 1.12 Different levels o f atherosclerotic inflammatory reactions
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1.2.1.2 Characteristics ofMarkers o f Inflammation and relation to CAD
Interleu kin-1 B (IL-IB): Interleukin-1, a glycoprotein, is a primary 
proinflammatory cytokine (10-12). It exists in two major biologically active 
forms, IL-1 a  and IL-ip (12,13). Of these IL-1 p is the predominant circulating 
isoform in humans (13). IL-1 may mediate the inflammatory response 
occurring in the vascular wall during atherogenesis by activating monocytes 
and expression of adhesion molecules on endothelial cells, inducing secretion 
of other cytokines, chemokines and growth factors (12,13). In addition, IL-1 
may enhance atherogenesis by promoting vascular smooth muscle cell 
proliferation (14,15) and increasing endothelial cell procoagulant activity (16).
As a key mediator of inflammation, IL-1 is expected to play a major role in the 
pathogenesis of ACSs. Increased synthesis of IL-1 has been demonstrated in 
human arterial plaques (67,68) and serum concentrations of IL-lp are raised in 
patients with minimal coronary artery diseases (69).
Tumor necrosis factor -a  (TNF-a): Originally described for its antitumor
activity, TNF-a is now recognized as a cytokine with multiple biological
capacities (70). In addition to cytostatic and cytotoxic effects on certain tumor
cells, TNF-a is a primary proinflammatory cytokine (10,11) with a potent
negative inotropic effect (71). It is a non-glycosaylated protein and acts via
two distinct cell surface receptors which are called TNF Receptor I (P55) and
TNF Receptor II (P75) (72,73). These receptors have been identified on
virtually all cell types except erythrocytes (72,73). Besides the cell-bound
forms of the TNF receptors, soluble forms are known which are capable of
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binding TNF-a. These soluble receptors can therefore compete with the cell- 
bound forms and can inhibit the effects of TNF-a (74).
Monocytes and macrophages are the main producers of TNF-a, but other cells 
such as T-lymphocytes, natural killer cells, smooth muscle cells, endothelial 
cells and some tumor cells also produce TNF-a (70). Biological effects of 
TNF-a and IL-ip, particularly those associated with systemic and local 
inflammation, are very similar (75). Therefore, TNF-a is also expected to have 
a major role in the pathogenesis of CAD, and it has been detected in human 
atherosclerotic plaques (76).
Increased levels of TNF-a have been observed after acute myocardial 
infarction (77). The concentration of soluble TNF receptors also increases 
rapidly and markedly after AMI (78). In addition, TNF-a plays important 
roles in the regulation of the synthesis of some acute phase proteins which are 
established risk factors for atherosclerosis, such as fibrinogen (79).
Interleukin-6 (IL-6); Interleukin-6 is a secondary multifunctional 
proinflammatory cytokine (10,11). It regulates humoral and cellular responses 
and plays a central role in inflammation and tissue injury (80). IL-6 can be 
produced by many vascular cells including endothelium, smooth muscle cells, 
lymphocytes and macrophages (80) as well as by adipocytes (81,82). Because 
of its central role in the inflammatory responses, it is possible that IL-6 is 
linked to the pathogenesis of CAD. It is a major inducer of acute phase 
proteins and other cytokines and growth factors (21). In addition, IL-6 itself
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can activate platelets (22) and has procoagulant activity (23-25) and mitogenic 
activity for smooth muscles (26).
Large quantities of IL-6 are foimd in human atherosclerotic plaques (83) and 
several studies have found a direct link between serum IL-6 levels and CAD. 
In a population-based cross-sectional study, electrocardiogram abnormalities 
were associated independently with increased IL-6 levels (84). Serum IL-6 
levels appear to be predictive of fiiture heart disease (85) and are elevated in 
patients with unstable angina compared with those with stable angina (86). 
Patients with persistently elevated IL-6 levels are also at increased risk of a 
poor in-hospital outcome following admission with unstable angina (87,88).
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Chemokines: Chemokines or chemoattractant cytokines are members of 
superfamily of small polypeptides that mediate the migration, growth and 
activation of leukocytes, and a variety of other cells (89-91). The largest 
chemokine classes are designated CC and CXC, according to the spacing of 
the first two of four conserved cysteine residues (92,93). Monocyte 
chemoattractant protein-1 (MCP-1) is the prototype of the CC class, where the 
first two cysteines are adjacent while interleukin-8 (IL-8) is the prototype for 
the CXC class, where the first two cysteines are separated by a single amino 
acid residue (94,95). Chemokines are released in response to the first-wave 
proinflammatory cytokines (IL-1 p, TNF-a) at the site of insult. Macrophages, 
smooth muscle cells, and endothelial cells (96-98) express MCP-1 while IL-8 
is expressed mainly by macrophages in human lesions (99,100). MCP-1 and 
IL-8 probably play an important role in atherogenesis. Both molecules are 
chemotactic for monocytes and activated T-cells (101-104) and are also 
involved in the induction of adhesion of monocytes (104).
Adhesion Molecules: Adhesion molecules are specific proteins on the 
endothelial cell surface together with their counter receptor proteins (ligands) 
on the leukocyte surface that regulate the different steps of leukocyte 
emigration from the blood stream into the vessel wall (16-18). Members of the 
selectin family of adhesion molecules including lymphocyte L-selectin and 
endothelial E-selectin and P-selectin, mediate sticking and rolling adhesion of 
leukocytes and slow their passage across the endothelial surface to allow more 
stable interactions to occur (16-18). On the other hand, members o f the 
immunoglobulin superfamily including ICAM-1 and VCAM-1 mediate 
leukocyte arrest and migration between the endothelial cells into the vessel
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wall (16-18). These adhesion molecules are up-regulated on the endothelial 
surface and other vascular cells in response to various stimuli, including pro- 
inflammatory cytokines, such as IL - Ip and TNFa (8,61). Soluble forms of 
adhesion molecules originating from proteolytic cleavage of membrane bound 
molecules may serve as markers of endothelial cell activation and 
inflammation ( 105).
Higer levels of serum ICAM and E-selectin were observed in patients with 
coronary heart disease compared with healthy controls (106) and 
concentrations of ICAM-1 have been related to future risk of MI (107) and 
risk of early post angioplasty restenosis (108). Also serum concentrations of 
ICAM and VCAM have been shown to be high in patients with stable angina, 
unstable angina and MI compared with healthy controls (109-111).
C-reactive protein (CRP): C-reactive protein is an acute phase reactant 
synthesized by the liver and consists of five identical, non-glycosylated 
peptide subunits linked to form a cyclic polymer (112). The synthesis of CRP 
is stimulated by cytokines, primarily IL-6 released from inflamed tissue (20). 
Levels of CRP can increase up to 1000 fold during acute inflammation. (66). 
The role of CRP in atherosclerosis remains to be defined.
The presence of CRP immunoreactivity has been demonstrated in vulnerable 
and ruptured plaque (27). Whether this is locally expressed or absorbed from 
the blood stream is not yet clear. The possible mechanisms for direct 
involvement of CRP in atherosclerosis and thrombosis include complement 
activation through binding of damaged cell membranes (28) and ehciting
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tissue factor production by monocytes (29). Recent evidence suggests that 
CRP may contribute directly to the proinflammatory state by stimulating 
monocyte release of proinflammatory cytokines (such as IL-ip,TNF-a and IL-
6) (30), causing expression of ICAM-1 and VCAM-1 by endothehal cells(31), 
mediating MCP-1 induction in endothehal cells (32)and causing opsonization 
of LDL that mediates LDL uptake by macrophages(33).
Characterization of the CRP protein and the production of reliable antisera 
have led to highly specific, sensitive and reproducible quantitative methods for 
the measurement of CRP. The development of these high sensitivity assays 
for CRP has enabled the detection of mild elevation of CRP within the normal 
range (113). The apphcation of these assays in the last several years made it 
possible to study CRP in a wide variety of atherosclerotic diseases and to 
explore its role in predicting cardiovascular events. CRP was first identified as 
a risk factor in the setting of pre-existing cardiovascular disease (114,115) and 
its serum levels have been related to the presence and severity of coronary, 
cerebral and peripheral atherosclerosis (116). In addition, many studies have 
demonstrated that CRP has prognostic value in acute coronary syndromes 
(115,117-121) and that it is able to predict fiiture coronary events in 
apparently healthy men and women (122-131). Despite the results of these 
large epidemiological studies, CRP is still not considered as an established, 
independent cardiovascular risk fector and its measurement still does not have 
defined clinical applications (132). One reason behind that is the lack of well- 
established CRP levels that can be considered to represent accurate cutoff 
points to identify the individual patients at risk. Different analytical assays 
were used in different studies, and therefore CRP levels vary significantly
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among these studies. Another reason is that despite suggestions of stable CRP 
levels over tinle within individuals, some reports indicate intraindividual 
variability reaching as high as 42% and 63% (133). Moreover, it is not known 
whether increased levels of CRP reflect arterial inflammation or inflammation 
elsewhere in the body, and studies suggest that CRP represents only a non 
specific indication of inflammation and/or other mechanisms underlying the 
atherogenic process (134).
The basis for CRP being able to predict future coronary events might be 
related to the association between CRP levels and established traditional risk 
factors such as obesity, diabetes and smoking. Obesity is associated with 
elevated CRP levels, an observation consistent with the finding that adipocytes 
secrete IL-6, the main hepatic stimulus for CRP production (135). Diabetic 
patients also have elevated CRP levels, which may suggest a role for 
inflammatory processes in the pathogenesis of diabetes mellitus. Smokers 
have also been shown to have elevated levels of CRP, IL-6, and sICAM-1 
(136). Also, the basis for CRP and the prediction of fiiture coronary events can 
be related to the direct involvement of CRP in atherosclerosis and thrombosis 
as well as to its contribution to the proinflammatory state. However, it will be 
possible to test whether CRP has a pathogenic role only when drugs that 
selectively inhibit CRP production or binding are developed.
Until now there is no sufficient data to merit CRP measurement in clinic
patients. For CRP to make the transition fi*om clinical research to the routine
clinical setting, several important issues must be satisfactorily addressed such
as the availability of population-based cutoff points for interpretation and risk
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assessment, the reliability of the analytical systems used for measurement and 
the existence of potential therapeutic modalities.
Serum Amyloid A (SAA); SAA is the precursor of the amyloid A protein 
deposited in amyloid A amyloidosis (137). SAA proteins, a family of 
inflammatory apolipoproteins, are major acute phase reactants that are 
produced in response to various insults (138). Their concentrations can 
increase as much as 1000-fold during inflammation (66,139). The synthesis of 
SAA in inflammatory disease is largely due to the synergistic effects of IL-1 
and IL-6. (140,141). Although the liver is the primary site of synthesis of SAA 
proteins (66), extrahepatic production from normal and abnormal tissues has 
been reported (142). Recent studies have revealed the production of SAA by 
cells from human atherosclerotic lesions including endothelial cells, cultured 
smooth muscle cells and monocyte-macrophage cell liver (143,143).
SAA has been shown to be present in human atherosclerotic plaque (34). Its 
precise role in atherogenesis has not been fully elucidated. SAA’s 
concentration in serum usually parallels those of C-reactive protein although 
some studies indicate that SAA is a more sensitive marker of inflammatory 
disease (145). At present, assays for serum SAA are not widely available. 
Concentrations of SAA are increased in patients with coronary heart disease 
and seems to have a useful prognostic utility with acute coronary syndromes 
(104,115-118).
Fibrinogen: Fibrinogen, a glycoprotein dimer, is a key coagulation factor and 
acute phase reactant exclusively synthesized by the liver (66). As the substrate
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of the enzyme thrombin and the precursor to fibrin, fibrinogen plays a central 
role in thrombosis and strongly affects hemostasis, serum viscosity and 
platelet aggregation. All these processes play significant roles in the evolution 
of the atherosclerotic plaque (35,36). Plasma fibrinogen is affected by several 
other risk factors for atherosclerotic CAD including age, smoking, levels of 
physical activity and blood pressure (150). It has been found to be associated 
with an increased risk of CAD among healthy and high-risk individuals 
(114,151,152).
1.2.1.3 Clinical Utility ofMarkers of Inflammation
Raised serum concentrations of inflammatory markers may reflect different 
stages of the atherothombotic process and may correspond to the severity of 
disease in the continuum of acute coronary syndromes. Hence these markers 
have a potential role in the assessment of coronary risk and may also correlate 
with the severity and fiiture risk for CAD. In spite of these findings, the 
clinical utility of measuring these markers is limited by the availability of 
reproducible diagnostic test assays. It remains to be determined whether 
markers of inflammation have a direct pathophysiological role in 
cardiovascular disease, or simply reflect the disease process. Therefore, further 
well-designed prospective evaluation of each of these markers is needed 
before their use in routine practice.
Coronary interventions can induce an inflammatory response by causing 
plaque rupture, hematoma, arterial wall damage, release of inflammatory and
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chemotactic factors with leukocytes and platelet activation (153,154). They 
can also initiate an ischemia-reperfusion cycle by repeated balloon inflations. 
The acute inflammatoiy response to PCI appears to be related to the 
preexisting degree of systemic inflammation as assessed by baseline CRP 
levels (155). Therefore, a more intense inflammatory response. Which may 
cause more complications, is likely in patients with increased baseline levels 
of markers of inflammation.
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1.2.2 Markers of Myocardial Injury
1.2.2.1 Classification o f Markers ofMyocardial Injury:
Myocardial injury starts with the loss of myocardial cell plasma membrane 
integrity and ends with myocardial necrosis. Necrosis is associated with cell 
organelle disruption and the release of high molecular weight molecules. New 
sensitive immunological techniques have allowed the detection of a range of 
cardiac markers released following myocardial cell necrosis. Biochemical 
markers of myocardial injury may be classified according to their intracellular 
compartmentalization in the myocytes as: cytosolic, structural, or both 
cytosolic and structural (Table 1.5).
Intracellular location Cardiac Markers
Cytosolic myoglobin, FABP, CK-MB
Structural MLC, MHC, Actin
Cytosolic & Structural cTnT, cTnl
Table 1.5 Markers o f Myocardial Injury» CK-MB, creatine kinase MB; 
FABP, fatty acid binding protein; MLC, myosin light chains; MHC, myosin 
heavy chains; cTnT, cardiac troponin T; cTnl, cardiac troponin I
The group of cytosolic cardiac markers include of unbound cytosolic proteins 
like myoglobin, CK and CK-MB isoenzyme and fatty acid binding protein 
(FABP). The structural macromolecules include myosin heavy chains (MHC), 
myosin light chains (MLC) and actin. The third group consists of cTnT and 
cTnl which are present in both minor cytosolic and major structurally bound 
protein pools (150,156).
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1.2.2.2 Kinetics o f appearance in plasma o f markers o f myocardial injury:
The release kinetics of a marker from a cell depends on several characteristics 
including: its molecular weight and intracellular concentration; whether it is 
bound or free in the cell or plasma; its sub-cellular localization (e.g. cytoplasm 
or mitochondria); its stability in the circulation and its rate of excretion, 
catabolism or degradation. The serum concentration is also affected by 
perfusion of the infarct zone (157). The kinetics of myoglobin and FABP are 
very similar and characterized by their earlier appearance, short time to a peak 
value, and a short duration of elevation above baseline (Fig. 1.13).
The appearance in serum of the myofibrillar proteins (e.g. actin and troponin) 
depends on the activation of proteolytic enzymes, leading to disassembly of 
the contractile apparatus. This process takes a relatively long time to occur and 
results in a prolonged release of these markers from necrotic myocytes. As a 
consequence, the kinetics of these markers is characterized by a late 
appearance, prolonged time to a peak value, a long duration of elevation, and 
relative insensitivity to reperfusion of the infarct zone (157).
The cardiac troponins exist both in a free cytosoHc and structurally bound 
protein pools. Hence they have an early release kinetics resembling other 
cytosolic markers and a late release resembling structurally bound molecules 
(Fig. 1.13). Reperfusion of the infarcted zone significantly affects the release 
kinetics of the cytosolic but not the structurally bound pool (158).
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(A) Myoglobin, CK-MB isoform s, FABP.
(B) CK-MB.
(C) cTnT.
(D )cT n l.
(E) MLC. MHC, Actin.
Days After Onset
Figure 1.13 Release kinetics o f cardiac markers in patients with acute myocardial 
infarction, (see section 1,3,2 fo r  the explanation o f the release kinetics o f cT nl and
cTn T), CK-MB, creatine kinase MB; FABP, fatty acid binding protein; MLC, myosin 
light chain; MHC, myosin heavy chain; cTnT, cardiac troponin T; cTnl, cardiac 
troponin I.
1.2.2.3 Characteristics o f Markers o f Myocardial Injury 
(Table 1.6 & 1.7)
Most cytosolic cardiac proteins such as, myoglobin, CK, etc., lack cardiac 
specificity since they are also expressed by skeletal muscles and other tissues. 
Serum concentrations are increased in patients with renal failure probably as a 
consequence of skeletal myopathy (159).
CK-MB: CK-MB has proven utility in the diagnosis of cardiac injury. Serial
serum measurements show a characteristic rise and fall of the enzyme that is
virtually pathognomonic for the diagnosis of acute MI (160). CK-MB is also
useful in assessing re-infarction or infarct extension because after an acute MI,
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CK-MB returns to base line concentration within 2-3 days. Increases in CK- 
MB concentration after that time would enable the detection of reinfarction or 
infarct extension.
CK-MB mass assays have been shown to be superior to activity based assays, 
such as immunoinhibition or electrophoresis (161,162). They measure CK-MB 
directly and provide mass measurements with no interferences from other 
proteins such as inhibitors of the enzyme activity, modified forms and 
fragments of the enzyme. They also reliably measure low CK-MB 
concentrations in samples with low total enzyme activity (<100 U/L) and with 
high total enzyme activity (>10,000 U/L).
Despite its wide application as a cardiac marker, CK-MB is not an ideal 
marker for a number of reasons. Skeletal muscle contains high concentrations 
of CK activity and may contains up to 3% of the CK-MB isoform (163). In 
patients with concomitant myocardial and skeletal muscle injury this leads to a 
diagnostic dilemma. The calculation of the percent relative index [(CK- 
MB/total CK) X  100] may assist in the differentiation between myocardial and 
skeletal muscle causes of increased CK (164,165). However, other 
investigators have concluded that the relative index degrades the sensitivity of 
CK-MB to an unacceptable degree and should be abandoned (135,136). In 
addition to the issue of tissue specificity (166,167), CK-MB may be 
insensitive in identifying patients with minimal myocardial damage (150,168). 
It also requires 8-12 hours to rise significantly, and falls 2-3 days after the 
onset of symptoms which makes it less reliable for the early and late 
retrospective diagnosis of cardiac necrosis.
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Myoglobin: Myoglobin has a low molecular weight which facilitates direct 
entry into the blood stream, bypassing the lymphatics and leading to the rapid 
appearance of the protein in the serum after an acute MI (169). Serum 
myoglobin levels rise rapidly reaching twice baseline values within 2 hours 
and peaking within 4 hours of an acute MI (170). For this reason, myoglobin is 
the marker of choice for determining the time of myocardial necrosis 
(171,172) and for monitoring reperfusion (173) (Table 1.6). A recent study 
showed that a diagnostic strategy which included the measurement of serum 
myoglobin, CK-MB, and an assessment of clinical indicators, such as time to 
treatment and the grade of chest pain, was a highly efficient mean of assessing 
reperfusion after thrombolytic therapy (174). In addition, myoglobin enhances 
the sensitivity of biochemical testing for early myocardial infarction (175). 
But, since myoglobin is the same molecule in cardiac and skeletal muscle, it 
lacks cardiac specificity. Myoglobin is also a very sensitive marker for skeletal 
muscle injury and is also increased in patients with renal failure (176,177).
CK-MB isoforms: The CK-MB isoforms (also termed subforms) have also 
been shown to be early markers for acute MI with release kinetics similar to 
that of myoglobin (178). Upon its release into the circulation, CK-MB is 
converted into MB-2 and MB-1 isoforms (Figure 1.14), due to the proteolytic 
activity of carboxypeptidase-N, an enzyme present in the blood of all 
vertebrates (179). Carboxypeptidase-N cleaves the terminal amino acid, 
lysine, ftrom the M subunit o f the CK-MB, which is positively charged, 
leaving the remaining molecule more negatively charged (MB-1). The more 
negative form (MB-1), upon electrophoresis, separates fi’om the parent tissue 
form (MB-2), giving rise to the two forms of CK-MB in plasma. In plasma,
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Lys® ®  Lys
Intracellular
Cerboxypeptidase
Lys®
Blood
Figure 1.14 Molecular mechanism o f MB Creatine Kinase isoform 
conversion in the blood. Loss o f a single positively charged lysine residue 
(Lys +) yields a more negatively charged molecule, resulting in faster anodal 
migration, {From Roberts R. Rapid MB CK subform assay and the early 
diagnosis o f myocardial infarction. Clinics in Laboratory Medicine, 1997; 17: 
669-683.)
the CK-MB subforms are in equilibrium, with a ratio of MB-2 to MB-1 of 1 to 
1 (179). When infarction occurs, MB-2, the tissue form is initially released 
into the circulation in minute amounts so that total CK-MB remains within the 
normal range, but the ratio of MB-2 to MB-1 changes markedly and provides 
the basis for an early diagnosis of myocardial infarction. Currently, CK-MB 
isoforms are most effectively measured by high-voltage electrophoresis, and 
are currently used in few routine hospital laboratories (180,181). However, 
With simplification in analytical methodologies, the routine use of these 
markers might increase.
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Structurally bound myofibrillar: proteins such as MLC, MHC and actin 
lack cardiac specificity since they are expressed in skeletal muscles. After 
acute MI, the persistent detection of these structural proteins in the circulation 
represents ongoing release up to the 10^  ^day after onset of chest pain. This 
results in a diagnostic utility of the assays of these proteins that extends until 
l40 hours after the onset of chest pain. This diagnostic utility is three times 
that of CK-MB. In-spite of their potentially higher sensitivity and wider 
temporal diagnostic window (157), these proteins lack well established assays 
for their measurements and are not routinely used.
FABP: Although the results of a number of limited recent studies suggest that 
FABP might have a higher specificity than myoglobin (182), it is uncertain 
whether this marker is sufficiently better than myoglobin which has been 
evaluated in many trials during recent years.
Cardiac Troponins: Because of their unique biochemical makeup and 
location, cTnT and cTnl have emerged as sensitive and more cardio-specific 
indicators of myocardial cell necrosis. This has allowed an improvement in 
risk stratification (Table 1.6) and may facilitate therapeutic decision making in 
patients with acute coronary syndromes. Cardiac troponins are discussed in 
details in section 1.3.
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CHARACTERISTICS CARDIAC MARKERS
Early Release Myoglobin, CK-MB isoforms, FABP.
Prediction of Reperfusion Myoglobin, CK-MB, CK-MB isoforms.
High Specificity cTnT, c Tnl, CK-MB isoforms, CK-MB.
Wide Diagnostic Window cTnT, cTnl, MLC, MHC.
Predictive of Clinical Outcome cTnT, cTnl, CK-MB.
Tablel.6 Characteristics o f Cardiac Markers, FABP = heart fatty acid binding 
proteins; MLC = myosin light chain; cTnl = cardiac troponin I; cTnT = cardiac 
troponin T; CK- MB ~ MB isoenzyme of creatine kinase (CK); MHC = myosin 
heavy chain.
Marker MW(D)
Range of 
times to 
initial 
elevation (h)
Mean time to 
peak elevations 
(non­
thrombolysis)
Time to 
return to 
normal 
range
Most common sampling 
schedule
Myoglobin 17,800 1-4 6-7 h 24 h Frequent; 1-2 h after CP
CK-MB
isoforms
86,000 2-6 18h Unknown 60-90 min after CP
FABP 14,000-15,000 1.5 5-10 h 24h On presentation, then 4 h 
later
MB-CK 86,000 3-12 24 h 48-72 h Every 12 h x 3*
cTnl 23,500 3-12 24 h 5-10 d Once at least 12 h after CP
cTnT 33,000 3-12 1 2 h - 2 d 5-14 d Once at least 12 h after CP
MLC 19,000-27,000 6-12 2-4 d 6-12 d Once at least 12 h after CP
MHC 400,000 48 5-6 d 14 d Once at least >2 d after CP
Table 1.7 Cardiac markers used or proposedfor use in the diagnosis o f myocardial 
injury, FABP = heart fatty acid binding proteins; MLC = myosin light chain; cTnl = 
cardiac troponin I; cTnT = cardiac troponin T; CK- MB = MB isoenzyme of creatine 
kinase (CK); MHC = myosin heavy chain; CP = chest pain. (Modified from Adams, 
J , III, Abendschein, D., andJqffe, A.: Biochemical markers o f myocardial injury. Is 
MB creatine kinase the choice for the 1990s? Circulation, 1993; 88:750).
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1.3 CARDIAC TROPONINS
1.3.1 Biochemistry of cardiac troponins
1.3.1.1 Structure and function o f Cardiac Troponins:
Troponins T, I and C form a trimeric complex (figure 1.15) that regulates the 
calcium-modulated interaction of actin and myosin in both skeletal and 
myocardial striated muscles (183,184). Troponin T functions to bind the 
troponin complex to the tropomysin strand; troponin I functions to inhibit the 
activity of actomyosin-adenosine triphosphate; and troponin C serves to bind 
four calcium ions, thus regulating contraction (185,186).
Tn-C
Tn-T2
Tn-TI
Tn-
Actin Tropomyosin
Head-to-Tail Overlap of
Tropomyosin
Figure 1.15 Structure o f cardiac troponins. cTnT, cardiac troponin T; cTnl, 
cardiac troponin I, cTnC, cardiac troponin C. (  From Katus HA, Scheffold T, 
Remppis A, Zehlein J.: Proteins o f the troponin complex. Laboratory Medicine. 
23:303-305, 1992.)
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1.3.1.2 Specificity o f Cardiac Troponins:
The subunits of the cardiac troponin complex are the product of different
genes and are not related to each other in protein structure (187). Troponins T
and I both have cardiac isoforms that are the product of unique gene sequences 
with corresponding unique protein structures that differ from the skeletal 
muscle homologues (187-192). This has permitted the development of cardiac 
troponin specific monoclonal antibodies that have been used in assays that 
differentiate the cardiac isoforms from those produced in skeletal muscle
(193.194). The aminoacid sequence of troponin C is identical in cardiac and 
skeletal muscle tissue, precluding its use as a specific cardiac marker
(183.195).
1.3.1.3 Physical and Chemical Properties o f Cardiac Troponins:
The ventricular myocardium contains 10.8 mg.g"  ^net weight of cTnT and half
that amount of cTnl (196). The molecular weights of cTnT and cTnl are
37,000 and 24,000 Da respectively (185,186). Whilst both proteins are
predominantly found bound to the contractile apparatus of muscle, there are
free cytosolic pools containing 6-8% of total cTnT compared with 3-4% for
cTnl (150,156). Cardiac troponin T appears in blood of patients with acute MI
as a mixture of complexes cTnT-I-C and free cTnT. The initial release is of
free cTnT with subsequent release of a mixture of cTnl-C complex with some
cTnT fragments (197). Cardiac troponin I is more hydrophobic and appears in
blood predominantly in the binary complex cTI-C found with smaller amounts
of the complexed cTnT-I-C (Fig. 1.16). The ratio between cTnl-C complex
and free cTnl varies followiug acute MI, with a maximum concentration of
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total cTnl of 5-12 times that of free cTnl and a maximum concentration of free 
cTnl appearing early after the acute MI (197).
1.3.2 Release kinetics of cardiac troponins
Following myocardial injury, a biphasic release pattern is usually noticed with 
an early peak corresponding to release from the free cytosolic pool and a 
sustained release of intact complexes from the myofibrils (127). This is more 
clear with cTnT than cTnl, possibly because free cTnT is initially released 
from the free cytosolic pool, and subsequently derived from the cTnT-I-C 
complex, whilst cTnl is predominantly derived from the complexed form 
(197). This may also explain the shorter duration of elevation of cTnl (5-7 
days) compared to cTnT (7-10 days) since the degradation of the complexed 
cTnl leads to faster clearance of the protein (198).
cTnl-C
cTnT
Bound
(cTnlcTnl
Free cTnC
^(cTnTcTnT
BloodCytoplasm
Figure 1.16 Release o f troponin subunits from  damaged myocytes to the 
circulation. cTnT, cardiac troponin T; cTnl, cardiac troponin I, cTnC, cardiac 
troponin C. (From Wu A H, Feng Y J. : Biochemical differences between cTnT and 
cTnl and their significance for diagnosis o f acute coronary syndromes. Eur Heart J, 
79; Æ2J-29, 79960.
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1.3.3 Issues related to cTuT and cTnl
13.3.1 The Specificity issue;
Cardiac troponin I is not expressed in skeletal muscle throughout ontogeny. 
After the ninth postnatal month, it is expressed only in myocardium (167). On 
the other hand, cTnT is expressed in fetal skeletal muscle and reexpressed in 
adult skeletal muscle after injury (168,199). Early studies have questioned the 
clinical specificity of cTnT assays in patients with chronic renal failure 
(200,201). With the development of a second-generation assay for cTnT, the 
frequency of positive results in these patients is lower than the frequency using 
the first-generation assay, although still higher than cTnl (202,203). 
Subsequent studies have shown that the anti troponin antibodies in the second- 
generation assays are specific for cTnT isoforms but do not detect the cTnT 
isoforms expressed in diseased skeletal muscle, and therefore do not produce 
false-positive cTnT results in skeletal muscle disease and renal patients 
(204,205). Preliminary reports show that increased levels of cTnT in patients 
with chronic renal failure are associated with a higher incidence of cardiac 
death (206). The importance of these findings is not completely known and the 
prognostic significance of the increased cardiac troponin level in chronic renal 
failure remains unclear, pending completion of ongoing outcome studies 
(207). Continuing analytical issues have promoted manufacturers of troponin 
assays to produce new generation kits to improve assay sensitivity and 
specificity. A clear example was the problem of nonspecific binding of 
antibodies to skeletal muscle troponin encountered by the first-generation
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assay of cTnT and this has been corrected with the subsequent generation of 
assays (205).
1.3.3.2 Other ongoing issues:
Ongoing issues include lack of standardization of cTnl assays. Results from 
different manufacturers using standards or calibrators of free native or 
recombinant cTnl produce cTnl values that differ by a factor of about 10 fold 
(197). Changing the calibrant to recombinant TIC-complex results in 3 fold 
differences in cTnl values. The optimal calibrator has been suggested to be 
TIC-complex derived from cardiac tissue (208). Convergence on 
standardization is expected to eliminate this problem for cTnl. On the other 
hand, lack of standardization is not a problem for cTnT assays as they are 
available from only one manufacturer and are standardized to a single 
reference material (197).
Other issues that affect cardiac troponin assays include reproducibility and 
imprecision due to heterophilic antibodies (209).
1.3.4 Utility of Serum Cardiac Troponins in Diagnosis (Table 1.8 & 1.9)
1.3.4.1 Role in Myocardial Infarction:
Cardiac troponins may be useful to confirm a suspected myocardial infarction, 
particularly in the diagnosis of equivocal cases. They may also assist in 
triaging patients (161).
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Confirmation of a suspected MI; Because of their particular kinetics, 
cardiac troponins have a wide diagnostic window, permitting both very early 
and late detection of MI (150,210). Measurement of cardiac troponins can 
reliably detect MI with a sensitivity and specificity that is claimed to be 
superior to CK-MB. Recent studies, however, show that the sensitivity of 
troponins to detect MI is greater than CK-MB after 6-12 hours but before this 
time, levels of CK-MB or myoglobin have equivalent or superior sensitivity 
(211,212).
1.3.4.2 Detection o f minor degrees o f myocardial damage:
Defining the severity of disease within the spectrum of ACS: Elevated 
levels of cardiac troponins can be detected in some patients with normal levels 
of CK-MB in the serum and no diagnostic ECG changes. The detection of this 
minor degree of ischemic damage is very important in defining the severity of 
disease within the spectrum of acute coronary syndromes.
Risk Stratification in patients with ACSs: Several studies have 
demonstrated an increased number of cardiac events in patients with ACS who 
have elevated serum cardiac troponins, even for those in whom CK-MB levels 
are not elevated (213-216). Recently, large prospective studies showed that 
patients with detectable levels of cardiac troponins have a significantly worse 
prognosis when compared to those without elevated levels (217-219).
In the Global Use of Strategies To open Occluded coronary arteries Ha
(GUSTO Ha) trial, 854 patients who presented within 12 hours of the onset of
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acute myocardial ischemia were studied in a prospective analysis (217). The 
investigators found that elevated serum troponin levels were associated with a 
significantly higher 30 day mortality rate, both in total study population 
(11.8% vs. 3.9%) and in all electocardiographic subgroups examined. The 
Fragmin during Instability in Coronary artery disease (FRISC) study, 
examined peak cTnT over the 24-hour period after initial presentation in 976 
patients with unstable coronary artery disease (218). This study revealed that 
the risk of an adverse cardiac outcome increased as the serum cTnT 
concentration increased, indicating that cTnT measured within the first 24- 
hours provides valuable prognostic information over the following 5 months, 
that is independent of age, hypertension, number of antianginal drugs, and 
initial ECG changes (218). Similarly, in the Thrombolysis In Myocardial 
Infarction Illb (TIME mb) study cTnl was investigated in 1404 patients with 
unstable angina or non-Q wave MI and increased levels of serum cTnl were 
associated with significantly higher mortality at 42 days (3.7% vs 1% in 
patients with undetectable levels of the marker) (219).
1.3.4.3 Assessment in triaging patients with chest pain:
Qualitative assays of both cTnT and cTnl were investigated in patients having
chest pain with a non-diagnostic ECG and were found useful for predicting
risk in this patient population (220). In his trial, Hamm et al. showed that
patients with elevated levels of cardiac troponins had a high incidence of short
term cardiovascular events, whereas those with no detectable levels of cardiac
troponins had a low event rate. Therefore, cardiac troponins can be used to
triage patients for appropriate placement within the hospital. It should be
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noted, however, that in the TEMI m b study as well as in the study by Hamm et 
a l, absence of cardiac troponins does not equate to the absence of 
cardiovascular risk. A proportion of those patients with chest pain and 
undetectable cardiac troponins did still suffer short term cardiovascular events, 
although at a much lower rate (219,220). Hence, those patients with 
undetectable cardiac troponins still require follow-up but less urgent testing to 
determine if their chest pain is related to coronary ischemia.
1.3.4.4 The utility o f cardiac troponins in guiding therapeutic decision 
making:
Pharmacological Therapies; Because of their ability to identify high-risk 
patients, cardiac troponins may facilitate therapeutic decision making. Recent 
studies have shown that increased cardiac troponin concentrations can 
identify patients who would benefit from treatment with low molecular weight 
heparin or glycoprotein Ilb/IIIa inhibitors (221-223). Given the relatively high 
cost of these medications when compared with other standard antithrombotic 
and antiplatelet therapies, it is possible that the measurement of cardiac 
troponins will allow for the optimum utilization of these treatments.
Intervention-based strategy: A recent study of 860 patients with ACSs 
without ST segment elevation showed that early catheter-based intervention 
was associated with low incidence of postintervention Mis and death even in 
patients with increased levels of troponins (224). This suggests that such 
patients may benefit from intervention-based strategy. However, more studies
are required before the recommendation of such strategy.
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1.3*4.5 Differentiation of skeletal from cardiac muscle injury:
In different skeletal muscle diseases: The specificity of the newer assays for 
cardiac troponins allows the differentiation of myocardial damage from 
skeletal muscle injury seen in acute skeletal muscle trauma or chronic muscle 
disease, including patients with Duchenne muscular dystrophy, polymyositis 
and chronic myopathy, as well as well-trained marathon runners (167).
Detection of perioperative myocardial damage: The use of nonspecific 
cardiac markers such as CK, CK-MB and myoglobin have limited usefiilness 
in the detection of perioperative myocardial damage because they are released 
from noncardiac tissues as a consequence of the procedure itself. Because of 
their cardiac specificity, cardiac troponins may be usefiil in diagnosing 
perioperative myocardial damage (225-229).
■Confirmation of suspected MI
■Early and late detection of ME (6 hours -  1 week)
■Detection of minor degrees of myocardial damage
■Assessment in triaging patients with chest pain
■Risk stratification in patients with acute coronary syndromes
■Guide therapeutic decisions with LMWH, Gp Ilb/ Ilia inhibitors and ? PTC A
■Differentiation of skeletal from cardiac muscle injury
■Detection of perioperative ME and assessment of cardioprotective measures
Table 1.8 Diagnostic utility o f cardiac troponins, MI, myocardial infarction;
LMWH, low molecular weight heparin; Gp, Glycoprotein; PTCA, percutaneous 
transluminal coronary angioplasty.
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Class I  recommendations fo r which there is evidence and /  or general
agreement
• In patients with a diagnostic ECG on presentation (ST-segment elevations, 
presence of Q waves or left bundle branch block in two or more 
contiguous leads), the diagnosis of AMI can be made and acute treatment 
initiated without results of acute cardiac marker testing.
• In acute MI patients with diagnostic ECGs, biochemical marker testing at a 
reduced frequency of blood collection (e.g., twice per day) is valuable for 
confirmation of diagnosis, to qualitatively estimate the size of the 
infarction, and to detect the presence of complications such as a 
reinfarction.
• For those emergency departments in which patient triage decisions are not 
made within the first few hours after emergency department presentation, 
the use of an early marker such as myoglobin may be unnecessary. In this 
case, only one definitive marker such as cardiac troponin is needed. The 
frequency of blood collection should also be reduced.
• Chest pain patients with laboratory results for cTnT and cTnl between the 
upper limit of the reference interval and the decision limit for acute MI 
should be labeled as having “myocardial injury”. These patients should be 
admitted and acutely treated to reduce the risks associated with this injury
• The World Health Organization definition of acute MI should be expanded 
to include the use of serial biochemical markers and not be limited to 
enzyme changes. It should be emphasized that rule-out of acute MI cannot 
be made on the basis of data from a single blood collection. However, 
when very specific cardiac markers are used, the presence of an abnormal 
concentration from a single specimen can be highly diagnostic of 
myocardial injury.
• cTnT or cTnl should be used for the detection of perioperative acute MI in 
patients undergoing noncardiac surgical procedures. The same acute MI 
decision limit should be used.
• There is no longer a role for lactate dehydrogenase and its isoenzymes in 
the diagnosis of cardiac diseases.
Table 1.9-A Class I  recommendations o f the National Academy o f Clinical 
Biochemistry for the use o f cardiac markers in coronary artery disease,
(from Wu AHB, Apple FS, Gibier WB, Jesse RL, WarshawMM, Valdes R. 
National Academy o f Clinical Biochemistry Standard o f laboratory practice: 
recommendations for the use o f cardiac markers in coronary artery diseases^ 
1999; 45:1104-1121).
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Class II recommendations for which there is conflicting evidence and/or
divergence o f opinion about its usefulness /  efficacy, but where the weight/
evidence is in its fervor.
• For routine acute MI diagnosis, two biochemical markers should be used: 
an early marker (reliably increased in blood within 6 h after onset of 
symptoms e.g. myglobin) and a definitive marker (increased in blood after 
6-9 h, but has a high sensitivity and specificity for myocardial injury, 
remaining abnormal for several days after onset e.g. cardiac troponin).
• For detection of acute MI by enzyme or protein markers, in the
absence of definitive ECGs, the following sampling frequency is 
recommended:
Marker Admission 2-4 h 6-9 h 12-24 h
- Early (<6 h) x x x (x)
- Late (>6 h) x x x (x)
(x) indicates optional determinations.
• Two decision limits are needed for the optimum use of sensitive and 
specific cardiac markers such as cTnT or cTnl. A low abnormal value 
establishes the first presence of true myocardial injury, and a higher value 
is suggestive of injury to the extent that it qualifies as acute MI, as defined 
previously by WHO.
For assessment of reperfusion status following thrombolytic therapy, at 
least two blood samples are collected and marker concentrations 
compared: time = 0, defined as just before initiation of therapy, and time = 
1, defined as 90 min after the start. From these values, the determination 
of the {a) slope value [(markert = % -  markert=o)/90 min]; (^) absolute 
value of markert = %, in minutes; or (c) the ratio of markert=90/markert = 0 
can be used as the discriminating factor between successfiil and 
unsuccessful reperfiision.
Cardiac troponin (T or I) is the new standard for diagnosis of myocardial 
infarction and detection of myocardial cell damage, replacing CK-MB.
Table 1.9-B Class II recommendations o f the National Academy o f Clinical 
Biochemistry for the use o f cardiac markers in coronary artery disease:
(from Wu AHB, Apple FS, Gibier WB, Jesse RL, WarshawMM, Valdes R. 
National Academy o f Clinical Biochemistry Standard o f laboratory practice: 
recommendations fo r the use o f cardiac markers in coronary artery diseases, 
1999; 45:1104-1121).
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Class III recommendations fo r  which there is evidence and /o r general
agreement that a procedure is not useful or effective.
At this time, there are no data available to recommend use of cardiac 
markers such as cTnT or cTnl for screening asymptomatic patients for the 
presence of acute coronary syndromes. The likelihood of detecting silent 
ischemia is extremely low and cannot justify the costs of screening 
programs. Additionally, there is no evidence that cardiac marker analysis 
of blood following stress testing can indicate the presence of coronary 
artery disease.
Cardiac markers should not be routinely used for infarct-sizing because the 
existing markers are inaccurate in the presence of spontaneous, 
pharmacologic, or surgical reperfusion.
Table 1.9-C Class III recommendations o f the National Academy o f Clinical 
Biochemistry for the use o f cardiac markers in coronary artery disease:
(from Wu AHB, Apple FS, Gibier WB, Jesse RL, Warshaw MM, Valdes R. 
National Academy o f Clinical Biochemistry Standard o f laboratory practice: 
recommendations for the use o f cardiac markers in coronary artery diseases, 
1999; 45:1104-1121).
1.4 PERCUTANEOUS CORONARY INTERVENTION (PCI)
1.4.1 Percutaneous Transluminal Coronary Angioplasty (PTCA)
1.4.1.1 Definition
Percutaneous transluminal coronary angioplasty is a well-established 
technique for myocardial revascularization that involves the use of special 
balloon catheters to dilate narrowed coronary arteries (Fig. 1.17). This 
teqnique was conceived and shepherded into worldwide acceptance and 
application by Andreas R. Gruentzig. He reported his first five cases in 1978 
followed by 50 cases in 1979 (230-231).
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Figure 1,17 Percutaneous transluminal coronary angioplasty (PTCA) (1-4) with 
stenting (5-6). (From cardiology patient atlas, Gold star medical publication, Parke- 
Davis, Maroussi, P: 14,1997).
Development of an over-the-wire balloon catheter by Simpson (in 1982) 
combined with advances in guidewire and balloon catheter technology 
resulted in a steerable balloon catheter system (232). The use of percutaneous 
revascularization has increased dramatically over the recent years, exceeding
130,000 procedures in the United States in 1986 and 400,000 in 1995 (233).
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1.4.1.2 Procedure
After an occlusive coronary atherosclerotic lesion has been identified by 
angiography, the special catheter is passed into the afifected vessel via a 
femoral artery. The patient is anticoagulated using heparin and a guiding 
catheter is passed to the orifice of the diseased coronary artery under 
angiographic control. The balloon catheter, inserted through the guiding 
catheter, is passed across the obstruction. When the position is optimal, as 
judged by fluoroscopy, the balloon is inflated. Several inflations may be 
required and further angiography is performed to assess the results. Aspirin 
(as an antiplatelet drug) is usually started before and nitroglycerin (as a 
coronary vasodilator) might be used during the procedure.
1.4*2 Coronary Stenting
Stents are small expandable wire mesh tubes that can be positioned in a 
diseased vessel segment to create a normal vessel lumen. Intravascular stents 
may be used to support and maintain stretch of a diseased segment of artery, 
thus eliminating acute or chronic recoil, scaffolding disrupted or friable 
atherosclerotic tissue, minimizing contact between blood and thrombogenic 
subintimal arterial wall components, obliterating any local dissection, and 
optimizing coronary blood flow dynamics (234). Stenting, which was 
approved by the Food and Drug Administration (FDA) in 1993, is currently 
performed most often in combination with balloon angioplasty. In addition to 
providing a larger acute lumen than does conventional balloon angioplasty, 
stenting can reduce the incidence of emergency coronary artery bypass
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grafting after PTCA and can reduce the incidence of subsequent restenosis by 
nearly one-third (234). The global use of this technique has increased rapidly 
in recent years (235).
1.4.3 PTCA, coronary stenting and myocardial injury
Minor myocardial infarction, as assessed by elevation of cardiac enzymes after 
percutaneous coronary interventions, is relatively common and reported in 
approximately 8% to 15% of patients undergoing PTCA (236-239). These 
minor degrees of cardiac injury were previously thought to be of little 
consequence, resulting in no permanent sequelae (236,237). However, more 
recent trials confirm an increased risk for future cardiac events in patients with 
elevated postintervention myocardial isoenzyme levels (240-244). There is 
controversy as to the source of mild isoenzyme elevations of CK and CK-MB 
activity in patients undergoing PTCA. The cause of these elevations in cardiac 
markers has been related to distal microembolization, side branch occlusion, 
or abrupt vessel closure. It is more common following multivessel procedures 
and after directional coronary atherectomy (243,245). Enzyme elevations, in 
the setting of percutaneous interventions, may or may not reflect irreversible 
ischemia (246-250).
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Biochemical Detection of Minor Myocardial Injury
After Elective Uncomplicated Successful 
Percutaneous Coronary Intervention in Patients with Stable Angina.
CHAPTER- 2
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2.1 FIRST HYPOTHESIS
Front the literature: Serum cardiac troponins are sensitive and specific 
markers for the detection of minor myocardial injury. They have been used to 
assess prognoses in patients with unstable angina and acute myocardial 
infarction (219, 251-253). However, they have been rarely used to monitor 
myocardial injury after PCI in patients with stable angina. The degree of 
minor myocardial damage associated with PCI may be related to the serum 
concentrations of cardiac markers.
Hypothesis: In addition to minor myocardial damage being caused 
following PCI in patients with unstable angina, we believe that it also occurs 
in patients with stable angina who have had a successful procedure. This 
minor injury may be best detected by measuring cardiac troponin levels in 
serum after the procedure.
2.2 SECOND HYPOTHESIS
From the literature: The cause of the minor injury following PCI may not be
fiilly explained by a single aetiological factor. It is important to understand
more fully the mechanism of minor myocardial injury after coronary
intervention in order to prevent its occurrence as well as its possible adverse
sequelae. No study has ever related the etiology of minor myocardial injury to
the state of systemic inflammation. Coronary interventions can induce an
inflammatory response and the release of inflammatory markers by causing
plaque rupture, hematoma, arterial wall damage, release of inflammatory and
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chemotactic factors with leukocytes and platelet activation (153,154). The 
acute inflammatory response to PCI is strongly related to preexisting degree of 
systemic inflammation reflected by baseline markers of inflammation levels 
(155). Therefore, more intense inflammatory response is expected in patients 
with increased baseline markers of inflammation. This exaggerated response 
may be associated with more leukocyte activation leading to more secretion of 
inflammatory mediators, growth factors, and tissue factors which may 
aggravate endothelial damage, trigger coronary spasm, enhance smooth 
muscle cell proliferation, stimulate platelet aggregation and directly initiate the 
extrinsic pathway of coagulation (254-157). These intense cellular and 
molecular responses can cause small vessel occlusion and/or 
microembolization that will lead to MMI. With this in mind, and with the 
observation that increased risk associated with systemic inflammation may be 
modified by certain preventive therapies, markers of inflammation may help to 
identify those who would benefit most from these pharmacological therapies 
before coronary interventions.
2nd Hypothesis: Minor myocardial injury after PCI may be caused by the 
occlusion of small side-branch or intramyocardial vessels which may be due in 
part to the instability of the procedural coronary vessel, and may relate to 
circulatory concentration of inflammatory markers such as GRP.
2.3 THIRED HYPOTHESIS
From the literature'. Recent studies demonstrated that minor elevations of
creatine kinase-MB (CKMB) after coronary interventions are associated with
adverse late outcome (240-244). Patients with such elevations more often had
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cardiac complications such as myocardial infarction, cardiac death, or need for 
coronary intervention. However, long term outcome of patients with such 
minor injury has been rarely assessed (258). Relating the occurrence of minor 
myocardial injury after coronary intervention to outcome have important 
implications for the intervintional cardiology practice. With this in mind, 
preventing the occurrence of this injury will prevent its possible adverse long­
term sequelae.
3ed Hypothesis: The long-term prognoses may be determined by the 
occurrence of the minor myocardial damage.
2.4 SPECIFIC OBJECTIVES OF THE STUDY
In order to test the above hypotheses we recruited a group of patients vyith 
stable angina undergoing PTCA with or without coronary stenting. Serum 
cardiac troponin levels were measured before and after coronary intervention, 
and compared with changes in serum CKMB. Changes in serum cardiac 
troponin levels were also related to the development of small side branch 
occlusion after the procedure. Base line serum levels of high-sensitivity CRP, 
IL-6, TNF-a, and sICAM-1 were related to the occurrence of minor 
myocardial injury after elective uncomplicated successfiil procedure. Patients 
were followed up for 24 months for cardiac events which included recurrent 
angina, nonfatal myocardial infarction, cardiac death, repeat PCI, or coronary 
bypass surgery.
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3.1 PATIENT POPULATION
3.1.1 Subjects
Ninety eight consecutive Saudi patients (75 men and 23 women with an age 
range = 35 -  79, and mean ± SD and 53 ± 11 years) with stable angina who 
were admitted electively for cardiac catheterization and had uncomplicated 
successful PTCA with or without coronary stenting were included in the study. 
The age ranges for men and women were 35-79 and 42-75 years, respectively. 
All patients gave informed consent and the local ethics committee approved 
the study.
3.1.2 Inclusion criteria
•  All patients included in the study had stable angina, defined clinically by 
transient chest pain, precipitated by physical activity or emotional upset and 
relieved by rest within a few minutes, and a positive stress test for ischemia.
•  All patients had normal renal fiinction, reflected by normal serum 
creatinine, before undergoing coronary interventions.
•  All patients included in this study had a successful procedure. "Success" 
was defined as an increase of >20% in luminal diameter with a final percent 
diameter stenosis of <50% and no major complications such as emergency 
bypass surgery or myocardial infarction.
3.1.3 Exclusion criteria
Patients were excluded if they had one of the following:
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• An acute myocardial infarction within 2 weeks (defined by history of 
typical chest pain, electrocardiographic changes and abnormal levels of 
cardiac markers).
• Elevated cardiac markers before cardiac catheterization.
• 12-lead resting electrocardiogram (ECG) with right or left bundle branch 
block, interventricular conduction delay or paced rhythm (abnormalities that 
can mask ischemic changes caused by significant myocardial damage).
3.1.4 Patient characteristics
Patient data obtained from the studied subjects included:
• Age (yr.)
• Gender (male/female)
• Baseline body Mass Index (kg/m^)
• Risk factors (smoking, diabetes mellitus, hypertension, 
hypercholesterolemia)
• Medications (statin-type drugs, beta blockers, calcium channel blockers, 
nitrates, angiotensin converting enzyme inhibitors).
3.2 BALLOON ANGIOPLASTY AND STENT IMPLANTATION
3.2.1 Procedure
• Balloon angioplasty and stent implantation were performed according to 
standard clinical practice by the femoral approach.
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• Results before and after coronary interventions were evaluated with on­
line quantitative coronary angiography (Digital Cardiac Imaging, Philips 
Medical Systems, Best, The Netherlands).
• All patients received aspirin (81 mg daily), ticlopidine (Sanofi Winthrop, 
Gentilly, France) (250 mg twice daily) and a calcium channel blocker or 
nitrate before the procedure.
• A total of 10,000 U of intravenous heparin (Bum, Melsungen, Germany) 
was administered at the beginning of the procedure followed by additional 
boluses as needed to maintain an activated clotting time >300 seconds.
3.2.2 Angiographic characteristics
Angiographic data obtained fi-om the coronary angiograms included:
• Type of coronary artery disease (single-vessel, multivessel).
• Procedure (PTCA, Stenting).
• Involved artery (Left anterior descending. Right coronary artery. Left 
circumflex coronary artery).
• Degree of Stenosis (%).
•  Lesion type (A, B, C, According to classification o f the American Heart 
Association and the American College o f Cardiology) (52).
- Type A  lesion -  Discrete (<10 mm in length), concentric and non- 
angulated.
- Type B lesion -  Tubular (10-20 mm in length), eccentric, 
moderately angulated.
- Type C lesion -  Diffuse (>20 mm in length), with excess tortuosity 
o f proximal segment and extremely angulated.
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3.2.3 Procedural Characteristics
Data related to the procedure included:
• Total number of inflations.
• Total time of inflation (sec).
• Maximal inflation pressure (atm).
• Balloon diameter (mm).
• Occurrence of side-branch occlusion diagnosed by the angiogram.
3.3 ELECTROCARDIOGRAPHIC MONITORING AND ECG
• ST-segment monitoring was begun before PTCA was started and was 
continued during the whole procedure.
• All patients were transferred to the ward and monitored. The patient's ECG 
was monitored continually during their stay in the hospital.
• A 12-lead ECG was taken before, immediately after, and the day after 
PTCA or coronary stenting.
3.4 FOLLOW-UP DATA
• The purpose of this part of the study was to evaluate prospectively the 
frequency, correlates, and prognostic significance of elevation in cardiac 
markers after elective uncomplicated successful PCI in patients with stable 
angina.
• Different cut-off values (0.5,1.0,2.0, 1.5 and 2.5 pg/L) were used to study 
the power of the cTnl measurements in predicting outcome.
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• All patients were followed up after discharge fi’om the hospital to record 
cardiac events (recurrent angina, nonfatal myocardial infarction, cardiac 
death, repeat PCI, or coronary bypass surgery).
• All patients were followed up for exactly 24 months . Information was 
obtained by review of the patient’s ongoing records and by direct phone 
contact.
3.5 BLOOD SAMPLES
• In the first 50 patients, 15 ml of venous blood was drawn before and 6, 24, 
and 48 hours after coronary intervention. In the remaining 48 patients, blood 
samples were drawn before and 6,12, and 24 hours after the procedure.
• The blood was allowed to clot and samples were centrifuged at 1900 g  for 
10 minutes at room temperature.
• Serum CK and CKMB were measured immediately and the serum was 
fi*ozen at - 40°C until cardiac troponins and inflammatory marker 
measurements, with one thaw cycle, keeping in mind that storage stability of 
the tested markers is up to one year at - 40°C.
3.6 ANALYTIC TECHNIQUES
3.6.1 Analysis of Cardiac Markers
Evaluation of the studied cardiac markers for the detection of myocardial 
injury was done just before the project was started (259), results of the 
predictive values for these markers and myocardial injury is shown in table 
3.1.
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Calculated
parameters Sensitivity Specificity
(+) Predictive 
value
(-) Predictive 
value
CKMB 92% 89% 89% 96%
cTnT 100% 96% 93% 100%
cTnl 100% 99% 98% 100%
Table 3.1 predictive values fo r  these markers and myocardial injury, 
CKMB = creatine kinase, cTnT = cardiac troponin T, cTnl = cardiac troponin I
3 .6 .1 .1  Creatine Kinase and CK-MB
• Total CK activity (reference value <195 lU/L) and CK-MB activity 
(reference value < 24 lU/L) were measured on a Hitachi 917 (Boehringer 
Mannheim) analyzer using a kinetic enzymatic method.
• Principle of the procedure;
i . CK (N-acetylcystine_Activation Method):
CK is rapidly inactivated by oxidation of sulfhydryl groups in the active 
center. The enzyme can be reactivated by addition of N-acetylcystine. 
Interference by adenylate kinase is prevented by the addition of diadenosine 
pentaphosphate and (AMP).
Test Principle (Determination o f CK using reverse reaction):
CK
Creatine phosphate + ADP - - Creatine + ATP
Hexokinase
Glucose + ATP ^   glucose-6-P + ADP
G-6-Phosphatase
Glucose-6-P + NADP ^ ^  gluconate-6-P + NADPH + H^
The photometrically measured rate of formation of NADPH at a wavelength 
of 340 nm is proportional to the CK activity.
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il. CK-MB:
CKMB consists of the subunits CK-M and CK-B. By means of a specific 
anti-CK-M antibody the CK-M subunits are inhibited without the CK-B 
subunits being affected. The remaining CK-B activity which corresponds 
to half of the CKMB activity is determined using the CK (N-acetylcystine) 
activation method (as above). Inter-assay coefficients of variation (C Vs) 
were 8.8% at 9.3, 5.3% at 33.1 and 3.9% at 113.7 lU/L.
3 .6 .1 .2  Cardiac Troponin T (cTnT)
• Cardiac TnT was assayed by an electron chemiluminiscence immunoassay 
on a 2010 Elecsys System (Roche Diagnostic, formerly Boehringer 
Mannheim, Mannheim, Germany). The reference value of cTnT utilizing this 
method to assess for myocardial injury was 0.1 ng/ml (as evaluated in our 
laboratory for Saudi subjects) with a lower detection limit of 0.01 ng/ml. 
Inter-assay coefficients of variation (CVs) were 9.1% at 0.009 and 9.0% at 
4.37 ng/ml.
• Principle of the procedure:
i. In the first incubation step: serum samples are incubated with a 
biotinylated monoclonal anti-troponin T antibody (mouse) and a 
monoclonal TnT specific antibody (mouse) labeled with (2,2-bipyridyl) 
ruthenium (II) complex to form a sandwich complex.
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ii. The second incubation step: Streptavidin-coated microparticles are added 
to the complex that becomes bound to the solid phase via the interaction 
of biotin and streptavidin (fig. 3.1).
iii. The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the electrode. 
Unbound substances are then removed with Procel (phosphate buffer 300 
mmol/L, triproylamine 180 mmol//L; detergent < 0.1%; preservative, pH 
6.8). Application of a voltage to the electrode then induces 
chemiluminescent emission that is measured by a photomultiplier.
iv. Results are determined using a calibration curve that is instrument 
specifically generated by 2-point calibration and a master curve provided
Ruthenium (II) 
Complex
Streptavidin Biotin Antigen 
Antibody 
Peptide 
Nucleic acidParamagnetic microparticle
via the reagent bar code.
Figure 3.1 The basic immunoassay principle o f the Elecsys machine, 
(Roche Diagnostic, formerly Boehringer Mannheim, Mannheim, Germany).
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• Sample freeze-thaw stability
Aliquots of serum samples (with high and low cTnT values) were stored at -  
40 °C and thawed two times and cTnT levels were determined. There was no 
significant change in cTnT concentration between 0 and the freeze-thaw 
cycles [values were (0.13 and 0.14) and (0.45 and 0.47) ng/ml].
3 .6 .1 .3  Cardiac Troponin I  (cTnl)
# Cardiac Tnl assays were performed on an AxSYM random access 
immunoanalyzer (Abbott Laboratories, Abbott Park, Illinois, USA) using 
microparticle enzyme immunoassay technology with a reference value of 2 
ng/ml (as evaluated in our laboratory for Saudi subjects) and a lower 
detection limit of 0.3 ng/ml. Inter-assay coefficients of variation (CVs) were 
8.2% at 2.1, 7.6% and 10.9 and 6.8% at 34.9 ng/ml.
• Principle of the Procedure:
i. AxSYM Troponin I is a microparticle enzyme immuno assay (MELA) for 
quantitative determination of cardiac Troponin I in human serum or 
plasma
ii. MEIA technology (fig. 3.2) uses a solution of suspended, submicron-sized 
latex particles that are coated with a specific capture antibody (mouse 
monoclonal) for cardiac Troponin I.
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iii. The first step is the incubation of the sample with the capture Ab, the 
reaction mixture is then transferred to an inert glass fiber matrix. 
Irreversible binding of the microparticle causes the immune complex to be 
retained by the glass fibers while the reaction mixture flows rapidly 
through the large pores in the matrix.
iv. Antitroponin I (goat polyclonal) alkaline phosphatase conjugate is added 
to the glass fiber matrix prior to the addition of 4-methylumbelliferyl 
phosphate (MUP). The conjugate catalyzes the hydrolysis of MUP to 
methyumbelliferone (MU). Measurement of the fluorescent MU as it is 
generated on the matrix is proportional to the concentration of the analyte 
in the sample.
• Sample freeze-thaw stability
Aliquots of serum samples (with high and low cTnl values) were stored a t-  
40 °C and thawed two times and cTnl levels were determined. There was no 
significant change in cTnl concentration between 0 and the fi-eeze -thaw 
cycles [values were (1.0 and 1.1) and (10.6 and 10.4) ng/ml].
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Figure 3.2 Typical microparticle enzyme immuno assay (MEIA) schematic 
reaction sequence o f the AxSYM  system, (Abbott Laboratories, Abbott Park, 
Illinois, USA)
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3.6.2 Markers of inflammation
The IMMULITE system used for the measurement of CRP, TNF-a and IL-6 
was evaluated by the investigator before the beginning of the project (260).
3.6.2.1 High Sensitivity C-Reactive Protein Assay
• C-Reactive Protein (CRP) was measured in all subjects by a 
chemiluminescent enzyme labeled immunometric assay IMMULITE system 
(Diagnostic Products Corporation, Los Angeles, California, USA) with a 
reference value of 6 mg/L (i.e., the upper value found in 95% of healthy 
Saudi controls ) and a lower detection limit of 0.1 mg/L. Inter-assay 
coefficients of variation (CVs) were 7.7% at 1.04 and 5.8% at 13.97 mg/L.
•  Principle of the Test
i. All samples were diluted 1:101 (10 pL of serum + 100 pi CRP sample 
diluent which is CRP free protein/buffer matrix).
ii. The prediluted patient sample, a ligand-labeled anti CRP murine 
monoclonal antibody and alkaline phosphatase (bovine calf intestine) 
labeled anti CRP rabbit polyclonal antibody were simultaneously 
introduced into the test unit containing an anti-ligand-coated polystyrene 
bead with intermittent agitation. During this time, CRP in the sample 
forms an antibody sandwich complex that in turn binds to anti-ligand on 
the solid phase. Unbound conjugate was removed by a centrifugal wash 
(the test unit was spun at high speed about the vertical axis. Reaction fluid
was forced up and completely captured in the sump chamber (Fig. 3.3).
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Figure 3.3 Centrifugal wash of the IMMULITE test unit (Diagnostic 
Products Corporation, Los Angeles, California, USA).
iii. The chemiluminescent substrate (a phosphate ester of adamantyl
dioxetane) was then added and the test unit is incubated for further 10 
minutes, during which the substrate undergoes hydrolysis in the presence 
of alkaline phosphatase to yield an unstable intermediate (unstable 
dioxetane (Fig. 3.4). The continuous production of this intermediate results 
in the sustained emission of light thus improving precision by providing a 
window for multiple readings.
iv. The bound complex-and also the photon output, as measured by the
luminometer is proportional to the concentration of CRP in the sample.
V. Patient results were automatically corrected for the dilution factor.
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Figure 3.4 Chemiluminescent substrate reaction o f the IMMULITE system,
(Diagnostic Products Corporation, Los Angeles, California, USA)
•  Critical differences and inraindividual variability
Because of the high intraindividual variability (see section 1.2.1.2), CRP 
levels may vary significantly in some persons. Individuals with normal levels 
of about 1.5 mg/L may have increases up to 10 mg/L during intercurrent 
(sub)clinical disease associated with the occurrence of mild clinical symptoms 
such as cough or backache. These slight increases of CRP usually persist for 
days to weeks. Hence, a single determination of CRP may not yield reliable
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information about baseline levels, even when reproducibility assay is used 
(261). Therefore, it is possible that repeated determinations (for example, 3 
times) at monthly intervals might provide a better estimation of baseline 
levels. This issue becomes very important in view of the fact that in the large 
epidemiological studies, the difference in CRP levels between individuals with 
increased risk of cardiovascular events and those with low risk was only 
slight, albeit significant (132).
3.6.2.2 Tumor necrosis factor a  (TNF-^ a)
• Tumor necrosis factor a  (TNF-a) concentrations were measured in all 
subjects using an IMMULITE system with a solid phase two-site 
chemiluminescent enzyme immunometric assay kit (Diagnostic Products 
Corporation, Los Angeles, California, USA) with a reference value of 9.4 
pg/ml (i.e., the upper value found in 95% of healthy Saudi controls ) and a 
lower detection limit of 1.7 /?g/ml. Inter-assay coefficients of variation (CVs) 
were 6.4% at 17.0 and 5.3% at 33.0 /?g/ml.
• Principle of the Procedure
i. A solid phase polystyrene bead enclosed within the IMMULITE test unit 
is coated with murine monoclonal anti-TNFa antibody.
ii. The patient samples and alkaline phosphatase (bovine calf intestine) 
labeled anti-TNFa rabbit polyclonal antibody were incubated for 60 
minutes at 37°C in the test unit with intermittent agitation, TNFa in the
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sample is bound to form an antibody sandwich complex. Unbound 
conjugate is then removed by a centrifugal wash, after which substrate (a 
phosphate ester, of adamantyl dioxetane) is added and the test unit is 
incubated for further 10 minutes.
iii. The chemiluminescent substrate undergoes hydrolysis in the presence of 
alkaline phosphatase to yield an unstable intermediate (unstable 
Dioxetane). The continuous production of this intermediate results in the 
sustained emission of light, thus improving precision by providing a 
window for multiple readings.
iv. The bound complex and thus also the photon output as measured by the 
luminometer is proportional to the concentration of TNFa in the sample.
3.6.2.3 Interlekin-6 (IL-6)
• IL-6 concentrations were measured in all subjects by a solid phase two-site 
chemiluminescent enzyme immunometric assay kit (Diagnostic Products 
Corporation, Los Angeles, California, USA) with a reference value of 12.3 
/7g/ml (i.e., the upper value found in 95% of healthy Saudi controls) and a 
lower detection limit of 2.1 /?g/ml. Inter-assay coefficients of variation (CVs) 
were 8.4% at 11.13 and 5.7% at 29.6/?g/ml.
• Principle of the Procedure
i. A solid phase polystyrene bead enclosed within the IMMULITE test unit
is coated with monoclonal murine anti-IL 6 antibody.
80
ii. The patient samples and alkaline phosphatase (bovine calf intestine) 
labeled anti-IL 6 polyclonal sheep antibody were incubated for 
approximately 60 minutes at 37®C in the test unit with intermittent 
agitation. IL-6 in the sample forms a sandwich complex with the two 
antibodies which recognize different epitopes of the IL-6 molecule. The 
sandwich is bound to the solid phase by the ligand-antiligand bridge. 
Unbound conjugate is then removed by a centrifugal wash, after which the 
substrate (a phosphate ester of adamantyl dioxetane) is added and the test 
unit is incubated for a fiirther 10 minutes.
iii. The chemiluminescent substrate undergoes hydrolysis in the presence of 
alkaline phosphatase to yield to unstable intermediate (unstable 
Dioxetane). The continuous production of this intermediate results in the 
sustained emission of light, thus improving precision by providing a 
window for multiple readings. The bound complex and thus also the 
photon output, as measured by the luminometer is proportional to the 
concentration of IL-6 in the sample.
3.6.2 4 Soluble Intercellular Adhesion Molecule-1 (sICAM-1)
• Soluble ICAM-1 concentrations were measured in all subjects by enzyme 
linked immunosorbent assay (ELISA) kits (MedSystems Diagnostics 
GmbH, Vienna, Austria) with a reference value of 450 wg/ml (i.e., the 
upper value found in 95% of healthy Saudi controls ) and a lower 
detection limit of 0.3 wg/ml.
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• Principle of the Procedure (fig. 3.5)
i. Microwell strips coated with anti-sICAM monoclonal antibody (murine) 
were removed from the alumitium pouches immediately prior to use. They 
were rinsed twice with wash solution (phosphate buffered saline) and used 
immediately.
ii. The standard provided in the kit contained sICAM-1 of a concentration of
10 ng/ml. Serial dilutions of the standard were made using the sample 
diluent provided. A standard curve was run in duplicate for each assay 
using 100 pi from each of the following concentrations (10,5,2.5,1.25, 
0.625 ng/ml).
iii. One hundred microliters of sample diluent was added to the blank well and 
was run in duplicate. One hundred microliters pre diluted patient samples 
and controls (1:100) were added to the wells. Fifty microliters of 
horseradish peroxide conjugate (HRP-conjugate) was added to all wells, 
the plate was covered and incubated at room temperature for one hour on a 
rotating mixer (Microshaker A from Dynatech Product) set at 100 rpm.
iv. Tetramethyl benzidine substrate solution (TMB) was prepared a few 
minutes prior to use by mixing equal amounts of substrate solution I 
(tetramethyl benzidine) with substrate solution II (0.02% buffered 
hydrogen peroxide) and 100 micro liters of the prepared TMB was added to 
each well.
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V . The microwell strips were incubated at room temperature for about 10
minutes on a rotating mixer set at 100 rpm. The enzyme reaction was 
stopped quickly by adding 100 microliters of stop solution (IM phosphoric 
acid). Results were read immediately after the stop solution was added.
vi. The absorbance of each microwell was read on an ELISA plate reader 
(ELISA Processor II Plus from Dade Behring) using 450 nm as the 
primary wavelength and 620 nm as the reference wavelength. The 
absorption of the standard, the controls and samples were determined and 
the precision data was calculated for each standard (Table 3.2).
vii. A standard curve was created (Fig. 3.6) by plotting the mean absorbance 
for each standard concentration on the ordinate against sICAM-1 
concentration on the abscissa and the best fit curve was drawn through the 
points of the graph. sICAM-1 concentration of the samples and controls 
were determined using the standard curve, and the results were multiplied 
by the dilution factor (xlOO).
• Sample freeze-thaw stability
Aliquots of serum samples (with high and low sICAM-1 values) were stored at 
-  40 and thawed two times and sICAM-1 levels were determined. There 
was no significant change in sICAM-1 concentration between 0 and the freeze 
-thaw cycles [values were (239 and 244) and (740 and 752) ng/ml].
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Figure 3.5 Summary o f the sICAM ELISA test
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Standard concentration 
ng/ml
Mean absorbance 
450 nm
%CV
10 1.372 0.2
5 0.684 2.16
2.5 0.322 9.89
1.25 0.173 6.96
0.625 0.110 1.7
Blanks 0.018 15.5
Table 3.2 Mean absorption and calculated precision (%oCV) 
values fo r each standard used in our study.
1.4
s
0.8
0.6
0.4
0.2
CONCENTRATION ng/ml
Figure 3.6 Representative standard curve from  our work fo r  sICAM-1 
ELISA. Plotting the mean absorbance for each standard against sICAM-1 
concentration created this standard curve. Soluble ICAM-1 concentration of 
the samples and controls were determined using the standard curve.
3.7 STATISTICAL ANALYSIS
Continuous variables were expressed as mean ± SD and were compared 
by the Student’s t test.
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• Categorical variables were compared by the Fisher's exact test.
- Comparison was made between patients with (Troponin +) and 
without (Troponin -) post-procedure serum cardiac troponin marker 
values above the reference range with regard to different patient, 
angiographic and procedural characteristics as well as to the 
occurrence of side branch occlusion.
- Comparison was also made between the PTCA and the stent groups 
as well as between the patients with normal and those with 
abnormal cardiac markers.
- Comparison was also made between the troponin positive and the 
troponin negative groups with regard to the development of cardiac 
events during the follow-up period.
• Because CRP, TNF-a, IL-6 and ICAM were skewed, values were 
expressed as median and inter-quartile ranges, representing the 25* and 
75* percentile of the distribution, and log transformation was applied 
to normalize the data for analysis.
• Positive and negative predictive values with the corresponding 
sensitivity and specificity figures for cTnl and adverse cardiac events 
that occurred during the follow-up period were calculated for the 
different used cut-off values.
• Follow-up events were analyzed with actuarial methods and Kaplan -  
Meier curves were constructed. Differences in late events among cTnl 
positive and cTnl negative were compared with the log rank test.
• Results with ap  value < 0.05 (two tailed) were considered statistically 
significant.
• All analysis were performed with SPSS 9.0 (SPSS Inc.).
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Biochemical Detection of Minor Myocardial Injury
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CHAPTER- 4
Detection by Cardiac Markers
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4.1 RESULTS
4.1.1 Patients characteristics (Appendix-1).
• A total of 98 patients, 75 males and 23 females, were studied (table 4.1).
• Age ranged from 35 to 79 years (mean age = 53 ± 11). The age ranges for 
men and women were 35-79 and 42-75 years, respectively.
• Assessed risk factors included smoking (39 patients), diabetes mellitus (56
patients), hypertension (51 patients), and hypercholesterolemia (82 patients).
• Twenty seven patients had PTCA alone and 71 had coronary stenting after 
PTCA. (The diameter o f the reference vessels was >2.5 mm in all patients 
who received stents).
4.1.2 Biochemical markers (Appendix-1)
• Preprocedural values of studied cardiac markers were below the reference 
range in all patients
• At 6 hours 3 patients had elevated CKMB, 13 had elevated cTnT and 14 
had elevated cTnl.
• Abnormal peak values of one or more markers at 24 hours after coronary 
intervention were observed in 28 patients (29 %); of these, 5 had PTCA 
alone (19% of PTCA patients) and 23 had PTCA with stenting (32% of 
stenting patients).
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Variable MeaniSD or n(%)
Age (yr) 53 ±11
Gender
male 75 (77)
female 23 (23)
Risk factors
Smoking 39 (40)
Diabetes mellitus 56 (57)
Hypertension 51 (52)
Hypercho lesterolemia 82 (84)
Procedure
PTCA 27(28)
Stenting 71(72)
Table 4.1 Patients data fo r  the detection o f minor myocardial injury 
by cardiac markers.
89
4.1.3 Frequency of abnormal markers (Table 4.2)
• CK-MB activity was elevated significantly in 6 patients (6.1%), 1 
from the PTCA group (3.7%) and 5 from the stenting group 
(7.0%).
• cTnT  was elevated significantly in 18 patients (18.4%), 3 from the 
PTCA group (11.1%) and 15 from the stenting group (21.1%).
• cTnl was elevated significantly in 26 patients (26.4%), 5 following 
PTCA alone (18.5% ofPTCA patients) and 21 following stenting 
(29.6% of stenting patients).
•  *The frequencies o f abnormal cTnl and cTnT were significantly 
higher than that o f CK-MB after coronary intervention (26.4% and 
18.4% vs. 6.1%;p  = 0.00016and 0.015, respectively).
• The frequencies o f abnormal cTnl and cTnT in the stent group 
were not significantly higher than those in the PTCA group (18.5% 
and 11.1% v& 29.6% and 21.1%; p  = 0.316 and 0.382, 
respectively).
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Abnormal
markers
PTCA 
(n = 27)
Stent 
(n = 71)
Total 
(n = 98)
CK-MB 1 (3.7%) 5 (7.0%) 6 (6.1%)
cTnT 3(11.1%) 15(21.1%) 18 (18.4%)*
cTnl 5 (18.5%) 21 (29.6%) 26 (26.4%)**
Table 4.2 Number and frequency o f patients with post-procedure serum
cardiac marker values above the reference range.
• *Differences between cTnT and CKMB are significant (p = 0.015).
• **Differences between cTnl and CKMB are significant (p = 0.00016).
• The frequencies of abnormal cTnT in the stent group were not 
significantly higher than those in the PTCA group {p ~ 0.382)
• The frequencies of abnormal cTnl in the stent group were not significantly 
higher than those in the PTCA group (p = 0.316)
CK-MB, creatine kinase MB activity; cTnT, cardiac troponin T; cTnl, cardiac 
troponin I; PTCA, percutaneous transluminal coronary angioplasty.
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4.1.4 Demographic characteristics
• Patient variables of both troponin positive and troponin negative groups 
are shown in table 4.3.
• Abnormal cardiac troponin values post procedure were not significantly 
related to age, gender or associated risk factors including, smoking, diabetes 
mellitus, hypertension, and hypercholesterolemia.
4.1.4 Angiographic Variables (Appendix-2)
• Angiographic variables of both troponin positive and troponin negative 
groups are shown in table 4.3.
• Abnormal cardiac troponin values post procedure were not significantly 
related to procedure (PTCA with or without stenting), lesion type (A, B or 
C) or degree of stenosis.
• More patients with left circumflex coronary artery disease were noticed in 
the troponin positive patients. This is most likely an incidental finding that 
does not have a clinical significance.
92
Characteristics
Troponin (+) 
(n = 28)
Troponin (-) 
(n = 70)
Age (yr.) 56 ±13 55±11
Gender (male/female) 18/10 57/13
Risk factors
Smoking 11(39) 28(40)
Diabetes mellitus 17(61) 39(56)
Hypertension 15(54) 36(51)
Hypercholesterolemia 25(89) 57(81)
Procedure
PTCA 5 (18) 22 (31)
Stenting 23 (82) 48 (69)
Involved artery
Left anterior descending 13 (46) 36(56)
Right coronary artery 5(18) 23 (33)
Left circumflex* 10 (36) 8(11)
Lesion type **
A 1(4) 9(13)
B 18 (64) 45 (64)
C 9(32) 16 (23)
Stenosis (%) 89±8 86 ± 8
Table 4.3 Demographic and angiographic characteristics o f patients with (Troponin 
+) and without (Troponin -) post-procedure serum cardiac troponin marker (I or I)  
values above the reference range. Data are given as mean ± SD or number of patients 
(%). Differences between the two groups are not significant (except for left circumflex 
artery, *P = 0.008).
**According to classification of the American Heart Association and the American 
College of Cardiology:
Type A lesion -  Discrete (<10 mm in length), concentric and non-angulated;
Type B lesion -  Tubular (10-20 mm in length), eccentric, moderately angulated;
Type C lesion -  Diffused (>20 mm in length), with excess tortuosity o f proximal 
segment and extremely angulated
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4.1.6 Procedural Characteristics
Abnormal cardiac troponin values post procedure were significantly related to 
total time of balloon inflation (223 ±128 vs. 170 ± 105 seconds; p  = 0.008) 
and maximum inflation pressure time (12.9 ± 2.3 vs. 12.0 ± 2.7 atm; p  = 0.04). 
On the other hand differences between the two groups were not significant for 
the total number of inflations, longest single inflation, and balloon diameter 
(Table 4.4).
Side-branch occlusion was noticed in 36% (10/28) of the troponin positive 
patients and in 6% (4/70) of the troponin negative group, p  = 0.00047. Nine of 
the 10 patients in the troponin positive group who developed side-branch 
occlusion were positive for cTnl, 6 for cTnT and only 2 for CK-MB. Also 9 
out of these 10 cases occurred after stenting.
Characteristics
Troponin (+) 
(n = 28)
Troponin (-) 
(n = 70) P  value
Total number of inflations 5.2 ±1.7 4.5 ± 2.2 0.125
Total time of inflation (sec) 223 ± 128 170 ±105 0.008
Longest single inflation (sec) 59 ±19 53 ±16 0.07
Inflation maximal pressure ( atm) 12.9 ±2.3 12.0 ± 2.7 0.04
Balloon diameter (mm) 2.95 ±0.30 3.00 ± 0.43 0.20
Occurrence of side-branch occlusion 10 (36) 4(6) 0.0005
Table 4.4 Procedural Characteristics fo r  patients with (Troponin +) and
without (Troponin -) post-procedure serum cardiac troponin marker (I or T) 
values above the reference range. Data are given as mean ± SD or number of 
patients (%).
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4.2 DISCUSSION
Elevation of cardiac enzymes after percutaneous coronary interventions is 
relatively common and reported in approximately 8% to 15% of patients 
undergoing PTCA (236-239). Minor myocardial injuries diagnosed by these 
enzyme elevations were previously thought to be relatively benign, resulting 
in no permanent sequelae (236,237). However, more recent trials confirm an 
increased risk for fiiture cardiac events in patients with elevated post­
intervention myocardial isoenzyme levels (240,244). There is controversy as 
to the source of mild isoenzyme elevations of CK and CKMB activity in 
patients undergoing PTCA, but such elevations have been linked to distal 
microembolization, side branch occlusion, multivessel procedures, abrupt 
vessel closure and directional coronary atherectomy (243,245).
In 98 consecutive patients with stable angina treated by elective PTCA with or 
without stenting, 6 (6.1%) had elevation above the reference range of CKMB 
activity. This result is consistent with other series that have reported elevation 
of both creatine kinase and CKMB activity (>5%) from 0% to 11.5% after 
uncomplicated coronary interventions (239,243,262,263). Although it has 
been recommended to monitor CK-MB levels after coronary interventions 
(214), this marker is not sensitive for the detection of minor myocardial injury 
and does not meet the current needs for a highly sensitive marker of minor 
myocardial tissue damage (150,168).
The cardiac troponins are highly sensitive and specific markers for myocardial 
injury (150,168,213-219). However, there are few published data on their use
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for monitoring of myocardial injury after successful PTCA (2 6 2 -2 6 5 ). Our 
results show that overall 26.4%  of the patients had cardiac troponins above the 
reference range after elective uncomplicated successfiil PTCA with or without 
stent implantation. This result is consistent with previous studies showing a 
very high diagnostic sensitivity of cTnT versus CK-MB in the detection of 
minor myocardial injury after PTCA (262 ,2 6 3 ,2 6 6 ). There is no gold standard 
for detecting myocardial injury nor have there been many studies assessing 
cardiac troponins after coronary stenting (258). In this present study we have 
demonstrated that cTnl and cTnT were more sensitive than CK-MB (26.4%  
and 18.4%  vs 6.1% , p  = 0 .00016  and 0 .015 , respectively). Cardiac Tnl 
appears to significantly identify a higher proportion of patients with what 
appears to be minor myocardial injury after elective uncomplicated successful 
PTCA with or without stenting. Although the incidence of elevated serum 
cTnl and cTnT was higher in the stent group than in the PTCA group (29.6%  
and 21.1%  vs 18.5%  and 11.1%  respectively), these values did not reach 
statistical significance (p = 0 .3 1 6  and 0 .3 8 2 , respectively). 10 out of the 28  
cases of the troponin positive patients had side-branch occlusion and of these 9 
occurred after stenting. The higher balloon catheter dilatation pressure used in 
the stent group may be the cause of deeper injury of the vessel wall, which 
may act as a stimulus for platelet deposition and microembolization. Hence the 
use of Ilb/IIIa antibodies during the procedure might prevent the occurrence of 
minor myocardial injury (26 7 ,2 6 8 ). Although occlusion of small side-branch 
vessels, visualized by angiography, may explain the mechanism of the minor 
myocardial injury in these patients, it does not explain the mechanism in the 
other 18 patients. Occlusion of small intramyocardial vessels, not visualized 
by angiography, might be the mechanism of minor myocardial injury in those
96
patients (fig. 4.1). One of these 18 patients, who had elevation of the three 
markers, underwent opening of a totally occluded artery which may have been 
associated with distal embolization.
Epicardial surface
3- intramyocardial 
vessel occlusion
(-) EGG changes 
{-) seen by angiography 
(+) cardiac troponin
4- Collateral vessel 
occlusion
(-) EGG changes 
(-) seen by angiography 
(-) cardiac troponin
Endocardial surface
1- Large side-branch 
occlusion
(+) EGG changes 
(+) seen by angiography 
(+) cardiac troponin
2- Small side-branch 
occlusion
{-) EGG changes 
{+) seen by angiography 
(+) cardiac troponin
Figure 4.1 Possible vascular occlusions that might occur during percutaneous 
coronary intervention and their evaluation by ECG, angiography and cardiac 
troponin measurement (1) Large side-branch occlusions are usually associated with 
ECG changes of ischemia or infarction can be detected by angiography and are 
associated with significant rises in cardiac markers including cardiac troponins. 
Patients with such occlusions were not included in our study. (2) Small side-branch 
occlusions usually does not cause significant ECG changes but still can be detected by 
angiography and might be associated with above the reference range rises in cardiac 
troponins. This type of occlusion was observed only in 10/28 (36%) of the troponin 
positive patients in our study. (3) Occlusion of the small intramyocardial vessels is not 
usually associated with ECG changes and cannot be demonstrated by angiography. 
This type of occlusion might be associated with rises in troponin levels that might 
explain the rises in the remaining 18 patients of the troponin positive group. (4) 
Occlusion of the intramyocardial collateral vessels is usually not associated with ECG 
changes or rises in cardiac troponins and cannot be demonstrated by angiography.
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Since the release kinetics of cardiac troponins indicate ongoing release from 
necrotizing myocytes, it is possible that the elevated troponin levels in our 
patients reflect true myocardial injury. Such finding becomes very important 
vs^ ith the growing body of evidence linking minor myocardial injury that 
occurs after percutaneous procedure to an adverse long-term prognosis (240- 
244). In-spite of our small sample size, we demonstrated that the release of 
cardiac troponins after elective uncomplicated successfiil PTCA with or 
without stenting is not uncommon and that these markers, especially cTnl, are 
probably more sensitive than CKMB for the detection of minor myocardial 
injury following these procedures. Follow-up evaluation was required to 
investigate the possible adverse effect of these abnormal cardiac troponins on 
long-term prognosis. In a small study of similar patients, elevation of cTnl 
post successfiil PTCA was not associated with worse long-term prognosis 
(269). To correctly answer the question of prognostic value of cardiac 
troponins after PTCA more studies are needed. Also, fiirther investigations are 
required to more fully understand the mechanism of minor myocardial injury 
after coronary intervention in order to prevent its occurrence and to prevent its 
possible adverse long-term sequelae.
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Markers of Inflammation 
And the Association With 
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5.1 RESULTS
5.1.1 Patients characteristics
• A total of 85 patients, 65 males and 20 females, were studied (table 5.1).
• Age ranged from 35 to 75 years (mean age = 55 ± 11). The age ranges for 
men and women were 35-75 and 42-75 years, respectively.
• Assessed risk factors included smoking (25 patients), diabetes mellitus (48
patients), hypertension (41 patients), and hypercholesterolemia (72 patients).
• Twenty four patients had PTCA alone and 61 had coronary stenting after 
PTCA.
• None of the patients had evidence of infection at the time of the procedure. 
This was confirmed by negative history for recent infection, normal 
physical examination (including normal temperature) and normal white 
blood cell count.
5.1.2 Cardiac Troponin I data
• All patients had normal values for all cardiac markers before the coronary 
intervention.
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• Abnormal values of one or more markers at 24 hours after coronary 
intervention were observed in 25 patients (29 %) of whom 5 patients had 
PTCA alone (21% of PTCA patients) and 20 patients had PTCA with 
stenting (33% of stenting patients).
• Patient and angiographic variables of both troponin positive and troponin 
negative groups are shown in table 5.2. Apart fi*om gender, all variables 
including age, body mass index, cardiac risk factors, medications, type of 
coronary artery disease, procedure, involved artery, lesion type and degree 
of stenosis were not significantly different.
• Side-branch occlusion was noticed in 32% (8/25) of the troponin positive 
patients and in 5% (3/60) of the troponin negative group, p = 0.002. Seven 
out of these 11 cases occurred after stenting.
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Variable Mean±SD or n(%)
Age (yr) 55±11
Gender
male 65 (76)
female 20(24)
Risk factors
Smoking 25(29)
Diabetes mellitus 48 (56)
Hypertension 41 (48)
Hypercholesterolemia 72 (85)
Procedure
PTCA 24(28)
Stenting 61(72)
Table 5.1 Patients data form arkers o f inflammation 
and the association with post PCI myocardial injury.
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Characteristics
cTnl (+) 
(n = 25)
cTnl (-) 
(n = 60)
Age(yr) 57 ±12 . 54 ±17
Gender (male/female) * 15/10 50/10
Body Mass Index (kg/m^) 28.7 ±4.6 28.7 ±4.7
Risk factors
Smoking 9(36) 26 (43)
Diabetes mellitus 16 (64) 32 (53)
Hypertension 13 (52) 28 (46)
Hypercholesterolemia 23 (92) 49 (82)
Medications
Statin-type drugs . 14 (56) 35 (58)
Beta blockers 12 (48) 37(62)
Calcium channel blockers 9(36) 20 (33)
ACE inhibitors 9(36) 23 (38)
Nitrates 19 (76) 46 (77)
Type of coronary artery disease
Single-vessel 11(44) 21(35)
Multivessel 14 (56) 39 (65)
Procedure
PTCA 5(20) 19 (32)
Stenting 20 (80) 41 (68)
Involved artery
Left anterior descending 13 (52) 33 (55)
Right coronary artery 5(20) 19 (32)
Left circumflex 7(28) 8(13)
Lesion type **
A 0(0) 8(13)
B 16 (64) 27 (45)
Ç 9(36) 25 (42)
Stenosis (%) 90 ±14 86±8
Table 5.2 Clinical demographic and angiographic characteristics fo r  
study population. Data are given as mean ± SD or number of patients 
(%). There were no significant differences between the two groups 
(except gender, *p = 0.027).
**According to classification of the American Heart Association and the 
American College of Cardiology, same as figure 4.3.
ACE = Angiotensin Converting Enzyme.
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5.1.3 Makers of inflammation data (Appendix-3 and appendix-4)
• A control group of 22 healthy subjects, matched for age and sex with the 
population of patients, without coronary artery disease and who had no 
history of myocardial infarction, coronary heart disease, other 
cardiovascular disease or cancer was recruited from a population of 
volunteers.
• The median concentrations of CRP, TNF-a, IL-6 and sICAM were 
significantly higher in the patient group than the normal control group 
(Table 5-3).
• In contrast to TNF-a, IL-6 and sICAM, baseline CRP was the only marker 
that related significantly to the occurrence of MME post PCI (table 5.4).
5.1.4 C-reactive protein data
Using the reference value of 6.0 mg/L (i.e., the upper value foimd in 95% of 
healthy controls) serum CRP levels, measured before the procedure, were 
abnormally elevated in 41% of patients; of these, 46% developed MMI after 
PCI compared to 18% of patients with normal CRP levels (p = 0,008). After 
the procedure, MMI occurred in 29% of patients; in these, CRP levels were 
significantly higher when compared with patients without MMI [median and 
inter-quartile range, 9.0 (3.2-14.8) vs 3.8 (1.7-8.6) mg/L, p = 0.018]. Serum 
CRP levels remained significantly higher in patients with MMI when patients 
with no visualized side-branch occlusion by angiography were considered 
separately [10.3 (3.9-18.3) vs 3.7 (1.7-9.0) mg/L, p = 0.015].
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Markers Controls Patients P  value
CRP (mg/L) 3.00 (2.55 - 3.75) 4.51 (2.06-9.98) <0.0001
TNF-a (pg/ml) 3.45 (2.78-6.25) 4.20 (3.63-6.25) 0.013
IL-6 (pg/ml) 8.80 (6.20-10.80) 10.30 (7.15-10.30) 0.004
sICAM (ng/ml) 258 (216-351) 414 (353-510) <0.0001
Table 5.3 Serum makers o f inflammation fo r  study population. Data are 
given as median (interquartile ranges). Serum concentrations of CRP, TNF-a, 
IL-6 and sICAM were significantly higher in the patient group than the normal 
control group.
Markers
cTnl
negative
cTnl
positive P value
CRP (mg/L) 3.78 (1.72-8.75) 9.02 (3.20-14.75) 0.018
TNF-a (pg/ml) 4.05 (3.60 - 5.85) 4.70 (3.75 - 7.05) NS
IL-6 (pg/ml) 10.30 (7.00- 12.80) 9.90 (7.70- 14.60) NS
sICAM (ng/ml) 420 (358-518) 414 (353 -510) NS
Table 5.4 Serum makers o f inflammation in relation to post-procedural 
cTnl release. Data are given as median (interquartile ranges). In contrast to 
TNF-a, IL-6 and sICAM, baseline CRP was the only marker that related 
significantly to the release of cTnl post PCI.
NS, not significant.
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5.2 DISCUSSION
5.1.1 Markers of inflammation and stable angina
In this study of patients with stable angina and angiographically documented 
coronary artery disease, serum concentrations of CRP, TNF-a, IL-6 and 
sic AM were significantly increased when compared with age and gender 
matched apparently healthy controls. This finding is in agreement with other 
studies that report rises in markers of inflammation in patients with stable 
angina (270). In their case-controlled study, Rifai et.al. found that 
concentrations of CRP and IL-6 were increased in similar stable angina 
patients with angiographically documented CAD.
In our assessment of the systemic inflammatory state before PCI, we studied 
serum levels CRP, IL-6, TNF-a and ICAM to represent the different levels of 
the inflammation reactions. Other markers involved in the different levels of 
the inflammation reactions as well as interleukin-10 as an antiinflammatory 
cytokine can also be used for such evaluation.
5.2.2 Cardiac Troponin I elevation After PCI
Proportion of patients with cTnl above the reference range in this study is 
(29%) similar to that reported previously (18-29% in similar patients with 
coronary disease) (271,272). However, In contrast with other reports 
(258,273) our results did not show that stenting was associated with a higher 
frequency of MMI than was conventional PTC A.
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The release of cTnl after PCI in our study appeared to be related to small side 
branch occlusion and the total time of inflation. Small side branch occlusion 
can explain the mechanism of some, but not all, periprocedural MMI (271). 
Similarly, prolonged inflation can represent a cause of MMI during 
intervention, although the duration of occlusion and myocardial ischemia in 
uncomplicated PCI is usually well tolerated by myocardium (262). Therefore, 
predictors of MMI after elective uncomplicated PCI in patients with stable 
angina are not well-characterized.
5.2.3 Markers of inflammation and cTnl elevation after PCI
In contrast to the other markers of inflammation evaluated in this study, CRP 
was the only marker that related significantly to the occurrence of MMI after 
PCI. Whether this difference could be related to methodological or 
physiological causes is unclear. CRP levels remain stable over long periods of 
time in the absence of new stimuli. They depend almost entirely on the hepatic 
production rather than factors influencing protein clearance (274,275) and are 
precise objective index of the overall inflammatory activity in the body; as 
they amplify the underlying cytokine signal. On the other hand, other markers 
of inflammation such as TNF-a, IL-6 and sICAM are involved in complex 
molecular and cellular cascades and have short in vivo half-lives. Furthermore, 
in contrast to many other markers of inflammation, immunoassays for CRP are 
technically easy, highly sensitive and generally reliable (276).
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5.2.4 Increased CRP levels as predictors of MMI
C-reactive protein, an acute-phase reactant that reflects low-grade systemic 
inflam m ation, has been studied ina variety of cardiovascular diseases (114- 
116). Several studies have shown strong association between CRP and the risk 
of coronary disease (122-126). This study shows that increased levels of CRP 
are common in patients with stable coronary disease and are significantly 
associated with a higher risk of MMI after elective uncomplicated successful 
PCI. These increased levels were independent of other major factors that affect 
CRP concentration and remained significantly higher in patients with MMI 
after excluding those with side-branch occlusion fi-om the analysis indicating 
involvement of the systemic inflammatory state in the etiology of this 
periprocedural myocardial injury.
Our finding of increased CRP levels in 41% of patients with stable angina 
confirmed the existing relation between CRP and the presence of coronary 
artery disease. One interesting observation from our study is the significant 
association between baseline CRP and the development of MMI after elective 
uncomplicated PCI.
Several risk factors can modulate the inflammatory response and affect CRP 
concentrations. Adipose tissue can secrete interleukin-6, the primary stimulant 
of hepatic synthesis of CRP (81,82). Therefore, obesity is directly associated 
with increased CRP concentration. Other factors have also been shown to be 
associated with elevated CRP levels including age, cigarette smoking, 
diabetes, and hypertension (277-282). In our study, patients with and without 
MMI did not differ with respect to body mass index, smoking, diabetes
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mellitus, hypertension and hyperlipidemia. In addition, CRP levels may be 
affected by certain therapies such as Aspirin and statins (131,283,284). All our 
patients were receiving Aspirin, and there was no significant difference in the 
other medications used in patients with and those without MMI after PCI, 
which included statin-type drugs, angiotensin converting enzyme inhibitors, 
beta-blockers, and calcium channel blockers.
In our study the male to female ratio was lower in patients with MMI. 
However, serum CRP was shown to be a predictor of future coronary events in 
both men and women (124,131) and because the relative risks did not vary 
significantly between men and women, a single risk assessment algorithm 
utilizing the same levels of CRP has been suggested for both genders (124). 
Therefore, the difference in gender among our patients should not aSect the 
results of the study. On the basis of these findings, increased baseline CRP 
levels seem to represent a significant and independent determinant o f MMI 
after elective uncomplicated PCI.
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CHAPTER 6
Clinical Outcome
no
6.1 RESULTS
6.1.1 Patients characteristics
• A total of 96 patients, 73 males and 23 females, were studied (Table 6.1).
• Age ranged from 35 to 79 years (mean age = 55 ± 11). The age ranges for 
men and women were 35-79 and 42-75 years, respectively.
• Assessed risk factors included smoking (38 patients), diabetes mellitus (55 
patients), hypertension (50 patients), and hypercholesterolemia (81 patients).
• Twenty seven patients had PTC A alone and 69 had coronary stenting after 
PTCA.
6.1.2 Biochemical markers
• All patients had normal values for all cardiac markers before the 
coronary intervention.
• CKMB activity was elevated significantly in 6 patients (6.3%), 1 from the 
PTCA group (3.7%) and 5 from the stenting group (7.2%).
• cTnl was elevated significantly in 26 patients (27%), 5 following PTCA 
alone (19% of PTCA patients) and 21 following stenting (30% of stenting 
patients).
I l l
Variable MeaniSD or n(%)
Age (yr) 55 ±11
Gender
male 73 (76)
female 23 (24)
Risk factors
Smoking 38 (40)
Diabetes mellitus 55 (57)
Hypertension 50 (52)
Hypercholesterolemia 81 (84)
Procedure
PTCA 27(28)
Stenting 69(72)
Table 6.1 Characteristics o f patients studied fo r clinical 
outcome assessment
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6.1.3 Patient and Angiographie Variables
Patient and angiographie variables of both troponin positive and troponin 
negative groups are shown in table 6.2. Both groups did not differ with respect 
to age, gender, risk factors, type of coronary disease (single-vessel or 
multivessel), procedure, involved artery, lesion type and degree of stenosis.
6.1.4 Procedural Characteristics
When compared with troponin negative patients, abnormal cardiac troponin 
values were significantly related to total time of inflation (224 ± 131 vs. 170 ± 
105 seconds; p  = 0.012). On the other hand differences between the two 
groups were not significant for total number of inflations, longest single 
inflation, inflation maximal pressure, and balloon diameter (Table 6.3).
Side-branch occlusion was noticed in 35% (9/26) of the troponin positive 
patients and in 6% (4/70) of the troponin negative group, p  -  0.0008. Eight of 
the 9 cases occurred after stenting.
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Variable cTnl (+) 
(n = 26)
cTnl(-) 
(n = 70)
P  value
Age (yr.) 55 ±13 55 ±11 0.91
Male Sex 16(62) 56(81) 0.11
Risk factors
Smoking 10(39) 28(40) 1.000
Diabetes mellitus 16(62) 39(56) 0.649
Hypertension 14(54) 36(51) 1.000
Hypercholesterolemia 24(92) 57(81) 0.342
Coronary disease type
Single-vessel 10(39) 25(36) 0.815
Multivessel 16(62) 45(64) 0.815
Procedure
PTCA 5(19) 22 (31) 0.311
Stenting 21 (81) 48 (69) 0.311
Involved artery
LAD 12 (46) 36 (56) 0.819
RCA 5(19) 23 (33) 0.311
Left circumflex 9(35) 8(11) 0.015
Lesion type*
A 1(4) 9(13) 0.278
B 17(65) 45 (64) 1.000
C 8(31) 16 (23) 0.437
Stenosis (%) 89±8 86 ±8 0.36
Table 6.2 Patient demographic and Angiographie Characteristics. Values are mean ± SD or number of
patients (%) ‘According to classification of the American College of Cardiology and the American Heart 
Association, same as figure 4.3. LAD = Left anterior descending, RCA= Right coronary artery.
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Variable cTnl (+) 
(n = 26)
cTnl (-) 
(n = 70)
P  value
Total number of inflations 5.2 ±1.8 4.5 ±2.2 0.22
Total time of inflation (sec) 244 ±131 170 ±105 0.012
Longest single inflation (sec) 59 ±20 53 ±16 0.10
Inflation maximal pressure 
(atm)
13.0 ±21 12.0 ±27 0.09
Balloon diameter (mm) 2.95 ±0.30 3.00 ± 0.43 0.20
Occurrence of side-branch 
occlusion
9(35) 4(6) 0.0008
Table 6.3 Procedural Characteristics, Values are mean ± SD or n (%). 
Raised cardiac troponin values above the reference range (cTnl + ) were 
significantly related to total time of inflation and the occurrence of side-branch 
occlusion.
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6,1.5 Follow-up data
• Positive and negative predictive values with the corresponding sensitivity 
and specificity figures for cTnl and adverse cardiac events that occurred 
during the follow-up period were calculated using the cut-off values of 0. 
5, 1.0,1.5,2.0 and 2.5 pg/L (Table 6.4). The highest positive and negative 
predictive values (54% and 81%, respectively) were noticed with the cut­
off value of 2.0 pg/L.
Cut-off value of 
cTnl (pg/L)
Sensitivity Specificity (+) Predictive 
value
(-) Predictive 
value
P value*
0.5 49% 55% 36% 67% 0.7750
1.0 49% 71% 47% 73% 0.0670
1.5 42% 71% 44% 70% 0.2224
2.0 42% 71% 54% 81% 0.0198
2.5 33% 81% 48% 70% 0.1489
Table 6.4. Predictive values for cTnl and adverse cardiac events at different cut-offs.
* Calculated using Kaplan-Meier survival analysis and log rank test fo r differences in 
late cardiac events among cTnl positive and cTnl negative patients._________________ _
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• Over the follow-up period of 24 months there was no significant 
difference in the medication used (Table 6.5) between the cTnl positive 
and negative subgroups. Fourteen (54%) of the cTnl positive patients 
experienced recurrent angina. All these patients had another event (12 
repeat PCI, one coronary bypass surgery and one cardiac death). On the 
other hand 19 (27%) of the cTnl negative patients experienced recurrent 
angina. Only 16 of these patients had another event (13 repeat PCI, 3 
coronary bypass surgery and no cardiac death) (Table 6.5).
Variable cTnl (+) 
(n = 26)
cTnl (-) 
(n = 70)
P  value
Medications
Beta-Blockers 15(58) 49(70) 0.331
Calcium Channel Blockers 11(42) 36(51) 0.495
Nitrates 20(77) 55(77) 1.000
Lipid lowering drugs 21(81) 50(71) 0.439
ACE inhibitors 14(54) 37(52) 1.000
Cardiac events
Recurrent angina and any event 14(54) 19(27) 0.0198
Repeat intervention 12(46) 13(16) 0.0276
Coronary bypass surgery 1(4) 3(4)
Cardiac death 1(4) 0(0)
Table 6.5 Follow-up Data at 24 months. Values are n (%). Over the follow- 
up period of 24 months there was no significant difference in the medication 
used between the cTnl positive and negative subgroups. ACE, Angiotensin 
converting enzyme.
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• Kaplan-Meier survival analysis showed that cTnl elevation was an 
important determinant of a cardiac event (^ = 0.0198, by log rank analysis) 
(Figure 6.1) (Table 6.5). After excluding the effect of other cardiac events 
(recurrent angina alone and recurrent angina with coronaiy bypass surgery or 
cardiac death) from the analysis, the incidence of repeat PCI remained 
significantly higher in the cTnl positive patients ip = 0.0276, by log rank 
analysis).
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Figure 6.1 Kaplan-Meier curves displaying freedom from cardiac events for patients after 
successful percutaneous coronary intervention on the basis of cardiac troponin I (cTnl) 
release after the procedure. The numbers below the graph indicate the number of patients 
exposed to the risk at each time point.
► The relationship between diabetes, hyperlipidemia and treatment with 
statins and the occurrence with cardiac events during the follow-up period 
was examined. The frequencies of event occurrence in diabetics (36%), 
hyperlipidémies (38%) and patients treated with statins (35%) were not
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significantly different from those that occurred in nondiabetics (32%), 
nonhyperlipidemics (13%) and patients not treated with statins (38%) 
(p=0.54, 0.07 and 0.73, respectively).
6.2 DISCUSSION
Our follow-up evaluation showed that cardiac events are best predicted by 
cTnl when the cut-off value of 2.0 pg/L is used. Patients with cTnl elevation 
using this cut-off value had statistically significant worse long-term outcome 
than those without cTnl increase, because they more often had later cardiac 
events. In our study all patients had stable angina and underwent elective 
uncomplicated successful PCI. In addition, there was no significant difference 
in the severity of CAD or medication used during the follow-up period 
between cTnl positive and cTnl negative groups. This explains the differences 
between our findings and those of recently reported studies that evaluated 
postprocedural cTnl elevation and clinical outcome (285,286). In these 
studies, cTnl elevation was related to in-hospital complications but not to 
intermediate-term (8-12 months) adverse outcomes. On the other hand, cTnl 
elevation in our patients was not related to in-hospital complications but was 
associated with worse long-term (24 months) outcome. These differences may 
be due to the fact that those studies included patients with unstable angina, 
reaching 46% of the patients in one study and 71% of the other, as well as 
patients with periprocedural complications. In addition, the follow-up period 
in those studies was intermediate rather than long term and there was no 
differentiation during that period between the outcome of stable and unstable 
angina patients, patients who developed periprocedural complications and
those who did, and in the medications used by the different groups.
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CHAPTER 7
Conclusions and Clinical Implication
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7.1 BACKGROUND
Minor myocardial injury (MMI) is relatively common after complicated 
percutaneous coronary interventions (PCI) and is associated with increased 
risk for future cardiac events. MMI may be revealed by elevation of cardiac 
markers. However, the occurrence, mechanism and long term outcome of 
minor myocardial injury after uncomplicated successful elective PCI in 
patients with stable angina has not been assessed previously.
7.2 MAIN FINDINGS
Our work demonstrates that MMI is not uncommon after elective 
uncomplicated successful PCI in patients with stable angina and that cardiac 
troponins, especially cTnl, were more sensitive than CKMB for the detection 
of this MMI. This result is in agreement with other studies that report rises in 
cardiac markers following coronary interventions (239,243,262,263,266). In 
addition and for the first time, we demonstrated that increased serum CRP in 
patients with stable angina is a significant and independent determinant of 
MMI after elective uncomplicated successftil PCI indicating involvement of 
the systemic inflammatory state in the etiology of this periprocedural 
myocardial injury. Furthermore, we were able to show significant association, 
which has not been shown before, between rises of cTnl after elective 
uncomplicated successful PCI and adverse long-term outcome in this selected 
group of patients with stable angina.
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7.3 DISCUSSION
Coronary interventions can induce an inflammatory response by,causing 
plaque rupture, hematoma, arterial wall damage, release of inflammatory and 
chemotactic factors with leukocytes and platelet activation (153,154). They 
can also initiate an ischemia-reperfiision cycle by repeated balloon inflations 
(2874). The acute inflammatory response to PCI appears to be related to the 
preexisting degree of systemic inflammation as assessed by baseline CRP 
levels (155). Therefore, a more intense inflammatory response is likely in 
patients with high baseline CRP levels. This may be related to problems of 
CRP itself and may be translated into more leukocyte activation leading to 
more secretion of inflammatoiy mediators, growth factors, and tissue factors . 
which may aggravate endothelial damage, trigger coronary spasm, enhance 
smooth muscle cell proliferation, stimulate platelet aggregation and directly 
initiate the extrinsic pathway of coagulation (254-257). These intense cellular 
and molecular responses can cause small vessel occlusion and/or 
microembolization that will lead to MMI and cTnl elevations possibly reflect 
small zones of necrosis (microinfarcts). Such small zones of necrosis are not 
usually seen by coronary angiogrphy as revealed by animal studies of 
coronary microembolization (288). All of these may explain the significant 
association between the degree of systemic inflammation reflected by baseline 
CRP levels and the occurrence of MMI after elective uncomplicated PCI (fig. 
7.1).
The possibility that increased cTnl after PCI reflects small zones of necrosis
(microinfarcts) caused by microembolization can also be used to explain the
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mechanism by which increased cTnl affects long-term prognosis. 
Microembolization can increase the likelihood of future cardiac events 
through the compromise of coronary collaterals. Although occlusion of the 
intramyocardial collateral vessels by microembolization is not associated with 
ECG changes or rises in cTnl and cannot be demonstrated by angiography, 
interruption of collateral blood flow has been shown to potentiate the ischemic 
effects of subsequent coronary occlusion (289). This course of events can lead 
to a large ischemic area and a large infarction. In other words, the expected 
intense inflammatory response to PCI done for patients with elevated CRP 
will cause occlusion of small intramyocardial vessels as well as occlusion of 
intramyocardial collateral vessels. Following the loss of intramyocardial 
collateral blood flow, the subsequent narrowing or occlusion of the previously 
dilated lesion will lead to a larger area of ischemia and a larger area of 
infarction in the supplied segment of myocardium , which will result in a 
worse ischemic cardiac event and a worse outcome.
With this in mind and with the observation that increased risk associated with 
systemic inflammation may be modified with certain preventive therapies 
(131,283,284), measurement o f CRP before PCI may help to identify those 
who would benefit most from these pharmacological therapies before coronary 
interventions. Also, measurement of cTnl after the procedure may help to 
identify patients who would require aggressive preventive measures to prevent 
subsequent ischemic events and their expected detrimental effects on outcome.
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Figure 7.1 Association between the degree o f systemic inflammation and the 
occurrence o f minor myocardial injury after elective uncomplicated percutaneous 
coronary inten’ention.
Coronary interventions can induce an inflammatory response by causing plaque 
rupture, hematoma, arterial wall damage, release of inflammatory markers ( IL- 
1,TNF, IL-6, adhesion molecules, and acute phase proteins) and chemotactic (MCP-1 
and IL-8) factors with leukocytes and platelet activation. The preprocedural 
activation of inflammatory cells, reflected by increased levels of CRP, may play a 
major role in the modulation of the vessel-wall response to injury and a more intense 
inflammatory response is likely to occur in such cases. This may be translated into 
more leukocyte activation leading to more secretion of inflammatory mediators, 
growth factors, and tissue factors (free radicals, OxLDL and MMPs) which may 
aggravate endothelial damage, trigger coronary spasm, stimulate platelet aggregation 
and directly initiate the extrinsic pathway of coagulation. These intense cellular and 
molecular responses can cause small vessel occlusion and/or microembolization that 
will lead to MMI which can be detected by cardiac troponins.
CIU^ , C-reactive protein; GFs, growth factors; ICAM-1, intercellular adhesion 
molecule-l; IL-1, interleukin-1; IL-6, interleukin-6; IL-8, interleukin-8; MCP-I, 
macrophage chemoattractant protein-I; MMI, minor myocardial injury; MMPs, 
matrix metalloproteinases; OxLDL, oxidized Low density lipoprotein; SAA, serum 
amyloid A; TNF, tumor necrosis factor.
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In addition, the longer total time of inflation and the higher inflation maximal 
dilatation pressure used in the cTnl positive patients may be the cause of 
deeper injury of the vessel wall, which may act as a stimulus for platelet 
deposition and microembolization. In such case, as well as in cases where PCI 
is to be performed in patients with elevated CRP levels, the use of Gp Ilb/IIIa 
antagonists during the procedure might prevent the occurrence of minor 
myocardial injury and its possible adverse long-term sequelae.
Finally, To correctly answer the question of prognostic value of cTnl after PCI 
more studies with larger sample size are needed. Also, further investigations 
are required to more fully imderstand the mechanism of minor myocardial 
injury after coronary intervention in order to prevent its occurrence as well as 
its possible adverse long-term sequelae.
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Appendix-3; Markers of Inflammation Data - Patients
Patient
#
CRP
(mg/L) _ TNF(pg/mi)
iL-6
(pg/mi)
siCAM
(ng/mi)
2.37 3.5 19.4 362
2 1.35 4.1 4.5 541
3 1.10 3.7 7.0 362
4 0.83 2.8 15.8 412
5 3.26 3.3 18.4 249
6 9.21 2.8 18.2 384
7 18.10 3.6 5.9 464
8 3.06 4.0 12.0 475
9 7.98 19.2 7.2 541
10 7.06 3.2 11.5 345
11 21.10 3.9 19.8 463
12 1.69 39.7 11.0 533
13 3.66 4.1 14.9 403
14 9.80 11.7 7.2 533
15 1.43 3.3 11.1 358
16 17.70 4.0 14.6 363
17 9.20 6.2 8.1 348
18 17.10 1.9 5.3 414
19 10.50 3.6 11.6 318
20 0.46 3.4 11.6 443
21 25.20 6.8 11.0 574
22 10.90 3.7 23.7 423
23 1.41 3.9 19.1 443
24 9.80 4.8 16.1 513
25 4.91 2.9 6.6 398
26 4.20 3.0 7.0 292
27 12.40 16.5 22.9 283
28 9.19 4.0 7.9 542
29 0.59 4.2 8.2 363
30 0.94 3.7 3.9 460
31 8.71 4.5 9.3 358
32 9.97 2.6 13.1 409
33 25.10 5.8 14.6 257
34 4.57 13.6 13.0 272
35 10.80 3.5 12.3 343
36 1.13 5.2 9.1 227
37 4.32 4.0 7.9 334
38 2.09 4.0 12.3 487
39 4.53 3.4 9.7 358
40 7.75 4.5 12.0 404
42 26.20 3.6 17.4 508
43 7.16 3.2 22.4 503
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Patient
#
CRP
(mg/L) TNF (pg/mi)
iL-6
(pg/mi)
SiCAM
(ng/mi)
44 20.80 4.6 12.2 643
46 0.53 4.5 11.9 530
47 2.37 4.2 12.4 940
48 1.62 7.6 8.1 445
49 2.59 30.2 7.0 420
50 3.46 11.2 2.6 425
51 3.62 4.0 7.1 500
52 6.13 5.6 2.7 520
53 6.55 9.4 2.1 610
54 3.90 8.7 1.8 570
55 5.91 8.1 2.7 615
56 2.23 4.9 12.8 280
57 2.00 3.8 2.2 370
58 8.77 3.6 3.1 380
59 9.02 3.4 9.2 460
60 0.66 5.7 9.5 400
61 7.79 4.2 9.9 400
62 0.48 3.3 6.3 314
63 1.75 4.2 7.9 420
64 4.12 5.4 7.8 420
65 13.00 7.3 8.2 390
66 2.76 4.0 2.4 687
67 3.12 5.5 5.8 540
68 3.49 4.0 10.3 490
69 10.30 6.3 10.9 478
70 11.50 5.5 17.4 349
71 28.80 10.9 17.3 674
72 11.30 11.1 7.0 740
73 0.90 4.0 10.1 239
74 1.55 4.0 10.0 290
75 14.10 5.2 8.1 360
76 1.71 15.9 12.8 248
77 15.40 13.6 11.7 685
78 4.75 28.3 12.8 309
79 3.28 7.8 8.9 390
80 5.20 4.0 17.2 380
81 2.32 3.6 7.5 238
82 53.50 4.7 14.6 470
83 3.91 4.6 11.1 460
84 2.03 4.0 10.3 430
85 2.35 5.9 10.6 238
CRP, C-reactive protein; TNF, tumor necrosis factor; iL‘6, 
interieukin- 6; iCAM, interceiiuiar adhesion moiecuie.
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Patient
#
CRP
(mg/L) TNF (pg/mi)
iL-6
(P9/mi)
iCAM
(ng/mi)
1 6.00 9.6 8.7 450
2 2.81 3.3 11.4 453
3 3.60 2.0 9.2 333
4 4.20 2.8 7.5 347
5 6.10 2.8 8.9 216
6 1.80 2.7 12.1 333
7 5.10 6.6 10.6 452
8 3.00 6.2 9.9 180
9 3.00 2.0 6.7 216
10 2.90 3.8 12.0 226
11 3.00 9.4 12.5 211
12 3.00 4.3 5.8 217
13 2.80 2.7 9.1 164
14 1.64 3.3 6.2 236
15 3.00 3.0 12.3 156
16 1.72 3.5 9.4 342
17 1.80 , 3.4 4.6 363
18 5.00 4.0 4.2 239
19 1.80 4.1 6.6 239
20 3.00 8.3 7.2 278
21 2.80 7.6 4.5 345
22 3.00 2.5 6.2 394
CRP, C-reactive protein; TNF, tumor necrosis factor; iL-6, 
interieukin-6; iCAM, interceiiuiar adhesion moiecuie.
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Biochemical Detection of Minor Myocardial Injury
After Elective Uncomplicated Successful 
Percutaneous Coronary Intervention in Patients with Stable Angina.
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Biochemical Detection of Minor Myocardial Injury
After Elective Uncomplicated Successful 
Percutaneous Coronary Intervention in Patients with Stable Angina.
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C a r d i a c  m a r k e r s  f o r  a s s e s s i n g  t h e  
a c u t e  c o r o n a r y  s y n d r o m e s
A focus on cardiac troponins
Salam M. Saadeddin, MSc, mt(ASCP), Moh'dA. Habbab, FACP, F ACC, Gordon A. Ferns, MD, FRCPath.
ABSTRACT
Markers o f myocardial injury will continue to play an essential role in the assessment and management o f patients 
presenting within the spectrum o f acute coronary syndromes, a term representing the continuum o f acute myocardial 
ischemia ranging from angina through Q-wave myocardial infarction. Coronary artery lesion instability can be detected 
by markers o f plaque inflammation and disruption, platelets reactivity, and thrombosis. When myocardial injury occurs 
with severe impairment o f coronary blood flow, several markers are released from the damaged myocyte. For many 
years, creatine kinase-MB isoenzyme has been the conventional marker for myocardial infarction. Despite its inadequate 
sensitivity and specificity for myocardial injury, creatine kinase-MB remains an essential component in assessing re­
infarction or infarct extension, as well as in monitoring reperfusion after thrombolytic therapy when combined with 
myoglobin. Among the many cardiac markers for myocardial necrosis, cardiac troponins possess superior sensitivity and 
specificity for the detection o f myocardial injury. In addition to their superior performance in detecting minor myocardial 
damage, cardiac troponins can be useful in detecting perioperative myocardial infarction, infarct size, improving risk 
stratification, and facilitating therapeutic decision making in patients with acute coronary syndromes.
Keywords: Cardiac markers, cardiac troponins, coronary syndromes.
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D etermination o f cardiac enzymes coupled with suggestive symptoms and electrocardiographic 
(ECG) changes has traditionally been used to 
distinguish between patients with and without acute 
myocardial infarction (MI) and extensive myocardial 
damage.' However, this distinction becomes blurred 
with other manifestations of acute coronary 
syndromes (ACSs) which include stable angina, 
unstable angina, and non-Q myocardial infarction.^ 
History alone has proven to be a poor means of 
identifying patients with ACSs. Out o f the 8 million 
people who visit the emergency room each year in 
the United States with a chief complaint of chest
pain, only 30% have coronary artery disease as a 
cause o f the pain.^ Also symptoms o f myocardial 
ischemia can be non-specific in up to one-third of 
patients, particularly in diabetics and elderly.'*
Although ECG is an important tool for the early 
diagnosis o f patients with chest pain, its diagnostic 
sensitivity may be as low as 5 0 % . Equivocal  
ECGs are usually seen with smaller degrees of 
myocardial necrosis, intraventricular conduction 
delays (such as left bundle branch block) and 
posterior MI.^
Serum aspartate transaminase (previously known 
as glutamic-oxaloacetic transaminase) was noted to
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Risk of Acute Coronary Syndromes
P ath oD h vsio logv A<^Ss Continuum . T issue Injury
Massive necrdus Q-»flveM I t< rge  area
Non Q-wave MI Irrever» ib fe \
Plaque fissure & 
thrombus formation
Unstable angina Small area
Stable plaque Stable angina Resersible
Figure 1 - Risk of Acute Coronary Syndromes (ACSs) in relation to 
pathologic activation and tissue injury.
(A) Myoglobin. CK-MB Isoforms. FABP. GPBB.
(B) CK-MB.
(C) cTnT.
(E) MLC. MHC. Actin.
Days After Onset
F igure 2 - Release kinetics o f cardiac markers inpatients with acute 
myocardial infarction. CK-M B-creatine kinase MB, FABP- 
fatty acid binding protein, GPBB-glycogen phosphorylase 
isoenzyme BB, MLC-myosin light chain, M HC-myosin 
heavy chain, cTnT-cardiac troponin T, cTnl-cardiac 
troponin I.
be elevated in patients with acute MI approximately 
40 years ago to be elevated.^ About 10 years later, 
creatine kinase (CK) and its MB isoenzyme (CK- 
MB) provided superior cardiac sensitivity and 
specificity and the measurement of their levels has 
been used to diagnose myocardial injury since that 
time.'c However, this measurement does not 
adequately allow for identification o f patients with 
ACSs and minimal myocardial damage or 
microinfarction. " '^  Further, CK-MB measurement is 
less reliable for the early and late retrospective 
diagnosis o f cardiac necrosis. It is also associated 
with poor cardiac specificity in patients with 
concurrent skeletal muscle injury, thyroid disease, 
diabetes mellitus, pulmonary embolism, renal failure 
or intramuscular injections.
In addition to diagnosing acute MI, there is also a 
need to identify patients who have a high risk of 
future cardiac events in order to provide safe and 
efficient triage to patients with chest pain. It is 
crucial to determine promptly whether a patient 
requires hospitalization, consideration for urgent 
revascularization, a short observation period, or 
discharge.
The inadequate sensitivity and specificity o f CK 
and CK-MB for diagnosing myocardial injury and 
the need for improved safety and efficiency in the 
triage of patients with acute chest pain, has presaged 
the introduction of several novel markers for 
myocardial injury. Cardiac troponin T and I (cTnT 
and cTnl), CK-MB isoforms, and myoglobin are 
some of the current markers being evaluated for the 
diagnosis o f myocardial injury.
It has also been reported recently that biochemical 
indicators of activation of leukocytes and coagulation 
are raised in some patients with unstable angina and 
normal markers of myocardial i n j u r y . T h e  former 
markers of plaque stability may provide an index 
hence the new cardiac markers need to provide more
information than simply the presence or absence o f  
an acute myocardial infarction. Application o f these 
markers could improve risk stratification o f patients 
with ACSs and aid in selection o f different treatment 
strategies.
The purpose o f this review is to provide an 
overview of the characteristics o f these novel 
markers and to indicate their role in the clinical 
assessment and treatment o f patients with ACSs.
Spectrum o f  acute coronary syndromes. 
Throughout life, series o f genetic and environmental 
factors increase our risk o f developing clinically 
significant atherosclerotic changes leading to clinical 
disease.'^ Clinical studies and experimental animal 
models have provided an improved insight into 
molecular events that transform healthy c o r o n ^  
arteries into the clinically diseased vessels with 
multifocal lesions. The early fatty streak progresses 
sequentially to the bulging foam cell-filled fibro fatty 
plaque, the fixed stenotic lesions visible on coronary 
arteriography,’’ '^  and thence to the complicated 
lesion.
Patients with stable lesions may develop stable 
angina with reversible tissue injury and are at low  
risk for adverse events. With progression, 
inflammatory characteristics appear to accelerate the 
process leading to the instability o f the coronary 
artery plaques.’^
Plaque rupture, a process triggering throbogenesis, 
may occur repeatedly without clinical recognition 
and without proceeding to occlusion.” The 
propagation o f thrombus, with subsequent occlusion, 
may produce ischemic injury and myocyte 
necrosis.’”- ’ This destabilization o f fatty plaque may 
provoke complete and sudden occlusion with distal 
infarction and obvious clinical event or none that are 
recognizable except by biochemical markers o f  
myocyte necrosis.
ACSs represent a continuum of myocardial
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ischemia ranging from angina that indicates 
reversible tissue injury, through frank Q-wave MI 
with extensive tissue necrosis. This continuum also 
includes unstable angina and non Q-wave MI which 
are frequently associated with minor myocardial 
damage.’ The differentiation between these two 
conditions depends on the area o f ischemic injury 
which is usually more with non-Q wave MI. In 
addition to reflecting the pathophysiological process 
of acute myocardial ischemia, the continuum of 
ACSs is a continuum of risk (Figure 1).
In summary, identifying the location of an 
individual patient's disease in the continuum of ACSs 
has biological implications regarding the reversibility 
of injury and quantity o f ischemic cell injury, as well 
as the patient's relative risk for an adverse outcome.
Markers o f  instability o f  coronary artery lesions. 
Plaque inflammation and local thrombus formation 
are major determinants o f coronary artery plaque 
stability. Unstable coronary artery plaques are 
characterized by accumulation o f macrophages and 
activation of proinflammation genes in smooth 
muscles and endothelial cells.” Plaque disruption 
causes release of cytokines from activated monocytes 
and macrophages at the disrupted site.”  Among 
other effects, cytokines (including interleukin-6) 
promote hepatic synthesis o f the acute phase proteins 
C-reactive protein (CRP) and serum amyloid A .” -’"’ 
This results in higher levels of interleukin-6, CRP 
and serum amyloid A in blood of patients. Increased 
concentrations o f these markers may have a role in 
identifying patients having unstable coronary 
plaques. Circulating levels of these markers were 
found to be higher in patients with unstable angina, 
compared with healthy persons and their 
measurement may have a role in identifying patients 
having unstable coronary plaques.’ ”^  The levels o f  
CRP and serum amyloid A were found to carry 
prognostic significance in patients with unstable 
angina.” ’* CRP levels were also investigated for 
their ability to predict unfavorable outcomes and 
impairment of left ventricular function in patients 
with acute coronary necrosis or previous myocardial 
infarction.’^
Since platelet activation is important in the 
mechanism of thrombus formation, indicators of 
platelet activation such as platelet function assays or 
P-selection may help assess a patient's tendency for 
intracoronary thrombosis. P-selection is an adhesion 
molecule expressed on the surface o f platelets when 
activated by either exposed collagen, thrombus and 
or all other agonists reduced by plaque disruption.’” 
Expression of this protein is increased on the surface 
of platelets in patients with symptomatic coronary 
artery disease.’”
Markers o f thrombosis, including soluble fibrin 
and fibrin degradation products, may also indicate a 
recent thrombotic process or risk o f an impending 
event. Elevated levels of these markers are
pathognomonic o f procoagulant fibrinolytic activity 
and may predict patients at higher risk for Ml-related 
complications.” Other indicators of activation o f the 
coagulation system or inhibition o f fibrinolytic 
activity were also elevated in patients with unstable 
angina.” ”
However, the use o f the biochemical markers of 
inflammation and activation o f coagiilation is limited 
because o f their low specificity for the presence of 
unstable coronary artery disease. Furthermore, 
testing for activation o f coagulation suffers from lack 
o f standardization o f the analytical procedures and 
preanalytical difficulties.”  Thus the use o f these 
markers in the diagnostic work-up of patients with 
suspected acute coronary syndrome is uncertain.
Markers o f  myocardial injury. Myocardial injury 
starts with the loss o f myocardial cell integrity 
induced by myocardial ischemia and ends with cell 
death and myocardial necrosis. With the 
development o f new immunological techniques it 
became feasible to detect any cardiac constituent 
released following loss o f myocardial cell integrity. 
Currently used markers for myocardial injury can be 
subdivided according to their intracellular 
compartmentation in the myocytes into three groups: 
cytosolic, structural, or both cytosolic and structural 
(Table 1).
The cytosolic group consists o f unbound cytosolic 
proteins like myoglobin, CK and CK-MB isoenzyme, 
fatty acid binding protein (FABP) and glycogen  
phosphorylase BB (GPBB). The structurally bound 
protein group include myosin heavy chains (MHC), 
myosin light chains (MLC) and actin. The third 
group consists of.cTnT and cTnl which are present in 
both minor cytosolic and major structurally bound 
protein pools.””
The release kinetics o f a marker depends on its 
intracellular compartmentation. Unbound cytosolic 
markers appear early in circulation (Figure 2) and 
their serum concentration is significantly affected by 
perfusion o f the infarct zone. The kinetics of 
myoglobin, FABP and GPBB are the same and 
characterized by earlier appearance, shorter time to 
peak value, and shorter duration o f elevation 
compared with CK (Figure 2). The appearance in 
serum of the structurally bound myofibrillar proteins 
depend on the activation o f proteolytic enzymes, 
leading to disintegration o f the contractile apparatus. 
This process is time consuming and results in 
continuous release o f these markers from necrotizing 
myocytes. As a consequence, the kinetics o f all these 
markers are characterized by late appearance, long 
time to peak value, long duration o f elevation, and 
not significantly affected by reperfusion o f the infarct 
zone.”
Since cardiac troponins exist both in a free 
cytosolic and structurally bound protein pool, they 
have an early release kinetics resembling cytosolic 
and a late release resembling structurally bound
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Table 1 - Cardiac markers and pathologic activation.
Pathophysiology C ard iac  M a rk ers
Unstable coronary lesion
Plaque rupture CRP, Serum amyloid A
Intracoronary thrombosis Platelet activation, P-selectin, soluble fibrin
Myocardial injury
Tissue ischemia GPBB
Tissue necrosis
Cytosolic: myoglobin, FABP, CK-MB 
Structural: MLC, MHC, Actin 
Cytosolic & Structural: cTnT, cTnl
CK-MB - creatine kinase MB, FABP - fatty acid binding protein, GPBB - glycogen phosphorylase isoenzyme BB. MLC - myosin light chains, 
MHC - myosin heavy chains, cTnT - cardiac troponin T, cTnl - cardiac troponin I
molecules (Figure 2). Reperfusion o f the infarcted 
zone significantly affect the release kinetics of the 
cytosolic but not the structurally bound pool.’“^
Characteristics o f markers o f myocardial injuiy. 
Most cytosolic cardiac proteins lack cardiac 
specificity since they are also expressed in skeletal 
muscles and other tissues and are increased in renal 
failure patients probably as a consequence of skeletal 
myopathy.”
Over the years, CK-MB has proven useful in most 
situations in the accurate diagnosis of cardiac injury. 
Serial measurements and the characteristic rise and 
fall of the enzyme is nearly pathognomonic for 
diagnosing MI.” CK-MB is also an useful 
component in assessing re-infarction or infarct 
extension. CK-MB mass assay have been shown to 
be superior to activity based assays, such as 
immunoinhibition or electrophoresis.’* ” Despite this 
excellent performance, CK-MB is not the ideal 
marker. SW etal muscle has both higher total CK 
activity per gram of tissue and may have up to 3% 
CK-MB This results in nonspecificity, particularly 
in patients with concomitant myocardial and skeletal 
muscle injury. The calculation of the percent relative 
index [(CK-MB/total CK)xlOO] may assist in the 
differentiation between myocardial and skeletal 
muscle causes o f increased CK.'*'”  Whilst other 
investigators have concluded that the relative index 
unacceptably degrades the sensitivity o f CK-MB and 
should be abandoned.” '’^  In addition to the issue of 
tissue specificity'”” and its inadequacy in identifying 
patients with minimal myocardial damage,” ” CK- 
MB requires 8-12 hours to rise and falls 2-3 days 
after the onset o f symptoms which makes it less 
reliable for the early and late retrospective diagnosis 
of cardiac necrosis.
Myoglobin has a low molecular weight which 
facilitates direct access into blood stream, thereby 
bypassing the lymphatics leading to the rapid release 
of the protein during acute MI.”  As a result, serum 
myoglobin levels rise fast, reaching twice normal 
values within 2 hours and peaking within 4 hours o f  
acute MI.”  Due to this result, myoglobin is currently 
the marker o f choice for timing the onset o f  
necrosis” ’"'* and monitoring o f reperfusion.”  (Table 
2). A recent study showed that a diagnostic strategy 
which include myoglobin, CK-MB, and clinical 
indicators including time to treatment and the chest 
pain grade, show high efficiency and may provide an 
important new tool to assess reperfusion after 
thrombolytic therapy.’” In addition, myoglobin 
enhances early sensitivity o f biochemical testing for 
myocardial infarction.” But, since myoglobin is the 
same molecule in cardiac and skeletal muscle, it 
lacks cardiac specificity. Myoglobin is a very 
sensitive marker for skeletal muscle injury and is also 
increased in renal failure patients.” ”
Although the results o f small recent studies 
suggest that FABP and GPBB might have slightly 
higher specificity than myoglobin,” -”  it is uncertain 
whether these markers can replace myoglobin which 
has been evaluated in many trials during recent years.
The CK-MB isoforms (also termed subforms) have 
also been shown to be early markers for acute MI 
with a release kinetics similar to that o f myoglobin.”  
Currently, CK-MB isoforms are most effectively  
measured by high-voltage electrophoresis, and are 
currently used only in a few routine hospital 
laboratories.” ’”  However, with simplification in 
analytical methodologies, the routine use o f these 
markers might increase.
Structurally bound myofibrillar protein such as
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Table 2 - Characteristics of cardiac makers.
C haracteristics C ard iac  m ark ers
Early release 
Prediction o f reperfusion 
High specificity 
Wide diagnostic window 
Prediction of outcomes
Myoglobin, CK-MB isoforms, FABP, GPBB 
Myoglobin, CK.MB, CK-MB isoforms 
cTnT, cTnl, CK-MB isoforms, CK-MB 
cTnT, cTnl, MLC/MHC 
cTnT, cTnl, CK-MB
CK-MB - creatine kinase MB, FABP - fatty acid binding protein, GPBB 
- glycogen phosphorylase isoenzyme BB, MLC - myosin light chains, 
MHC - myosin heavy chains, cTnT - cardiac troponin T, 
cTnl - cardiac troponin I
MLC, MHC and actin lack cardiac specificity since 
they are expressed in skeletal muscles. Thus, despite 
of their potentially higher sensitivity and wider 
temporal diagnostic window,” these proteins are not 
routinely used.
Due to their unique biochemical makeup and 
location, cTnT and cTnl have emerged as sensitive 
and more cardio-specific indicators o f myocardial 
cell necrosis which improved the risk stratification 
process (Table 2) and may facilitate therapeutic 
decision making in patients with acute coronary 
syndromes.
Cardiac troponins. Troponins T, I and C form a 
trimeric complex that regulates the calcium- 
modulated interaction of actin and myocin in both 
skeletal and myocardial striated muscles.” ’” 
Troponin T functions to bind the troponin complex to 
the tropomysin strand; troponin I functions to inhibit 
the activity of actomyosin-adenosine triphosphate; 
and troponin C serves to bind 4 calcium ions, thus 
regulating contraction.” ”  These subunits of the 
troponin complex are the product o f different genes 
and are not related to each other in protein structure.” 
Troponin T and troponin I both have cardiac 
isoforms that are the product of unique gene 
sequences with corresponding unique protein 
structures.” -”  This has allowed the development of 
monoclonal antibodies used in assays that 
differentiate the cardiac isoforms from those 
produced in skeletal muscle.” ’” The aminoacid 
composition of troponin C is identical in cardiac and 
skeletal muscle tissue, precluding use of this protein 
as a specific cardiac marker.” ”
The ventricular myocardium contains 10.8 mg.g-' 
net weight of cTnT and half that amount of cTnl.”  
The molecular weights of cTnT are 37,000 and cTnl 
are 24,000 Da.” ” Whilst both proteins are 
predominantly found bound to the contractile 
apparatus of muscle, there is 6-8% free cytosolic pool 
for cTnT, compared with 3-4% for cTnl.*’”  Cardiac 
troponin T appears in blood of patients with acute MI
as a mixture o f complexed cTnT-I-C and free cTnT. 
Cardiac troponin I is more hydrophobic and appears 
in blood predominantly in the binary complex cTI-C 
found with smaller amounts o f the complexed cTnT - 
I-C.”
Following myocardial injury, a biphasic release 
pattern is usually noticed with an early peak 
corresponding to release from the free cytosolic pool 
and a sustained release o f intact complexes from the 
myofibrils.’"' This is more clear with cTnT than cTnl, 
possibly because of the absence o f free cTnl in the 
serum. This may also explain the shorter duration of 
elevation of cTnl (5-7 days) compared to cTnT (7-10 
days) since the degradation of the complexed cTnl 
leads to faster clearance o f the protein.”
Cardiac troponin I is not expressed in skeletal 
muscle throughout ontogeny. After the ninth 
postnatal month, it is expressed only in 
myocardium.” On the other hand, cTnT is expressed 
in fetal skeletal muscle and re-expressed in adult 
skeletal muscle after injury.'””  Early studies have 
questioned the clinical specificity o f cTnT assays in 
patients with chronic renal failure.” ’* With the 
development o f a second-generation assay for cTnT, 
the frequency of positive results in these patients is 
lower than the frequency in the first-generation assay, 
although still higher than for cTnl.’ *^” Subsequent 
studies have shown that the antibodies in the second- 
generation assays are specific for cTnT isoforms, do 
not detect the cTnT isoforms expressed in diseased 
skeletal muscle, and therefore do not produce false- 
positive cTnT results in skeletal muscle disease and 
renal patients.*' *’ Preliminary reports showed that 
increased levels o f cTnT in patients with chronic 
renal failure is associated with higher incidence of 
cardiac death.*’ The importance o f these findings is 
not completely known and the prognostic 
significance o f the low cardiac troponin level in 
chronic renal failure remains unclear, pending 
completion o f ongoing outcome studies.*"*
Continuing analytical issues have promoted 
manufacturers o f troponin assays to produce new 
generation kits to improve assay sensitivity and 
specificity. A  clear example was the problem of 
nonspecific binding of skeletal muscle troponin 
encountered by the first-generation assay o f cTnT 
and was corrected with the subsequent generation of 
assays.*’ Ongoing issues include lack of 
standardization of cTnl assays. Results from different 
manufacturers produce cTnl values that differ by a 
factor o f 20 or more.” This is not a problem with 
cTnT assays which are available from only one 
manufacturer and are standardized to a single 
material.”  Other issues that involve all cardiac 
troponin assays include within-run and total 
imprecision variability between commercial runs and 
the potential for false-positive results because o f the
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presence of fibrin clots and heterophile antibodies.*’ 
Role o f cardiac troponins. Due to their 
exceptionally high specificity for myocardial injury, 
cardiac troponins have gained special interest in a 
variety of clinical situations (Table 3). Thus cardiac 
troponins may be useful to confirm a suspected 
myocardial infarction, aid in the diagnosis o f difficult 
cases, and assist in the triaging o f patients with chest 
pain, a procedure for which demand is increasing.’* 
Because of their particular kinetics, cardiac troponins 
have a wide diagnostic window, permitting both very 
early and late detection of MI after the onset of 
symptoms.” *’
Measurement of cardiac troponins can reliably 
detect MI with a sensitivity and specificity superior 
to CK-MB. Recent studies, however, show that the 
sensitivity o f troponins to detect MI is greater than 
CK-MB after 6-12 hours but before this time, levels 
of CK-MB or myoglobin have equal or superior 
sensitivity.*’ ** Also, there is evidence that cardiac 
troponin measurement can be used for the estimation 
of MI size. The extent o f cardiac troponins release 
and scintigraphic evidence of infarct size has been 
correlated.* '^^” A single cardiac troponin level 
measured 3-5 days after MI may be useful for 
estimating infarct size in a wide variety of 
circumferences.”'
The measurement of cardiac troponins provide an 
absolutely cardiac specific marker for patients with 
minor degrees of myocardial damage. Elevated 
levels of cardiac troponins can be detected in some 
patients with normal levels of CK-MB in the serum 
and no diagnostic ECG changes. The detection of 
this minor degree o f ischemic damage is very 
important in defining the severity of disease within 
the spectrum of aciite coronary syndromes. In 
addition, several studies have demonstrated an 
increased number of cardiac events in patients with 
elevated cardiac troponins, even in those without 
elevated CK-MB levels.”’ ”’ Recently, large 
prospective studies showed that patients with 
detectable levels of cardiac troponins have a 
significantly worse prognosis when compared with 
those without elevated levels.”’ ”*
In the global use of strategies to open occluded 
coronary arteries Ila (GUSTO Ila) trial, 854 patients 
who presented within 12 hours of the onset of acute 
myocardial ischemia were studied in a large 
prospective analysis.”’ The investigators found that 
elevated troponin levels were associated with 
significantly higher mortality rates within 30 days, 
both in total study population (11.8% vs. 3.9%) and 
in all electocardiographic subgroups examined, 
another separate study, termed the fragmin during 
instability in coronary artery disease (FRISC) study, 
examined peak cTnT over the 24-hour period after 
initial presentation in 976 patients with unstable 
coronary artery disease.”’ This study concluded that 
the risk of an adverse cardiac outcome increased as
T able 3 - Role of cardiac troponins.
Confirmation of suspected MI
Early and late detection of MI (6 hours - 1 week)
Estimation MI size
Detection of minor degrees o f myocardial damage
Assessment in triaging patients with chest pain
Risk stratification in patients with acute coronary syndromes
Guide therapeutic decisions with LMWH, Gp Ilb/IIIa inhibitors and 
questionable PTCA
Differentiation of skeletal from cardiac muscle injury
Detection of perioperative MI and assessment o f cardioprotective 
measures
Assessment in the diagnosis o f myocarditis
Ml-myocardial infarction, LM W H-low molecular weight heparin, Gp- 
Glycoprotien, PTCA-percutaneous transluminal coronary angioplasty
the cTnT level increased, indicating that cTnT 
measured in the first 24-hour provides a valuable 
prognostic information over the following 5 months, 
which is independent o f age, hypertension, number of 
antianginal drugs, and ECG changes.”’ Similarly, 
when cTnl was investigated in 1404 patients with 
unstable angina or non-Q wave MI in the thrombosis 
in myocardial infarction Illb (TIMI Illb) study,”* 
increased levels of cTnl were associated with 
significantly higher mortality at 42 days (3.7% vs 1% 
in patients with undetectable levels o f the marker).
In addition, qualitative assays o f both cTnT and 
cTnl were investigated in patients having a non­
diagnostic ECG and were foimd useful for predicting 
risk in this patient population.”” In his trial, Hamm 
et al showed that patients with elevated levels of 
cardiac troponins had a high incidence o f short term 
cardiovascular events, whereas those with no 
detectable levels of cardiac troponins had a low event 
rate. Therefore, cardiac troponins can be used to 
triage patients for appropriate placement within the 
hospital. It should be noted, however, that in the 
TIMI Illb study as well as in the study by Hamm et 
al, absence o f cardiac troponins does not equal to the 
absence o f cardiovascular risk. Those patients with 
chest pain and undetectable cardiac troponins can 
still suffer short term cardiovascular events, although 
at a much lower rate.”*”” Thus, those patients still 
require subsequent but less urgent testing to 
determine if their chest pain is related to coronary 
ischemia.
Because o f their ability to identify high-risk 
patients, cardiac troponins may also facilitate 
therapeutic decision making. Recent studies showed 
that increased cardiac troponins concentrations can 
clearly identify patients who would benefit from 
treatment with low molecular weight heparin or
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glycoprotein Ilb/IIIa inhibitors.'”” '”  Given the 
relatively high cost of these medications when 
compared with other standard antithrombotic and 
antiplatelet therapies, it is hoped that the 
measurement o f cardiac troponins will allow for the 
optimum utilization o f these treatments. 
Furthermore, a recent study o f 860 patients with 
ACSs without ST segment elevation showed that 
early catheter-based intervention was associated with 
low incidence o f postintervention Mis and death even 
in those patients with increased levels of troponins.'”’ 
This suggests that such patients may benefit from 
intervention-based strategy. However, more studies 
are required before the recommendation o f such 
strategy.
Cardiac troponins can also distinguish true 
myocardial damage from concomitant skeletal 
muscle injury seen in acute skeletal muscle trauma or 
chronic muscle disease, including patients with 
Duchenne muscular dystrophy, polymyositis and 
chronic myopathy; as well as well-trained marathon 
runners.'’ Serum levels of cardiac troponins may be 
also used to identify and measure perioperative 
myocardial damage and may be useful in assessing 
the efficiency of cardioprotective measures.'”^ '”* 
Because of their cardiac specificity and wide 
diagnostic window, cardiac troponins may be useful 
in diagnosing myocarditis, particularly if  patients 
present late after the onset o f symptoms.'””
In conclusion, markers of myocardial injury will 
continue to play an essential role in the assessment 
and management of patients presenting within the 
spectrum of acute coronary syndromes, a term 
representing the continuum of acute myocardial 
ischemia ranging from angina through Q-wave 
myocardial infarction. Coronary artery lesion 
instability can be detected by markers o f plaque 
inflammation and disruption, platelets reactivity, and 
thrombosis. When myocardial injury occurs with 
severe impairment o f coronary blood flow, several 
markers are released from the damaged rnyocyte. For 
many years, creatine kinase-MB isoenzyme (CK- 
MB) has been the conventional marker for 
myocardial infarction. Despite its inadequate 
sensitivity and specificity for myocardial injury, CK- 
MB remains an essential component in assessing re­
infarction or infarct extension, as well as in 
monitoring reperfusion after thrombolytic therapy 
when combined with myoglobin. Among the many 
cardiac markers for myocardial necrosis, cardiac 
troponins possess superior sensitivity and specificity 
for the detection of myocardial injury. In addition to 
their superior performance in detecting minor 
myocardial damage, cardiac troponins can be useful 
in detecting perioperative myocardial infarction, 
infarct size, improving risk stratification, and 
facilitating therapeutic decision making in patients 
with acute coronary syndromes.
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SUMMARY
Cardiac troponins are sensitive and specific markers for the detection of minor myocardial injury. However, 
they have been rarely used to monitor myocardial injury after coronary stenting. The purpose of the study was to 
measure cardiac troponin I  (cTnl) and cardiac troponin T (cTnT) levels after apparently successful percuta­
neous transluminal coronary angioplasty (PTCA) with or without coronary stenting and to compare their 
results with serum creatine kinase (CK) and its isoform, creatine kinase-MB (CKMB). CTnl and cTnT levels 
were compared with those of CK or CKMB in 50 consecutive patients with stable angina undergoing visually 
successful PTCA with stenting (n =  35) or without stenting (n =  15). Cardiac Tnl, cTnT, CK and CKMB lev­
els were measured before and 6, 24, and 48 hours after the procedures was performed. None of the patients had 
abnormal cTnl or cTnT levels, CK activity, or CKMB levels before the procedures. Moreover, no patient 
showed electrocardiographic evidence of myocardial infarction. 13 patients (26%) had abnormal peak values 
of one or more markers at 24 hours after coronary intervention. Troponin I  was elevated in 10135 patients after 
coronary stenting (29%) and in 2U5 patients after PTCA (13%) (P =  0.327). Troponin T was elevated in 6 
patients (17%) and CKMB activity was elevated in 3 patients (9%) of the coronary stenting g^oup. CTnl was 
more significant than CKMB (P =  0.023) in detecting minor myocardial injury. When compared with cTnl 
and CKMB, cTnT did not reach significance (P =  0.129 and 0.489, respectively). 5 out of the 13 patients with 
abnormal markers (38%) developed side branch occlusion after stenting. In conclusion, cTnlwas a very sensi­
tive marker in detecting minor myocardial injury after coronary anaplasty with or without stenting. The fre­
quency of increased serum levels of cardiac troponins was higher in patients undergoing stent implantation than 
in those treated with angioplasty alone but did not reach significance. Side branch occlusion may have 
accounted for some, but not all, periprocedural minor myocardial injury in the stent group.
INTRODUCTION
Minor myocardial injury, as diagnosed by elevation  
of cardiac enzym es after percutaneous coronary  
interventions, is relatively com m on and reported in 
approximately 8% to 15% of patients undergoing 
PTCA [1-4]. These minor injuries w ere previously 
thought to be relatively benign, resulting in no per­
manent sequelae [1,2]. However, m ore recent tri-
a[s confirm  an increased risk for future cardiac  
events in patients with elevated post-intervention  
myocardial isoenzym e levels [5 -9]. There is contro­
versy as to the source of mild isoenzym e elevations 
of CK and CKMB activity in patients undergoing  
PTCA, but such elevations have been  linked to dis­
tal m icroem bolization, side branch occlusion, mul­
tivessel procedures, abrupt vessel closure and  
directional coronary atherectom y [8,10]. Coronary
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Stenting is considered a well established technique 
to improve outcom es of PTCA and to reduce the 
in cid en ce of em ergency coronary artery bypass 
grafting after PTCA (11]. The worldwide use of this 
technique is rapidly increasing in recent years [12].
CKMB is generally regarded as the reference stan­
dard for the diagnosis of myocardial necrosis and is 
com m only used to m onitor m yocardial dam age  
after coronary interventions [1 -9 ] . H ow ever, 
CKMB m easurem ent is not a sensitive test for the 
d etection  of m inor m yocardial tissue dam age  
[13,14]. Cardiac troponins are regulatory contrac­
tile proteins that are not normally found in the  
peripheral blood [15,16]. They are unique markers 
of m yocardial dam age b ecau se o f their cardiac  
specificity [17,18]. They have been  shown to be  
m ore sensitive and sp ecific than CKMB for the  
d etection  of m inor m yocardial dam age [13 ,14 , 
1 9 -2 5 ]. H ow ever, cardiac troponins have b een  
rarely used to monitor myocardial injury after coro­
nary stenting [26]. Accordingly, the purpose of the  
study was to measure cTnT and cTnl after appar­
ently successful PTCA with or w ithout coronary  
stenting and to com pare their resuit with serum CK 
and its isoform, CKMB.
MATERIAL AND METHODS__________________
The study con sisted  o f 5 0  co n secu tiv e  patients 
(40 m en and 10  w om en ) w h o  had und ergone  
elective single or multivessel PTCA with or w ith­
out coronary stenting at Prince Sultan Cardiac 
Center in Riyadh. Ail patients had stable angina  
and had normal renal function before undergoing  
coronary interventions. The patients w ere exclud­
ed  if they  had an a cu te  m yocardial infarction  
within 2 w eeks, elevated cardiac enzym es before 
cardiac catheterization, or a resting 12-lead  e lec ­
trocardiogram  (ECG) w ith  right or left b un dle  
branch block, interventricular conduction  delay, 
or p aced  rhythm. All patients in clu d ed  in this 
study had a successful procedure. 'Success' was 
defined  as an increase of >20%  in luminal diam ­
eter with a final p ercen t d iam eter sten osis  of 
<50%  and no major com plications. Major com ­
plications included em ergency bypass surgery or 
myocardial infarction.
Coronary lesions w ere assessed by coronary angio­
graphy with m ultiple v iew s. Balloon angioplasty  
and stent implantation w ere performed according 
to standard clinical practice by the femoral app­
roach. Results before and after coronary interven­
tions w ere evaluated with on-line quantitative
coronary angiography (Digital Cardiac Imaging, 
Philips M edical Systems, Best, The Netherlands). 
The contrast-filled guiding catheter w as used  as 
calibration for vessel d im ension  calcu lation. All 
patients received  aspirin, ticlop id in e (Sanofi 
W inthrop, Gentilly cedex , France) and a calcium  
channel blocker or nitrate before the procedure. 
1 0 ,0 0 0  units o f heparin (Brun, M elsungen, Ger­
many) w ere adm inistered intravenously at the  
beginning of the procedure follow ed by additional 
boluses as need ed  to maintain an activated clotting 
tim e > 3 0 0  seconds.
ST-segm ent m onitoring w as begun before PTCA 
and w as continued  during the w h o le  procedure. 
During the patient's stay in the hospital, the ECG 
w as m onitored continually. A 12 -lead  ECG w as 
taken before, im mediately after, and the day after 
PTCA or coronary stenting.
B lood  sam p les w ere  draw n b efo re  and  6 , 2 4 ,  
and 4 8  hours after coronary in terven tion . T he  
blood  sam ple w as centrifuged at 1 9 0 0  g for 10  
m inutes. CK and CKMB activities w ere  m easured  
and the serum  w as frozen at -2 0 ° C  until cTnT 
and cTnl m easurem ents. Total CK activity (nor­
mal < 1 9 5  lU/L) and CKMB activity (normal < 2 4  
lU/L) w ere m easured on a Hitachi 9 1 7  (Boehrin­
ger, M annheim , G erm any) analyzer w ith  a u to ­
m atic en zy m e  im m u n oassay  m eth o d . C ardiac  
TnT w as assayed  by an electron  ch em ilum in is- 
c e n c e  im m u n oassay  on a 2 0 1 0  Elecys System  
(Roche D iagnostic, form erly Boehringer, M ann­
heim , Germ any). The cu t-off valu e o f cTnT uti­
lizing this m ethod to assess for m yocardial injury 
w as 0.1 ng/mL w ith a low er d e te c tio n  lim it o f
0.01 ng/mL as recom m en d ed  by th e  m anu fac­
turer. Cardiac Tnl assays w ere perform ed on an 
AxSYM random  access im m unoanalyzer (Abbott 
Laboratories, A bbott Park, Illinois) using m icro­
particle en zym e im m unoassay (ME!A) tec h n o lo ­
gy with a cut-off value o f 2 ng/mL and a low er  
d etection  limit o f 0 .3  ng/mL as recom m en d ed  by 
th e m anufacturer.
Statistical analysis
The frequency of abnormal results was determ ined  
for each  marker and com pared  by th e Fisher's 
exact test. Peak post procedural levels for each  
marker w ere com pared and related to the occur­
rence o f side branch occlusion. Com parison w as 
m ade b etw een  the PTCA group and the sten t 
group. Also, com parison was m ade b etw een  the  
patients with normal cardiac markers and th ose
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with abnormal ones. A P value <  0 .05  was consi­
dered statistically significant.
RESULTS_________________________________
A total of 50  patients, 4 0  males and 10 fem ales, 
w ere studied. Their age ranged from 32 to 76 with 
a mean age of 53.1 ± 1 0 .8  years. 15 had only PTCA 
(mean age of 5 1 .6 ± 1 0 .9  years) and 35 (mean age 
of 5 3 .8 ± 1 0 .8  years) had coronary stenting after 
PTCA. The diameter of the reference vessels was 
> 2 .5  mm in all patients w ho received stents.
All patients had normal values for all biochemical 
markers before the coronary intervention. At 6 
hours on e patient had elevated CKMB activity, two  
had significantly elevated cTnT and three had e le ­
vated cTnl levels. Abnormal peak values of on e or 
m ore markers at 24  hours after coronary interven­
tion w ere observed in 13 patients (26%). 2 patients 
had only PTCA (13% of PTCA patients) and 11 
patients had stenting (31 % of stenting patients).
CKMB activity was elevated significantly in 3 pa­
tients after coronary stenting (6% of the total pa­
tients and 9% of the patients with stenting). CTnT 
was elevated significantly in 6 patients after coro­
nary stenting (12% of the total patients and 17% of 
the patients with stenting). CTnl was elevated sig­
nificantly in 12 patients (24% of the total patients), 
2 follow ing PTCA alon e (13% o f PTCA patients) 
and 10 following stenting (29% of stenting patients) 
(Table 1). Five out of the 13 patients with abnor­
mal markers (38%) developed  side branch occlu­
sion after stenting. All o f them  w ere positive for 
cTnl, 3 w ere positive for cTnT and one was posi­
tive for CKMB. Using Fisher's exact test for markers 
values at 24  hours after coronary intervention, the 
frequency of abnormal cTnl was significantly high­
er than CKMB (P =  0 .023) but did not reach signif­
icance w h en  com pared with cTnT (P =  0 .1 2 9 ). 
The frequency of abnormal cTnT was n ot signifi­
cantly higher than CKMB (P =  0 .4 8 9 ). The fre-
Tabie 1. Abnormal markers distribution.
Abnormal Number of patients % ot patients
markers PTCA Stent Total PTCA Stent Total
CKMB 0/15 3/35 3/50 0% 9% 6%
CTnT 0/15 6/35 6/50 0% 17% 12%
cTnl 2/15 10/35 12/50 13% 29% 24%
CKMB -  creatine kinase activity 
CTnT -  cardiac troponin T 
CTnl -  cardiac troponin I
PTCA -  percutaneous transluminai coronary angioplasty
quency o f abnormal cTnl in the stent group was 
not significantly higher than th ose  in the PTCA 
group (P =  0.327).
DISCUSSION______________________________
In our study of 50  consecutive patients treated by 
elective PTCA with or w ithout stent implantation, 
three (6%) had elevation  of CKMB activity. This 
result is con sistent with other series that have  
reported elevation  of both creatine kinase and  
CKMB activity (>5% ) from 0% to  11.5%  after 
uncom plicated coronary interventions [4 ,8 ,27 ,28]. 
Although it has b een  recom m en d ed  to m onitor 
CKMB levels after coronary interventions [9], this 
marker is not sensitive for the detection of minor 
myocardial injury and d oes not m eet the current 
n eed s for a highly sensitive marker o f m inor 
myocardial tissue dam age [13,14].
Cardiac troponins are highly sensitive and specific 
markers for myocardial injury [1 3 ,1 4 ,1 9 -2 5 ] . In 
sp ite o f this, they have rarely b een  used  in the  
m onitoring of m yocardial injury after successfu l 
PTCA [27 -30 ]. Our results show  that overall 26%  
of the patients had abnorm al cardiac troponins  
after elective PTCA or stent coronary interventions. 
This result is consistent with previous studies show ­
ing a very high diagnostic sensitivity of cTnT versus 
CKMB in the detection of minor myocardial injury 
after PTCA [27,28,31].
Cardiac troponins m easurem ent for th e m onitor­
ing of m yocardial injury after coronary sten ting  
w as rarely system atically reported [26]. In this 
study w e  dem onstrated that cTnl and cTnT w ere  
more sensitive than CKMB (29% and 17% vs 9%) 
and that cTnl was m ore sensitive than cTnT (29% 
vs 17%) in the d etec tion  o f m inor m yocardial 
injuries after successful stenting. W e sh ow ed  that 
the incidence of cTnl and cTnT release w as higher 
in the stent group than in the PTCA group (29%  
and 17% vs 13% and 0% respectively). The higher 
dilatation pressure used in the stent group m ay be  
the cau se o f d eep er  injury o f th e v esse l w all, 
which may act as a stimulus for platelet deposition  
and m icroem bolization. In spite of the small n um ­
ber o f patients in this study, the freq u en cy  of  
abnormal cTnl at 2 4  hours after intervention was 
statistically significant w hen  com pared with CKMB 
(P -  0 .023). O n the other hand, cTnT w as n ot sta­
tistically significant w hen  com pared  with CKMB 
and just failed to reach sign ificance w h en  c o m ­
pared with cTnl. Therefor, in this study, cTnl was 
the m ost sensitive marker in d etec tin g  m inor
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myocardial injury after coronary angioplasty with 
or w ithout stenting.
Five out of the 13 patients with abnormal markers 
(38%) developed  side branch occlusion after stent­
ing. All of them  w ere positive for cTnl, 3 w ere pos­
itive for cTnT and o n e  was positive for CKMB. 
Although sid e  branch occlusion  can explain the  
m echanism  of the minor myocardial injury in these  
patients, it can not explain the mechanism  in the 
other 8 patients. O ne of these 8 patients, w ho had 
elevation of the three markers, underwent opening  
of a totally occluded artery which can be associat­
ed with distal em bolization.
Cardiac troponins have proved to be m ore sensi­
tive and specific markers of myocardial necrosis. 
Ravkilde and colleagues [29] uncovered m yocar­
dial ischaem ia and/or m inor m yocardial dam age  
that was inapparent by ambulatory electrocardiog­
raphy in 13% of 23 patients with elevated cardiac 
troponin T m easurem ents after successful PTCA. 
H owever 5 of 6 patients with increased levels of 
cardiac troponin T had p ronounced  ch est pain 
during the procedure. Perioperative side branch 
occlusions w ere n ot seen . Hunt and co lleagu es  
[28] failed to dem onstrate any significant elevations 
o f CKMB or cardiac troponin I levels on im m u­
noassay after successful angioplasty in 22 patients, 
regardless of the instability of the angina, the sever­
ity of the stenosis, number of target lesions, num­
ber of duration o f inflations, and occurrence of 
chest pain during the procedure. Talasz and co l­
leagues [30] also could not dem onstrate a signifi­
cant increase in CKMB or cardiac troponin T con­
centrations in 16 patients undergoing uncomplicat­
ed PTCA but correlated an increase in CKMB mass 
and cardiac troponin levels in 5 and 3 patients, 
respectively, to the occurrence o f sid e branch 
occlusions. Genser and colleagues [31] investigated 
52 patients undergoing PTCA and found elevated  
cardiac troponin T levels in 13 patients (25%). All 
of these patients experienced either a minor com ­
plication, such as a side branch occlusion (9 pa­
tients), as a result o f the procedure or a major 
com plication afterward resulting in ischaemia with 
chest pain and electrocardiographic changes typi­
cal of acute myocardial infarction (4 patients). In 
contrast to the findings of previous investigators, 
Karim and colleagues [27] reported elevated car­
d iac troponin T concentrations in a m uch larger 
portion of patients undergoing successful PTCA. 
Although n one of their patients com plained  of 
ch est pain or had electrocardiographic changes  
indicating a new ly d ev elo p ed  acu te myocardial
infarction, they found increased cardiac troponin T 
levels in 11 (44%) of 25  patients. These different 
findings could be explained in part by the different 
exclusion criteria used. Because cTnT concentra­
tions w ere shown to be elevated until 1 to 2 w eeks  
after acute myocardial infarction, the former stud­
ies as well as our study, excluded all patients w ho  
had an acute myocardial infarction within the pre­
ceding 2 w eeks before PTCA. O n the other hand, 
Karim and colleagues [27] excluded only patients 
presenting with an acu te m yocardial infarction  
within the last 5 days. Thus, the cardiac troponin T 
levels may have been  elevated before the patients 
underwent PTCA.
The real question now  for the interventional cardi­
ology com m unity is how  to integrate th ese  find­
ings, as well as our findings, into clinical practice. 
The duration o f coronary occlu sion  and su b se­
q u en t m yocardial ischaem ia in uncom plicated  
PTCA with or without stenting is brief and usually 
well tolerated by the myocardium. O n e should be  
alerted to the possibility o f minor myocardial dam ­
age w h en  PTCA is com p licated  by sid e branch  
occlusion, abrupt vessel closure, clinical sym ptom s 
of chest pain, n ew  electrocardiographic abnormali­
ties, or difficult multivessel procedures. Since the 
release kinetics o f cardiac troponins indicate an 
ongoing release from necrotizing m yocytes, it 
seem s probable that the elevated levels likely pre­
sent true myocardial dam age. A growing body of 
ev id en ce  has accum ulated  linking the m inor 
m yocardial infarctions that occur after percuta­
neous procedures to an adverse long-term progno­
sis and particularly to an increase in late mortality. 
A bdelm eguid  and co lleagu es [29] reported that 
m odest increases of CKMB to 4 0  lU/L after coro­
nary interventions are associated  with a tw ofold  
increase in the risk of cardiac death.
T hese findings have im portant im plications for 
daily interventional cardiology practice and future 
research in coronary revascularization and highlight 
the risks associated with small non-Q -w ave infarc­
tions as a com plication of percutaneous coronary  
interventions. Further investigation is required to  
m ore fully understand and prevent these significant 
events and, on a secondary basis, to prevent their 
adverse long-term sequelae.
CONCLUSIONS____________________________
l .c T n l is a very sensitive marker in detecting mi­
nor myocardial injury after coronary angioplasty 
with or w ithout stenting.
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2. The frequency of increased serum levels of car­
diac troponins is higher in patients undergoing  
stent implantation than in those treated with 
angioplasty alone but does not reach significance.
3. Side branch occlusion may have accounted for 
som e, but not all, periprocedural minor myocar­
dial injury in the stent group.
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Summary
Many recent experimental and clinical studies have provided evidence for the presence of 
inflammation in atherosclerotic lesions. Ongoing inflammatory reactions within coronary ath­
erosclerotic plaques are increasingly thought to be crucial determinants o f the clinical course 
o f patients with coronary artery disease (CAD). These facts lead to a search for reliable mark­
ers reflecting the inflammatory process in the atherosclerotic plaques. Circulating markers 
may consist of cytokines directly released from inflammatory cells present in the plaques and 
tissues exposed to recurrent ischemia as well as other reactants produced in response to these 
cytokines such as adhesion molecules and acute phase proteins. Recent studies suggest that 
markers of inflammation may reflect different aspects o f the atherothrombotic process at dif­
ferent points in the continuum of acute coronary syndromes, have a potential role for the pre­
diction of risk for developing CAD, and may correlate with severity and future risk for CAD. 
In spite of these findings, the clinical utility o f measuring these markers is limited by the avail­
ability o f reproducible diagnostic test assays. In addition, it remains to be determined whether 
markers of inflammation actually have a causal relation with cardiovascular disease, or simply 
reflect the underlying disease process. Such determination becomes important with the poten­
tial use o f these markers in targeting preventive therapies. Therefore, further well-designed 
prospective evaluation of each of these markers is needed before their use in routine practice.
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Background
Accumulating evidence indicates that atherosclerosis is 
an inflammatory process involving a network o f vascular 
wall cells, monocytes, T-lymphocytes, proinflammatory 
cytokines, chemoattractant cytokines (chemokines) and 
growth factors [1-6], The fatty streak is the earliest 
manifestation o f atherosclerosis. It is an inflammatory 
lesion, consisting mainly o f monocyte-derived 
macrophages and T-lymphocytes [7]. Proinflammatory 
stimuli such as oxidatively modified low density lipopro­
tein (LDL) cholesterol, free radicals, cigarette smoke, 
elevated plasma homocystein and infectious organisms 
cause endothelial dysfuncdon which leads to compen­
satory responses that alter the normal properties o f the 
endothelium [I]. A cascade o f events ensues leading to 
the development o f isolated macrophages foam cells, 
fatty streak formation and finally stable or unstable 
fibrous plaque [1-3]. This cascade of events is mediated 
by proinflammatory cytokines, chemoattractant 
cytokines (chemokines), growth factors and adhesion 
molecules produced by acdvated inflammatory, vascular 
smooth muscle and endothelial cells [1-3,8,9].
Proinflammatory risk factors cause local (vascular) or 
systemic (extravascular) inflammation which triggers the 
production of primary proinflammatory cytokines such 
as interleukin-la (IL-ip) and tumor necrosis factor -  a  
(PNF-a) [10, II]. Measurement o f these cytokines in 
serum can provide information about the inflammatory 
status of an individual [12]. Primary proinflammatory 
cytokines and oxidatively modified LDL activate the 
endothelium and the expression o f adhesion molecules 
that are crucial to the recruitment of inflammatory cells 
from blood stream into the vessel wall [8,13]. These 
adhesion molecules may be released in soluble form into 
the blood stream and can serve as markers o f vascular 
inflammation [12,14-17]. In addition, primary proin­
flammatory cytokines stimulate the production of  
chemoattractant cytokines (chemokines) which may play 
a major role in atherogenesis [II] and can be used as 
markers of inflammation. Moreover, primary proin­
flammatory cytokines stimulate the production o f inter­
leukin-6 (IL-6), a secondar): proinflammatory cytokine 
[11], which in turn stimulates the production o f acute- 
phase proteins by the liver [18]. Examples o f these pro­
teins include C-reactive protein (CRP), serum amyloid A 
(SAA) and fibrinogen [19]. Both IL-6 and acute-phase
Table 1. Markers of Inflammation.
1. Cytokines
a. Primary proinflammatory cytokines (iL-1, TNF-a)
b. Secondary proinflammatory cytokines (IL-6)
c. Chemoattractant cytokines -chem okines- (IL-8, MCP-1) 
1. Adhesion Molecules
a. Selectins (P-selectin, E-selectin, L-selectIn)
b. Cellular adhesion molecules (iCAM-1, VCAM-1)
1. Acute Phase Proteins
a. Produced in very high concentration (CRP, SAA) 
_ _ _ _ _ _ _ b. Produced in low concentration (Fibrinogen)
proteins can be used as markers of inflammation. Thus, 
it is possible to measure markers of inflammation (Table 
I) at different levels o f atherosclerotic inflammatory 
reactions.
Interleukin-1 (IL-1)
Interleukin-I, a glycoprotein, is a primary proinflam­
matory cytokine [10,11,20]. It exists in two major bio­
logically active forms, IL -la and IL-Ip [20,21]. Of these, 
IL-ip is the predominant circulating isoform in humans 
[21]. Both IL -la and IL-lp bind to the same receptors 
on the surface o f their target cells [22,23]. There are 
two IL-1 receptors (IL-IR), type 1 and type II [20]. 
After binding IL-I type I receptor (IL-IRI) can trans­
duce a signal by forming a light affinity complex with 
IL-IR accessory  ^protein (IL-IR-AcP) [24], while type 11 
receptor (IL-IRII), also termed as ‘decoy’ receptor, acts 
as a sink and does not transduce a signd [25]. In addi­
tion to the regulation by IL -lR ll, the unique feature of 
the regulation o f IL-1 is mediated by the naturally 
occurring competitive IL-1 type I receptor antagonist 
(IL-IRa) which represents a third form of IL-I proteins 
[20,21]. Also the soluble proteins o f the IL-IRI (IL- 
IsRI) and IL-IRII (IL-IsRII) function as natural 
‘buffers’ binding IL -la , IL-Ip and IL-IRa (20). 
Although monocytes, macrophages and macrophage- 
derived foam cells are the main sources o f IL-I, other 
cells such as endothelial cells also produce IL-I [20, 21].
IL-I may mediate the inflammatory response occurring 
in the vascular wall during atherogenesis by activating 
monocytes and expression o f  adhesion molecules on 
endothelial cells, inducing secretion o f other cytokines, 
chemokines and growth factors and stimulating smooth 
muscle cell proliferation [20,21]. In addition, IL-1 may 
enhance atherogenesis by promoting vascular smooth 
muscle cells proliferation [26,27], increasing endothelial 
cell procoagulant activity [28] and by affecting lipid 
metabolism [29].
As a key mediator o f inflammation, IL-I is expected to 
play a ma jor role in the pathogenesis o f GAD. Increased 
synthesis o f IL-1 has been demonstrated in human arte­
rial plaques [30, 31] and serum concentrations of IL-ip 
are raised in patients with minimal coronary artery dis­
eases [32]. In addition, increased IL-IRa levels within 
48 hours from admission in patients with unstable angi­
na were found to be associated with increased risk of in- 
hospital coronary events [33] and IL-IRa genotype IL- 
RN*2 has been found to be significantly associated with 
single-vessel CAD [34].
Tumor necrosis factor - a  (TNF-a)
Originally described by its antitumor activity, TNF-a is 
now recognized as a cytokine with multiple biological 
capacities [35]. In addition to cytostatic and cytotoxic 
effects on certain tumor cells, TNF-a is a primary proin­
flammatory cytokine [10,11] with a potent negative 
inotropic effect [36]. It is a non-glycosylated protein 
which acts via two distinct cell surface receptors called 
TNF Receptor I (P55) and TNF Receptor II (P75)
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[37,38]. T’hese receptors have been identified on virtual­
ly all cell types except erythrocytes [37,38]. Besides the 
cell-bound forms o f the TNF receptors, soluble forms 
are known which are capable o f binding TNF-a. These 
soluble receptors can therefore compete with the cell- 
bound forms and can inhibit the effects of TNF-a [39].
Monocytes and macrophages are the main producers of 
TNF-a, but other cells such as T-lymphocytes, natural 
killer cells, smooth muscle cells, endothelial cells and 
some tumor cells also produce TNF-a [35]. Biological 
effects o f TNF-a and IL-lp, particularly those associated 
with systemic and local inflammation, are nearly identi­
cal [40]. Therefore, TNF-a is also expected to have a 
major role in the pathogenesis of CAD, and it has been 
detected in human atherosclerotic plaques [41].
Increased levels o f TNF-a have been observed after 
acute myocardial infarction [42]. The concentration of 
soluble TNF receptors also increases rapidly and 
markedly after AMI [43]. This rise might represent a 
protective mechanism against TNF-a release. Similar to 
IL-6, TNF-a plays important roles in the regulation of  
the synthesis o f other acute-phase proteins which are 
established risk factors for atherosclerosis, such as fib­
rinogen and factor VIII [44]. TNF has also profound 
effects on lipid metabolism [45] and has been implicated 
in insulin resistance which produces changes in lipid 
and glucose associated with cardiovascular risk [46,47].
Interleukin-6 (IL-6)
Interleukin-6 is a secondary multifunctional proinflam­
matory cytokine [10,11]. It regulates humoral and cellu­
lar responses and plays a central role in inflammation 
and tissue injury [48]. These effects of IL-6 appear to be 
mediated through the interaction ofIL-6 with its recep­
tor complex (IL-6R). This complex is composed of a lig­
and-binding protein (IL-6Ra), and a signal-transducing 
subunit, (IL-6RP or gP 130) [49]. In contrast with other 
soluble cytokine receptors, the complex between soluble 
IL-6Ra and IL-6 is able to interact with the signal-trans­
ducing subunit on the surface o f target cells and is thus 
biologically active [50]. On the other hand, the naturally 
produced soluble form of the signal-transducing IL-6RP 
subunit (sIL-6RP) inhibits the activity o f IL-6 by binding 
to IL-6/IL-6Ra complex [51].
IL-6 can be produced by many vascular cells including 
endothelium, smooth muscle cells, lymphocytes and 
macrophages [48]. Because o f its central role in the 
inflammatory responses, it is extremely likely that IL-6 
is linked to the pathogenesis o f CAD. It is a major 
inducer o f acute phase proteins, as well as other 
cytokines and growth factors [52]. In addition, IL-6 
itself can activate platelets [53] and has procoagulant 
activity [54-56] and mitogenic activity for smooth mus­
cles [57].
Large quantities o f IL-6 are found in human atheroscle­
rotic plaques [58] and several studies have found a 
direct link between IL-6 levels and CAD. In a popula­
tion-based cross-sectional study, electrocardiogram
abnormalities were associated independently with 
increased IL-6 levels [59]. IL-6 levels appear to be pre­
dictive of future heart disease [60] and elevated in 
patients with unstable angina compared with those ivith 
stable angina [61]. Patients with persistently elevated IL- 
6 levels are also associated with a worse in-hospital out­
come following admission with unstable angina [62,63].
Chemokines
Chemokines, or chemoattractant cytokines, are mem­
bers of a superfamily of small polypeptides that mediate 
not only migration but also growth and activation of  
leukocytes and a variety o f other cells [64-66]. The 
largest chemokine classes are designated CC and CXC, 
according to the spacing o f the first two o f four con­
served cysteine residues [67,68]. Monocyte chemoattrac­
tant protein-1 (MCP-1) is the prototype of the CC class, 
where the first two cysteines are adjacent, whereas inter­
leukin-8 (lL-8) is the prototype for the CXC class, 
where the first two cysteines are separated by a single 
amino acid residue [69,70].
Chemokines are released in response to the primary 
proinflammatory cytokines (IL-Ip, TNF-a) released at 
the site o f insult. MCP-I is expressed by macrophages, 
smooth muscle cells, and endothelial cells (71-73) while 
IL-8 is expressed mainly by macrophages in human 
lesions [74,75].
MCP-I and IL-8 play a major role in atherogenesis. 
Both molecules induce chemoattraction o f monocytes 
and activated T-cells [76—79] and are also involved in 
the induction o f adhesion o f monocytes [79]. Moreover, 
IL-8 is an angiogenic factor [80] and can induce vascu­
lar smooth muscle cell proliferation and migration [81]. 
In addition to causing local immune response, the 
recruited T-cells along with macrophages occur in large 
numbers at the sites o f plaque rupture [82]. 
Inflammatory cytokines secreted by the T-cells are capa­
ble o f inducing the expression o f metalloproteinase by 
macrophages leading to development o f unstable 
plaque [83]. Thus, through their recruitment of mono­
cytes and activated T-cells, chemokines are involved in 
the local immune responses and vascular remodeling 
which occur during the formation o f unstable athero­
sclerotic plaques. Targeting chemokines and their 
receptors might provide an effective mean to control 
atherosclerosis.
Adhesion Molecules
Adhesion molecules are specific proteins on the 
endothelial cell surface and counter receptor proteins 
(ligands) on the leukocyte surface which regulate the 
different steps of leukocyte migration from the blood 
stream into the vessel wall [84-86]. Members o f the 
selectin family of adhesion molecules including lympho­
cyte L-selectin, endothelial E-selectin and P-selectin, 
mediate sticking and rolling adhesion o f leukocytes and 
slow down their passage across the endothelial surface 
to allow more stable interactions to occur [84-86]. On 
the other hand, members o f the immunoglobuHn super­
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family including ICAM-1 and VCAM-I mediate leuko­
cyte arrest and migration between the endothelial cells 
into the vessel wall [84-86]. These adhesion molecules 
are induced on the endothelial surface and other vascu­
lar cells in response to various stimuli, including prima­
ry pro-inflammatory cytokines, such as IL -ip  and 
TNFa [8,13]. Soluble forms of adhesion molecules origi­
nating from proteolytic cleavage o f membrane bond 
molecules may serve as markers o f endothelial cell acti­
vation and inflammation [87].
Serum concentrations of adhesion molecules have been 
shotvn to be related to development of CAD [88], friture 
risk of MI [89] and the risk o f early post-angioplasty 
restenosis [90]. They have also been shown to be high in 
patients with stable angina, unstable angina and MI 
compared with healthy controls [91-93].
C-reactive protein (CRP)
C-reactive protein is an acute phase reactant synthesized 
by the liver and consists o f five identical, non-glycosylat­
ed peptide subunits linked to form a cyclic polymerase 
[95]. The synthesis o f CRP is stimulated by cytokines, 
primarily IL-6 released from inflamed tissue [18]. The 
levels of CRP can increase up to 1000-fold during acute 
inflammation. [19]. The role o f CRP in atherosclerosis 
remains to be defined. The presence of CRP immunore- 
activity has been demonstrated in vmlnerable and rup­
tured plaque [96]. It is not clear yet whether it is locally 
expressed or absorbed from the blood stream. The pos­
sible mechanisms for direct involvement o f CRP in ath­
erosclerosis and thrombosis include complement activa­
tion through binding o f damaged cell membranes [97] 
and inducing tissue factor production by monocytes [98]
The development of high sensitivity assays for CRP has 
enabled the detection of mild elevation o f CRP within 
the normal range [99]. The application o f these assays 
during the last few years has made it possible to study 
CRP in a wide variety of atherosclerotic diseases and to 
explore its role in predicting cardiovascular events. CRP 
was first identified as a risk factor in the setting of pre­
existing cardiovascular disease [100,101] and its levels 
were correlated with the presence and severity o f coro­
nary, cerebral and peripheral atherosclerosis [102]. In 
addition, many studies have demonstrated that CRP has 
prognostic value in acute coronary syndromes 
[101,103-107] and that it is able to predict future coro­
nary events in apparently healthy men and women 
[108-117]. Moreover, data have revealed that increased 
coronary risk associated with elevated CRP may be 
modified with certain preventive therapies, such as 
aspirin and statin-type drugs, and that CRP may help to 
identify those who would benefit most from these phar­
macological interventions [117 - 119].
Serum Amyloid A (SAA)
SAA is the precursor of the amyloid A protein deposited 
in amyloid A amyloidosis [120]. SAA proteins, a family 
o f inflammatory apolipoproteins, are major acute phase 
reactants ivhich are produced in response to various
insults [121]. Their concentrations can increase as much 
as 1000-fold during inflammation [19,122]. They rapid­
ly bind to high-density lipoproteins (HDL) after their 
synthesis and play a role in modifying cholesterol trans­
port during inflammatory conditions [123,124].
Synthesis o f SAA in response to pro-inflammatory stim­
uli is due largely to the synergistic effects o f IL-1 and 
IL-6. [125,126]. Although the liver is the primary syn­
thesis site o f SAA proteins [19], extrahepatic production 
from normal and abnormal tissues has been reported 
[127]. Recent studies have revealed the production o f  
SAA by cells from human atherosclerotic lesions includ­
ing endothelial cells, cultured smooth muscle cells and 
monocyte-macrophage cell liver [128,129].
SAA is present in human atherosclerotic plaque [130]. 
The exact role o f SAA in atherogenesis has not been 
fully defined. It is complicated by SAA role in the 
metabolism of HDL and otlier lipoprotein fractions, it  
may act as a signal for redirecting HDL to sites o f tissue 
destruction and cholesterol accumulation [131]. 
Additionally, it might influence HDL clearance of excess 
cellular cholesterol by displacing apo A-1 from HDL 
[132] and by modulating the activity of lecithin choles­
terol acyltransferase [133]. Other potential mechanisms 
include remodeling of the plaque by inducing the secre­
tion o f collagenase in smooth muscle cells [134,135], 
affecting thrombus formation by inhibiting platelet 
^ggi'Ggation and adhesion at the endothelial cell surface 
[136-138] and increasing the oxidation o f low-density 
Apoprotein (LDL) by causing adhesion and chemotactic 
recruitment of inflammatory cells to the sites o f inflam­
mation in atherosclerotic coronary arteries. [139]
SAA concentrations usually parallel those o f C-reactive 
protein, although some studies indicate that SAA is a 
more sensitive marker o f inflammatory disease. [123]. 
At present, assays for SAA are not widely available. 
Concentrations o f SAA are increased in patients with 
coronary heart disease and seem to have a useful prog­
nostic utility with acute coronary syndromes 
[119,140-143].
Fibrinogen
Fibrinogen, a glycoprotein dimer, is a key coagulation 
factor and acute phase reactant exclusively synthesized 
by the liver [19]. As the substrate of the enzyme throm­
bin and the precursor to fibrin, fibrinogen plays a cen­
tral role in thrombosis and strongly affects hemostasis 
serum viscosity and platelet aggiegation. All these play 
significant roles in the genesis o f an atherosclerotic 
lesion [144,145]. In addition, fibrinogen is involved in 
the earliest stages o f plaque formation as it is directly 
integi'ated into the artery wall where it may be convert­
ed to fibrin and fibrinogen degradation products. It also 
binds to HDL and sequesters more fibrinogen [146]. 
Moreover, both fibrinogen and fibrinogen degradation 
products may mediate the adhesion o f macrophages to 
the endothelial surface and further migration into the 
intima [147]. Fibrinogen and fibrinogen degradation 
products also stimulate smooth muscle cell proliferation
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and migration [148,149]. On the other hand, the 
inflammatory response to atherothrombosis causes the 
release of proinflammatory cytokine mediators of acute 
phase reaction such as IL-6 that elevates acute phase 
proteins including fibrinogen [150,151].
Fibrinogen is associated with a variety of other risk fac­
tors for atherosclerotic CAD including age, smoking, 
LDL-cholesterol, physical activity and blood pressure 
[146]. It has also been found to be associated with an 
increased risk of CAD in healthy as much as in high-risk 
individuals [100,152], to predict future CAD events 
[151,153] and to reflect the extent of subclinical disease 
in subjects free of symptomatic CAD [154].
Conc lusio n_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Recent research has established that inflammation plays 
a critical role in the development of atherothrombosis. 
Experimental and clinical studies suggest that markers 
of inflammation may reflect different aspects o f the 
atherothombotic process at different points in the con­
tinuum of acute coronary syndromes, have a potential 
role for the prediction of risk for developing CAD, and 
may correlate with severity and future risk for CAD. In 
spite of these findings, the clinical utility of measuring 
these markers is limited by the availability o f repro­
ducible diagnostic test assays. In addition, it remains to 
be determined whether markers of inflammation actual­
ly have a causal relation with cardiovascular disease, or 
simply reflect the underlying disease process. Such 
determination becomes important with the potential use 
of these markers in targeting preventive therapies. 
Therefore, further well-designed prospective evaluation 
of each of these markers is needed before their use in 
routine practice.
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